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Tobacco dependence is the leading cause of preventable death in the United States. 
Despite currently available smoking cessation therapies, there is a high rate of relapse in 
smoking among those attempting to quit. While the somatic signs of nicotine withdrawal 
(insomnia, increased appetite, weight gain) contribute to the continuation of smoking 
behavior, it has been hypothesized that the affective signs (depression, anxiety, craving, 
irritability) are greater motivators of relapse and continued tobacco use. There are few 
studies that assess the molecular and receptor-mediated mechanisms of nicotine 
withdrawal; therefore, our studies focus on identifying the nicotinic acetylcholine receptor 
(nAChR) subtypes and post-receptor calcium-dependent mechanisms involved in nicotine 
withdrawal behaviors.  
Using precipitated, spontaneous, and conditioned place aversion (CPA) models, we 
measured physical and affective signs of nicotine withdrawal in mice. Our data show that 
major nAChR subtypes have differential roles in nicotine withdrawal. Additionally, our 
results suggest a behavioral relevance for L-type calcium channels in physical nicotine 
withdrawal signs, while calcium/calmodulin dependent protein kinase II (CaMKII) appears 
to be involved in both physical and affective withdrawal behaviors. 
Additionally, we conducted biochemical studies in the ventral tegmental area (VTA) and 
nucleus accumbens (NAc) to examine the relationship between altered withdrawal 
behavioral responses and calcium-dependent molecular mechanisms that contribute to 
nicotine withdrawal behaviors. Our results suggest an important role for β2-containing 
nAChRs in nicotine-withdrawal induced decreases in CaMKII and synapsin I function in 
the NAc.  
Overall, our studies implicate a critical role for the α4α6β2* nAChR subtype in the 
behavioral and molecular aspects of nicotine withdrawal, thus aiding in the elucidation of 
nAChR subunits and mechanisms that contribute to nicotine withdrawal behaviors. The 
current studies are imperative for generating more successful smoking cessation therapies. 
 
 
 
 
 1 
GENERAL INTRODUCTION 
A.  Tobacco and Nicotine Dependence 
 
Tobacco dependence is the leading cause of preventable mortality in the United 
States. Maintenance of smoking behavior is largely due to nicotine, the main addictive 
component of tobacco (Stolerman and Jarvis, 1995; Bardo et al., 1999). Globally, 
smoking-related illnesses cause over four million smoking related deaths annually. 
Shockingly, every eight seconds, a human life is lost to tobacco use (Martin, 2002). 
Although many aspects of nicotine contribute to smoking, such as the rewarding and 
reinforcing effects, numerous studies suggest that avoidance of the negative emotional 
state produced by nicotine withdrawal represents a motivational component that 
promotes continued tobacco use and relapse after smoking cessation. In fact, the most 
commonly reported reason for relapsing into smoking during quit attempts is the desire 
to relieve the discomforts of smoking withdrawal (US Department of Health and Human 
Sciences, 1988). Among adult smokers, 80% report the desire to quit completely; 
however, those who attempt to quit on their own relapse within the first month and only 
3% remain abstinent after six months (Hughes et al., 1992). While there are smoking 
cessation therapies available, which include nicotine replacement therapies, the anti-
depressant bupropion (Zyban ®), and the partial nicotinic agonist varenicline (Chantix 
®) (Cummings et al., 2006; Jorenby et al., 2006), the success rate of these therapies after 
one year remains only about 20-25% (Gonzales et al., 2006). Indeed, severity of the 
withdrawal syndrome is a better predictor of unsuccessful smoking attempts than smoke 
intake or dependence (West et al., 1989). Because smoking is such a widespread health 
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problem, it is important to understand the molecular and behavioral mechanisms of 
nicotine withdrawal to generate more effective smoking cessation therapies.  
Smoking cessation after chronic tobacco use produces a well characterized and 
defined withdrawal syndrome. In humans, the nicotine withdrawal syndrome is 
characterized by somatic signs, which include bradycardia, gastrointestinal discomfort, 
and increased appetite, and affective signs, including irritability, anxiety, difficulty 
concentrating, disrupted cognition, nicotine cravings, depressed mood, and other mood 
disturbances (Stolerman and Shoaib, 1991; American Psychiatric Association, 1994; 
Mendreck et al., 2006). Indeed, in untreated smokers, nicotine withdrawal produces 
mood disturbances comparable in intensity to those seen in psychiatric outpatients 
(Hughes, 2006). The negative affective symptoms can start as soon as four hours after 
the last cigarette, peak in about three days, and are still measurable a month after 
cessation of tobacco use (Swan et al., 1996; Ward et al., 2001; Hughes, 2007).  
Animal models of drug abuse allow researchers to investigate molecular 
mechanisms involved in drug abuse and potential treatments for these problems. Several 
groups, including our laboratory, have reported utilization of rodent models of the 
nicotine withdrawal syndrome. These animal behavioral models of nicotine withdrawal 
are discussed in more detail in a later section. 
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B.  Molecular and Pharmacological Mechanisms of Nicotine Withdrawal 
Nicotinic Receptors 
 A major goal in nicotine research is to gain a better understanding of the 
molecular and receptor mediated mechanisms of nicotine dependence and withdrawal in 
order to generate more effective smoking cessation therapies. The initial targets for 
nicotine are ligand-gated ion channels called nicotinic acetylcholine receptors 
(nAChRs), which have been identified throughout the central and peripheral nervous 
systems, as well as at skeletal neuromuscular junctions. By mimicking the effects of the 
endogenous transmitter acetylcholine (ACh), nicotine acts on a variety of nAChRs 
distributed throughout these areas, having a wide range of effects on body function, 
depending on the subtype composition and location. nAChRs have a pentameric 
structure consisting of five membrane spanning regions around a central ion channel. 
Muscle expresses five nAChR subunits which can coassemble to form two subtypes. 
These are (α1)2β1 in embryonic muscle tissue, which converts to (α1)2β1 in adult 
muscle tissue. Currently, twelve neuronal nAChR subunits have been identified, 
including α2-α10 and β2-β4, making it possible to have much larger variety in subtype 
composition in the brain and a much larger range of pharmacological effects in response 
to nicotine. The high calcium (Ca
2+
) permeability of nAChRs in the brain and nicotine’s 
ability to elicit neurotransmitter release by binding to neuronal nAChRs, suggests a 
modulatory role for nAChRs in the brain (Role and Berg, 1996). Additionally, as will be 
discussed in later sections, studies indicate Ca
2+
-dependent mechanisms and nicotine-
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induced neurotransmitter release as having an important role in nicotine dependence; 
therefore, our studies will focus on nAChRs located in the brain. 
 In the brain, the majority of nAChRs are presynaptically located, although some 
nAChR populations are found at the soma and on postsynaptic terminals (McGehee and 
Role, 1995; Wonnacott, 1997). Binding of a nicotinic agonist induces a change in the 
conformational state of the receptor. The receptor can exist in a sequence of 
conformational states, which are interpreted in terms of the “conformational scheme” of 
Katz and Thesleff (1957). These states consist of a resting state, which is inactive, yet 
capable of activation, an activated state where the channel opens in response to 
stimulation by a nicotinic agonist, and a desensitized state where the channel is inactive. 
Upon channel opening, there is an influx of various cations into the cell, including 
sodium and Ca
2+
. With repeated exposure to nicotine, the receptor enters the 
desensitized state. A recent study revealed that β2* nAChR occupancy was ~88% after 
just one cigarette, and corresponding plasma levels were shown to lead to 50% 
desensitization of α4β2* nAChRs (Brody et al., 2006).  Receptor desensitization after 
chronic nicotine exposure also leads to a compensatory upregulation of nAChRs. 
Indeed, postmortem binding studies have revealed a significant increase in the number 
of nicotine and ACh binding sites in brains of smokers compared to non-smokers 
(Benwell et al., 1988; Breese et al., 1997). It has been proposed that this desensitization 
and upregulation of nAChRs following chronic nicotine exposure is influential in 
producing withdrawal symptoms upon cessation of smoking (Benwell et al., 1988; 
Balfour and Fagerstrom, 1996; Dani and Heinemann, 1996), and that maintained nAChR 
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desensitization may be important for relieving nicotine withdrawal in humans (Brody et 
al., 2006).  
Regular smokers have an excess number of nAChRs, and maintain levels of 
nicotine in the brain throughout the day that may keep many nAChRs in an inactive 
desensitized state; therefore, it has been proposed that hyperactivity of synaptic 
pathways due to this excess receptor number is one mechanism that may mediate 
withdrawal symptoms. After many hours of abstinence, such as overnight, a smoker’s 
nicotine levels fall, returning the inactivated nAChRs to a responsive state. As a result of 
an excessive number of nAChRs becoming responsive, there may be abnormal 
enhancement of synaptic activity in non-rewarding cholinergic pathways, which may 
contribute to the discomfort associated with nicotine withdrawal that drives smoking 
behavior (Dani and Heinemann, 1996). Stabilization of nAChRs in the desensitized state 
with low levels of nicotine may occupy the increased pool of nAChRs and could 
alleviate the hyperactivity in non-rewarding cholinergic pathways (Brody et al., 2006). 
While this model explains mechanisms associated with spontaneous withdrawal,   it 
does not account for symptoms that occur as a result of precipitated withdrawal. It is 
possible that while hyperactivity of non-rewarding pathways is one way that contributes 
to the manifestation of nicotine withdrawal signs, decreased activity in rewarding 
pathways may occur as a result of antagonist administration during chronic nicotine 
treatment, thus precipitating withdrawal signs.  
While nicotine exerts its pharmacological and physiological effects by acting on 
a variety of nAChR subtypes, the main subtypes in the brain are α7* and α4β2* 
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(Changeux et al.,1998), where * denotes possible assembly with other nicotinic receptor 
subunits. The α4β2* nAChRs are thought to have the highest affinity for nicotine 
(McGehee and Role, 1995; Picciotto et al., 1995), while α7* nAChRs are thought to 
have lower affinity for nicotine (Papke and Thinschmidt, 1998). α4β2* nAChRs are 
found on presynaptic dopaminergic and GABAergic neurons in the ventral tegmental 
area (VTA), a brain area that is part of the mesocorticolimbic drug pathway which has 
been hypothesized to be involved in mediating both the rewarding properties of drugs, as 
well as the aversive behavioral state associated with nicotine withdrawal (Laviolette et 
al., 2002; Laviolette et al., 2008).  The α5 and 6 nAChR subunits also coassemble with 
the β2 subunit in the mesocorticolimbic drug pathway on dopamine (DA) neurons and 
terminals to form functional receptors (Wada et al., 1989, 1990; Le Novère and 
Changeux, 1995; Le Novère et al., 1996; Klink et al., 2001). The α4α5β2 and α4α6β2 
nAChR subtypes are involved in nicotine-stimulated DA release in the striatum 
(Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). The α6 and α5 nAChR 
subunits are also expressed in brain areas that have been implicated as having a role in 
nicotine dependence behaviors. Expression of 6-containing nAChRs in the brain is 
largely confined to catecholaminergic nuclei, such as the VTA, substantia nigra (SN), 
and locus coeruleus (LC) ( Le Novère et al., 1996; Klink et al., 2001), while the more 
widely expressed α5 nAChR subunit is found in the cerebral cortex (Gerzanich et al., 
1998), cerebellum, thalamus (Flora et al.,2002) , striatum (Zoli et al.,2002), 
hippocampus, SN, and VTA (Wada et al., 1990), as well as peripherally in sympathetic 
and parasympathetic ganglia (De Biasi, 2002). The α3 subunit is coexpressed with α5 
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and β4 nAChRs in the peripheral ganglia, and medial habenula (MHb), and 
interpeduncular nucleus (IPN) (Wada et al., 1990; Zoli et al., 1995; Quick et al., 1999; 
Whiteaker et al., 2002). Further, α3 nAChR subunits are also expressed in brain areas 
which have been implicated as having a role in nicotine dependence behaviors, and can 
also coassemble with β2 nAChRs to form functional receptors on DA neurons and 
terminals (Le Novère and Changeux, 1995; Le Novère et al., 1996; Klink et al., 2001). 
Studies in the upcoming chapters will focus on identifying the role of these nAChR 
subunits in aspects of nicotine withdrawal. 
Molecular Mechanisms of Nicotine Dependence and Withdrawal 
The mesocorticolimbic drug pathway has been shown to be critically involved in 
the effects of several drugs of abuse, and is comprised of projections from the VTA to 
the NAc, amygdala, and prefrontal cortex. Presynaptic nAChRs are responsible for the 
positive modulation of neurotransmitter release (Wonnacott, 1997).  Nicotine 
administration stimulates the release of most neurotransmitters throughout the brain, 
including brain regions that comprise the mesocorticolimbic drug pathway (McGehee 
and Role, 1995). Stimulation of neurons in the VTA via α4β2* presynaptic nAChRs 
leads to enhanced DA release into the nucleus accumbens (NAc). Rapid desensitization 
of α4β2* nAChRs on inhibitory GABAergic neurons reduces GABAergic inputs to DA 
neurons, thus enhancing DA transmission. Additionally, stimulation of α7* nAChRs 
located on excitatory glutamatergic neurons (Mansvelder and McGehee, 2002) and on 
DA neurons (Pidoplichko et al., 1997) can enhance glutamate release onto DA neurons, 
also enhancing DA transmission. This complex pattern of brain activation in response to 
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nicotine plays a large role in the acute rewarding and reinforcing effects of nicotine, 
which motivate chronic and compulsive use.  
The neuroadaptations that occur as a result of chronic nicotine exposure are 
thought to reflect nicotine’s influence on these neurotransmitter systems (De Biasi and 
Salas, 2008). Many studies support the vital role of the neurotransmitter DA in nicotine 
dependence.  The nicotine induced increase in VTA DA neuron firing rate (Grenhoff et 
al., 1986), and subsequent DA release in the NAc is a process thought to underlie the 
addictive properties of nicotine (Ponteiri et al., 1996). Alternatively, studies report 
decreased DA neuronal activity in the VTA (Liu and Jin, 2004) and decreased DA 
output in the NAc after nicotine withdrawal (Hildebrand et al., 1998; Rada et al., 2001). 
Indeed, it is hypothesized that this relative deficiency in DA release following cessation 
of nicotine exposure accounts for many of the mood disorders, craving, and anhedonia 
that persist in many smokers long after quitting (Benowitz, 2008).  
Deficits in the neurotransmitter serotonin have also been suggested to play a role 
in mechanisms associated with nicotine withdrawal. Clinically, the 5HT1A  receptor 
partial agonist buspirone shows efficacy in smoking cessation trials and may reduce 
severity in abstinent smokers (Hilleman et al., 1992; Schnedier et al., 1996). 
Serotonergic antidepressant treatment with the selective serotonin reuptake inhibitor 
fluoxetine and a  5HT1A  receptor antagonist was also shown to reverse the anhedonic 
component of nicotine withdrawal in rats (Harrison et al., 2001).  
As proposed for other drugs of abuse, chronic exposure to nicotine is likely to 
involve modification of signaling cascades that modulate synaptic plasticity and gene 
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expression (Dani et al., 2001; Nestler, 2002).  There are many factors by which repeated 
drug exposure could alter gene transcription in the brain, including altered transcription 
rates, altered translation of mRNA into proteins, altered transcription of mature proteins 
to their intracellular sites of action, and alteration of several other mechanisms involved 
in gene transcription and translation (Nestler et al., 2001a). Several studies have shown 
that chronic drug use leads to homeostatic changes in the brain that result in dependence 
and withdrawal symptoms (Nestler and Aghajanian, 1997); however, it has been 
proposed that these homeostatic changes do not explain why people relapse, even years, 
after cessation of drug use. An alternative hypothesis suggests that long-term associative 
memory processes, which receive input from midbrain DA neurons, are involved in 
mediating relapse after long term cessation of drug use (Berke and Hyman, 2000; 
Robbins and Everitt, 2002; Hyman, 2005).  
Long-term potentiation (LTP) is a mechanism characterized by a strengthening 
of synapses, hypothesized to play a crucial role in many forms of experience-dependent 
plasticity, including various forms of learning and memory (Martin et al., 2000; 
Malenka et al., 1989; Malenka and Bear, 2004).  LTP could alter gene and protein 
expression in neurons, leading to reorganization of neural circuitry (Hyman et al., 2006); 
thus, LTP has become an important candidate mechanism involved in relapse after drug 
withdrawal. Evidence suggests that LTP occurs in both the VTA and the NAc (Hyman 
et al., 2006), and changes in some transcription factors involved in induction of LTP 
occur in response to drugs of abuse, including nicotine. Further, the synaptic changes 
that are induced by nicotine are similar to the synaptic plasticity that underlies learning 
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and memory (Pidoplichko et al., 2004). One transcription factor of interest is the cAMP 
response element-binding protein (CREB), best known for its role in learning and 
memory, which studies have shown to be involved in mechanisms associated with 
nicotine dependence, including reward (Walters et al., 2005) and withdrawal (Pandey et 
al.,2001; Brunzell et al., 2003; Pluzarev and Pandey, 2004). One mechanism of CREB 
activation is through phosphorylation by Ca
2+
-dependent proteins. A more thorough 
discussion of the nicotine-induced influx of Ca
2+
, the subsequent activation of Ca
2+
-
dependent mechanisms, and the role of Ca
2+ 
in nicotine dependence and withdrawal is 
discussed in further detail in the next section. 
C.  Calcium-Dependent Mechanisms in Nicotine Dependence and Withdrawal 
As a result of Ca
2+
 influx, presynaptic nAChRs facilitate Ca
2+
-dependent release 
of many neurotransmitters and the activation of various downstream signaling cascades 
involved in gene transcription (Wonnacott, 1997). Neuronal nAChRs can elevate 
intracellular Ca
2+
 both directly due to the Ca
2+
 influx through the Ca
2+ 
permeable 
nAChR channel, and indirectly because of the ability to induce membrane depolarization 
and activate voltage-gated Ca
2+
 channels (VGCCs), and Ca
2+
-induced Ca
2+
 release from 
intracellular stores (Fig. 1A).  Ca
2+
  influx through nAChRs  mediates neurotransmitter 
release through Ca
2+
 -dependent exocytosis of synaptic vesicles and by activating Ca
2+
 -
mediated cellular mechanisms. The nicotine-induced increase in intracellular Ca
2+
 
initiates a cascade of second messenger events, leading to the activation of a number of 
Ca
2+
 -dependent targets, including Ca
2+
 /calmodulin-dependent protein kinase II 
(CaMKII), CaMKIV, and protein kinase A (PKA). This leads to activation of 
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extracellular signal-regulated kinase or mitogen-activated protein kinase (ERK or 
MAPK) and CREB (Fig. 1B). 
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Figure 1. Calcium-dependent mechanisms and nicotinic receptors. 
A. Neuronal nAChRs can elevate intracellular Ca
2+
  both directly due to the Ca
2+
  
influx through the Ca
2+
  permeable channel, and indirectly because of the ability to 
induce membrane depolarization and activate voltage-gated Ca
2+
 channels 
(VGCCs), and Ca
2+
-induced Ca
2+
 release from intracellular stores. B. The nicotine-
induced increase in intracellular Ca
2+
 initiates a cascade of second messenger 
events, leading to the activation of a number of Ca
2+
-dependent targets, including 
Ca
2+
/calmodulin-dependent protein kinase II (CaMKII), CaMKIV, and protein 
kinase A (PKA), leading to activation of extracellular signal-regulated kinase or 
mitogen-activated protein kinase (ERK or MAPK) and CREB. 
 
Dajas- Bailador and Wonnacott, 2004 
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These Ca
2+
-dependent processes have been shown to play a role in the  
molecular mechanisms of the underlying synaptic plasticity involved in drugs of abuse 
such as cocaine (Nestler, 2001b). In fact, in the case of nicotine, decreased CREB 
activity was detected in the NAc (Brunzell et al., 2003; Pluzarev and Pandey, 2004), 
cortex, and amygdala (Pandey et al., 2001) after nicotine withdrawal, suggesting that 
decreased CREB activity may be associated with the dysfunction in reward mechanisms 
after nicotine withdrawal. Changes in CREB phosphorylation have also been observed 
following morphine (Lane-Ladd et al., 1997), cocaine (Kano et al., 1995) and 
amphetamine chronic administration (Shaw-Lutchman et al., 2003).  Animals with a 
decrease in CREB function do not find morphine rewarding, but find cocaine more 
rewarding (Walters and Blendy, 2001).  Taken together, CREB seems to play a major 
role in the cellular changes that occur in the brain after acute and chronic administration 
of several drugs of abuse.  
There are numerous phosphorylation sites on the CREB protein that 
differentially regulate its activity, including a site for CaMKII. The Ca
2+
-dependent 
protein, CaMKII, has not been extensively evaluated in drug abuse; however, the 
available studies suggest a role for CaMKII in morphine tolerance (Fan et al., 1999; 
Liang et al., 2004; Tang et al., 2006) and reward (Narita et al., 2004), as well as cocaine 
sensitization (Licata et al., 2004), and reinstatement (Anderson et al., 2008). 
Additionally, CaMKII has been shown in vitro to reduce CREB-mediated gene 
transcription (Matthews et al., 1994; Sun et al., 1994; Wu and McMurray, 2001). 
However, in vivo, CaMKII was shown to increase CREB activity in the spinal cord 
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(Miyabe and Miletic, 2005). Although the specific role is unclear, CaMKII appears to 
have a role in modulating CREB activity.  
CaMKII is the most abundant protein kinase in the brain, comprising 
approximately 1-2% of total protein. Upon nicotine binding, nAChR channels open, 
allowing a direct influx of Ca
2+
 and other ions, as well as an indirect Ca
2+
 influx through 
Ca
2+
 channels. Ca
2+ 
forms a complex with calmodulin, and this complex binds to and 
activates CaMKII. Once activated, CaMKII can auto-phosphorylate and preserve 80% of 
its activity, independent of Ca
2+
 (Schulman and Hanson, 1993). Presynaptically, 
CaMKII plays a role in neurotransmitter synthesis and release (Schulman and Hanson, 
1993). Tyrosine hydroxylase, the rate-limiting enzyme in DA synthesis, and synapsin I, 
a vesicle protein essential for regulation of neurotransmitter release, are CaMKII 
substrates.  Postsynaptically, CaMKII is essential for induction of LTP (Lisman et al., 
2002). Due to its role in CREB modulation, LTP, and activation of other substrates 
involved in neurotransmitter release and gene transcription, we believe that CaMKII is a 
candidate protein for having a role in nicotine dependence. 
 The α-CaMKII mutant mouse was generated as a tool to study the role of 
CaMKII in LTP (Silva et al., 1992a). It was noted that mutant mice displayed some 
behaviors consistent with animals that have hippocampal lesions. For example, animals 
with hippocampal lesions exhibit increased exploratory behavior and activity when 
placed in an open field activity cage or Y maze (Teitelbaum and Milner, 1963; Foreman, 
1983). When tested, α-CaMKII mutant mice showed increased exploratory activity in an 
open field and in a Y maze (Silva et al., 1992b).  Additional studies using the Morris 
15 
 
water maze also revealed that α-CaMKII mutant mice, like hippocampal lesioned 
animals, have impaired spatial learning, but no deficits in contextual learning (Silva et 
al., 1992b).  Conditional α-CaMKII mutants have also been used to study the role of α-
CaMKII in learning and memory. A functional mutated form of α -CaMKII was 
generated in vitro, and a highly selective inhibitor for the mutated α -CaMKII was 
generated (Wang et al., 2003).  Mice that overexpress the mutated α -CaMKII were 
generated, and it was found that the selective inhibitor could mask α -CaMKII activity in 
specific brain subregions of the mutated mice on the time scale of several minutes 
(Wang et al., 2003). Our studies using α-CaMKII mutant mice will be presented in 
Chapter 5. 
D.  Behavioral Models of Nicotine Withdrawal 
Animal models of nicotine withdrawal have been developed and are useful tools 
for elucidating mechanisms associated with nicotine withdrawal behaviors.  From these 
models, studies have shown that somatic signs of nicotine withdrawal are mediated by 
central and peripheral nAChRs, while affective signs are mediated solely through central 
nAChR populations (Watkins et al., 2000). Rodents are first chronically exposed to 
nicotine for a predetermined amount of time through osmotic mini pumps (Damaj et al., 
2003; Malin et al., 2006), chronic injections (Liu et al., 2005; Miura et al. 2006), oral 
route via drinking water (Grabus et al., 2005; Liu et al., 2005), or intravenous 
administration (Wilkinson and Bevins, 2008). Withdrawal may be precipitated in 
chronic nicotine exposed animals with nicotinic antagonists, such as the non-selective 
nAChR antagonist mecamylamine, or evaluated spontaneously by the cessation of 
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chronic nicotine treatment. Physical signs in rodents are typically measured as somatic 
signs (Malin et al., 1992; Hildebrand et al., 1997; Damaj et al., 2003), hyperalgesia 
(Salas et al., 2004; Grabus et al., 2005), and changes in locomotor activity (Nomikos et 
al., 1999; Hildebrand et al., 1999), while affective signs are typically measured as 
anxiety-related behaviors (Damaj et al., 2003; Schneider et al., 2007; Stoker et al., 
2008), elevated reward thresholds (Cryan et al., 2003; Bruijnzeel and Markou, 2004; 
Johnson et al., 2008), contextual fear conditioning (Davis et al., 2005), and conditioned 
place aversion (CPA) (Suzuki et al., 1996; Malin et al., 2006; Jackson et al., 2008).  
The somatic signs of nicotine withdrawal in rodents are indicative of signs of 
irritation, as irritability is experienced by humans as part of the nicotine withdrawal 
syndrome. Hyperalgesia, or increased pain sensitivity, has also been reported in some 
smokers after cessation of tobacco use (Allen et al., 2000). In fact, abstinent smokers 
who reported having two or more withdrawal symptoms had a higher odds ratio of 
experiencing chronic pain in three or more locations compared to individuals who did 
not experience withdrawal symptoms (John et al., 2008). Changes in locomotor activity 
after nicotine withdrawal may reflect alterations in DA transmission. Decreases in 
locomotor activity, which have been reported after nicotine withdrawal in rats, 
correspond to a reduction in NAc and striatal DA content 24 hours after cessation of 
chronic nicotine infusion through osmotic mini pumps (Fung et al., 1996). Indeed, 
decreased DA release in the NAc has been reported after mecamylamine-precipitated 
withdrawal (Hildebrand et al., 1998; Carboni et al., 2000).  
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Mice undergoing nicotine withdrawal show increased anxiety-related behavior as 
measured by the plus maze (Irvine et al., 2001; Damaj et al., 2003; Jackson et al., 2008) 
and the light-dark box (Schneider et al., 2007; Stoker et al.,2008); thus, these models 
could mimic the increase in anxiety reported in humans during nicotine abstinence. 
Elevations in reward threshold measured by the intracranial self stimulation (ICSS) test 
evaluate the anhedonia, or diminished interest in rewarding stimuli, associated with 
nicotine withdrawal. Depression, which is highly correlated with nicotine withdrawal, 
also produces anhedonia (Kenny and Markou, 2001). Contextual fear conditioning 
explores the cognitive deficits observed after nicotine withdrawal (Davis et al., 2005), as 
humans report difficulty concentrating and disrupted cognition after cessation of tobacco 
use (Stolerman and Shoaib, 1991; American Psychiatric Association, 1994; Mendreck et 
al., 2006). Nicotine withdrawal also produces deficits in contextual fear conditioning in 
rodents, suggesting decreased cognition after nicotine withdrawal (Portugal et al., 2008). 
The CPA paradigm measures the overall aversion, or negative mood, associated with 
nicotine withdrawal (Kenny and Markou, 2001). These models have been characterized 
in rodents to measure the nicotine withdrawal syndrome. Current studies strive to 
establish more of these models in mice in order to use transgenic mice to understand the 
nAChRs and post-receptor mechanisms associated with nicotine withdrawal. 
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E. Transgenic Mice: A Complementary Approach to Pharmacological Methods 
 The use of genetically engineered mice, such as knockout (KO) and knockin (KI) 
mice, provides a powerful tool to complement results derived from pharmacological 
studies. Because our studies use only KO mice to examine nicotine withdrawal 
behaviors, this section will focus on the alternatives and limitations of the use of KO 
animals in behavioral studies.  
The KO mouse is typically engineered using embryonic stem (ES) cells from the 
129/Sv inbred mouse. The gene of interest is inactivated by replacement of coding 
sequences essential for gene function with a neomycin cassette. Through homologous 
recombination, the normal gene on the chromosome is replaced with the targeted 
cassette, thus “knocking out” the gene function. The ES cells from the 129/Sv mouse 
that contain the homologous recombination construct are injected into C57Bl/6 (B6) 
mouse blastocysts, and implanted into a foster mother; thus, the pups born from this 
event are composed of cells from a B6 embryo and 129/Sv stem cells. The chimeric 
mice are then mated with B6 mice to transmit the KO allele, and ultimately generate KO 
mice in later generations. To date, several nAChR KO mice have been generated and the 
phenotypes have been characterized. These include α3 (Xu et al.,1999a), α4 (Marubio et 
al., 1999; Ross et al., 2000), α5 (Salas et al., 2003), α6 (Champtiaux et al.,2002), α7 
(Orr-Urtreger et al., 1997), α9 (Vetter et al., 1999), β2 (Picciotto et al., 1995), β3 
(Booker et al., 1999), and β4 (Xu et al., 1999b).  
Because of the overlapping expression patterns of nAChR subunits and the lack 
of selective pharmacological agents to identify specific nAChR subunits, KO mice have 
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proven to be useful in determining the subunit composition and physiological properties 
of nAChRs in vivo, complementing results obtained from pharmacological studies, and 
more recently, to test the selectivity of nicotinic receptor antibodies used for standard 
immunodetection procedures (Moser et al., 2007). Additionally, these genetically 
modified mice aid in elucidating the molecular and receptor-mediated mechanisms of 
many pharmacological actions of nicotine-mediated behaviors and various disease states 
including Alzheimer’s Disease, Parkinson’s Disease, and drug addiction. While it is 
clear that the KO approach offers many possibilities that cannot be achieved through the 
use of pharmacological agents, there are some important limitations to the model. 
One major setback to KO studies is the occurrence of developmental 
modifications that may occur as a result of gene deletion, and can interfere with 
interpretation of results. It may be difficult to determine if the mouse phenotype is as a 
result of the gene deletion, or simply a mutation that reflects the importance of the gene 
in development. In addition, compensatory mechanisms in KO animals may raise some 
difficulties in data interpretation. For example, the deletion of one nAChR subunit may 
induce a compensatory increase in the expression of another subunit which can take over 
function of the deleted subunit; however, the expression level of various nAChR 
subunits and enzyme functions were found to be normal in various nAChR subunit KO 
animals (Picciotto et al., 1995; Marubio et al., 1999; Ross et al., 2000; Champtiaux et 
al., 2002). One minor discrepancy may be the genetic background of the mouse strain 
used for breeding, which has a strong influence on the expression of certain phenotypes. 
It was shown that the same mutation in different mouse strains can produce different 
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phenotypes as a result of modifier genes, or genes that affect the phenotypic expression 
of other genes (Nadeau, 2001). Most nAChR KO mice are backcrossed to the B6 strain; 
however, the use of other strains for backcrossing the mutations may result in different 
phenotypes. Such studies stress the importance of utilizing KO mice from the same 
genetic background, and of the necessity to characterize the behavioral phenotypes of 
the background strains prior to evaluating results using KO mice. 
Our studies utilize the β2, α7, and α5 nAChR KO mice, and α-CaMKII 
heterozygote (HT) mice. The β2 nAChR subunit was the first subunit targeted for KO 
studies by Picciotto et al. (1995). In situ hybridization revealed normal mRNA levels of 
the α4, α5, β4, and β3 nAChR subunits, suggesting that these subunits were not 
upregulated as a result of the mutation. Studies showed that nicotine fails to stimulate 
the DA system in β2 KO mice (Picciotto et al., 1998); thus, several behaviors associated 
with nicotine-mediated DA release are abolished in β2 KO mice, including nicotine-
induced locomotor activitation (King et al., 2004), nicotine discrimination (Shoaib et al., 
2002), nicotine self-administration (Picciotto et al., 1998), and conditioned place 
preference (Walters et al., 2006), suggesting that the 2 nAChR subunit is crucial in 
various features associated with nicotine dependence.  
 Mice null for the α7 subunit used for our studies were generated as described by 
Orr-Urtreger et al. (1997).  While the α7 subunit has broad expression in the brain, 
studies show that α7 KO mice show normal nicotine conditioned place preference 
(Walters et al., 2006), lever-pressing behavior, nicotine-induced locomotor depression, 
and nicotine tolerance compared to wildtpe (WT) mice (Naylor et al., 2005), suggesting 
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that α7* nAChRs are not involved in nicotine reward or tolerance based on these testing 
paradigms. The α7*nAChRs, however, are involved in nicotine withdrawal-induced 
hyperalgesia, as nicotine-withdrawn α7 KO do not express this response (Grabus et al., 
2005). The α5 KO mouse used in our studies was generated and characterized as 
described by Salas et al. (2003). As with many other nAChR subunit KO mice, α5 KO 
mice have normal neuroanatomy and normal levels of α4, α6, α7, β2, and β4 mRNA 
with unchanged [
125
 I]- epibatidine and [
125
 I]α-bungarotoxin binding in the brain 
compared to WT littermates. While α5 KO mice were resistant to nicotine-induced 
seizures and to the hypolocomotive effects of nicotine (Salas et al., 2003), little work has 
been done to characterize the pharmacological effects of nicotine in α5 KO mice. Our 
experiments using these KO mice to identify nAChR subunit involvement in nicotine 
withdrawal are addressed in chapters 3 and 4. 
F.  Dissertation Objectives 
 The research in this dissertation focuses on identifying the major nAChR 
subtypes involved in nicotine withdrawal behaviors, and elucidating post-receptor Ca
2+
 
dependent mechanisms that mediate withdrawal behaviors. While the positive rewarding 
and reinforcing effects of nicotine motivate continued use (Kenny and Markou, 2001), 
few studies assess the negative motivational component associated with nicotine 
withdrawal, although the desire to relieve the discomforts of smoking withdrawal has 
been reported by abstinent smokers to be the reason for relapsing into smoking during 
quit attempts (US Department of Health and Human Sciences, 1988). To date, the role 
of major nAChR subtypes in nicotine withdrawal is unclear, largely due to the low 
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selectivity of many nAChR agonists and antagonists. Studies addressing the signaling 
mechanisms involved in nicotine withdrawal behaviors are also lacking; thus, our 
studies aim to identify the nAChR subtypes involved in affective and somatic nicotine 
withdrawal behaviors, elucidate the role of Ca
2+
-dependent mechanisms involved in 
nicotine withdrawal behaviors, and examine the relationship between withdrawal-
induced behavioral aterations and Ca
2+
-dependent mechanisms that mediate nicotine 
withdrawal behaviors. 
Based on background information and our preliminary data, we hypothesized 
that the major nAChR subtypes have differential roles in the nicotine withdrawal 
syndrome. Specifically, the α4α6β2* nAChR subtype is involved in affective nicotine 
withdrawal behaviors. This subtype also mediates nicotine-withdrawal induced 
decreases in CaMKII function in the NAc. The decrease in CaMKII function leads to 
decreased phosphorylation of CaMKII substrates, specifically synapsin I, a protein 
essential for regulation of neurotransmitter release. To test our hypothesis, we began by 
adapting nicotine withdrawal and CPA models for mouse studies. By adapting the 
current nicotine withdrawal models for mouse studies, we had the advantage of testing 
KO mice in these models to complement pharmacological data on nicotine withdrawal 
studies. Using our adapted models, we addressed three specific aims. 
Our first specific aim was to identify the major nAChR subtypes in affective and 
somatic nicotine withdrawal behaviors. These studies were conducted using 
pharmacological antagonists and mice null for specific nAChR subunits. We 
hypothesized that different nAChR subtypes have differential roles in nicotine 
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withdrawal. Specifically, the α4α6β2* nAChR subtype is involved in affective nicotine 
withdrawal behaviors, while α5*, α7*, and α3β4* nAChRs are involved in physical 
nicotine withdrawal. 
The second specific aim was to examine the role and behavioral relevance of 
Ca
2+
-dependent mechanisms, such as L-type VGCCs and CaMKII, in nicotine 
withdrawal. It was suggested that the sustained elevation of Ca
2+
 through nAChRs is 
dependent on the activation of VGCCs, largely L-type (Dajas-Bailador et al., 2002; 
Dickinson et al., 2007). Thus, we used L-type VGCCs selective antagonists and an 
agonist to elucidate the role of L-type VGCCs in affective and somatic nicotine 
withdrawal signs. We also chose to focus on the Ca
2+
-dependent protein CaMKII due to 
its abundance in the brain and large role in mediating several proteins involved in drug-
mediated behaviors. We used antagonists and CaMKII transgenic mice to examine the 
role of CaMKII in nicotine withdrawal. Our preliminary studies lead us to propose that 
LTCCs and CaMKII are relevant in nicotine withdrawal behaviors. 
In the final specific aim, we investigated the relationship between the altered 
behavioral responses in vivo and the in vitro receptor-mediated Ca
2+
-dependent 
mechanisms involved in nicotine withdrawal. Although nAChRs in the VTA are 
important for nicotine withdrawal behaviors, the subsequent neurotransmitter release 
after stimulation of VTA nAChRs occurs in the NAc, and involves presynaptic nAChRs; 
thus, we focused our studies on activity in the NAc after nicotine withdrawal. Using 
western blot analysis, we characterized the activity and expression level of CaMKII and 
synapsin I after acute nicotine exposure, and after nicotine withdrawal. Pharmacological 
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and transgenic approaches were used to determine the specific subunits through which 
the withdrawal-induced changes in CaMKII and synapsin I function were mediated. Our 
preliminary data lead is to hypothesize that CaMKII, and consequently, synapsin I 
activity, are decreased in the NAc after nicotine withdrawal. This decrease in activity is 
mediated through the 4α62* nAChR subtype, and is relevant to the expression of 
affective nicotine withdrawal behaviors. 
Overall, this study identifies specific nAChR subtypes, post-receptor 
mechanisms, and potential brain regions important in nicotine dependence and 
withdrawal. Further, by showing that the decrease in CaMKII and synapsin I function, 
which may contribute to the decreased DA release observed after nicotine withdrawal, is 
mediated through the α4α6β2* subtype, which is a subtype crucial for expression of 
affective nicotine withdrawal signs, this study stresses the importance of affective 
nicotine withdrawal as a motivational component of relapse in smoking behavior. The 
research in this dissertation will contribute to the understanding of the molecular and 
receptor-mediated mechanisms of nicotine withdrawal, and provide new insight into 
potential targets for more effective smoking cessation therapies. 
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CHARACTERIZATION OF A NICOTINE CONDITIONED PLACE AVERSION 
MOUSE MODEL 
 
A. Introduction 
The nicotine withdrawal syndrome is characterized by both somatic and affective 
signs. Because of the importance of affective nicotine withdrawal signs in nicotine 
addiction, nicotine withdrawal studies which assess the receptor-mediated mechanisms 
associated with this aspect of withdrawal are currently under investigation. The relative 
lack of selective agonists and antagonists for the different nicotinic receptor subtypes has 
lead to the generation of several α-conotoxins, which have greater selectivity for specific 
nAChR subtypes, as well as transgenic mice, such as KO mice; thus, we have established 
mouse models of nicotine withdrawal in order to use transgenic mice to elucidate nicotinic 
receptor involvement in nicotine withdrawal.  
Recently, some of the widely used affective models of nicotine withdrawal have 
been characterized in mice. The ICSS model, which evaluates brain reward function as a 
measure of the anhedonic component of withdrawal, has typically been evaluated in rats 
(Cryan et al, 2003; Bruijnzeel and Markou, 2004); however, recent studies have 
characterized the ICSS model in mice, providing the potential for measuring this affective 
component of withdrawal in transgenic mice (Johnson et al., 2008). Another measure of 
affective nicotine withdrawal used in the rat is the CPA model. The CPA model measures 
the aversive state associated with nicotine withdrawal. It is a form of classic Pavlovian 
conditioning where the animal learns to avoid a compartment that was previously paired 
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with an aversive stimulus. Previous work using this model in the rat has shown that 
nicotine withdrawal is associated with a negative affective state, and place aversion to 
previously neutral environmental stimuli represents a motivational component in the 
maintenance of drug use (Suzuki et al., 1996). The CPA protocol is advantageous over 
more complicated affective tests such as the ICSS protocol in that there is no need for 
extensive surgical procedures, and training sessions are typically shorter and less complex. 
Because the model also tests the animals in an antagonist-free state, it evaluates the 
important role of environmental stimuli in the maintenance of drug use. While the nicotine 
CPA model has been well defined in rats, this model has not been evaluated and 
characterized in mice. Indeed, the use of a mouse model would be advantageous in that it 
offers the possibility of exploring the underlying mechanisms of nicotine withdrawal 
through the use of genetically modified mice.  
For our studies, because of the relative importance of affective withdrawal signs in 
contributing to relapse, we used two nicotine withdrawal models that would allow us to 
measure affective signs in mice. The plus maze model, which measures the anxiety-related 
component of nicotine withdrawal, will be discussed in the next chapter. The focus of this 
chapter is characterization of a nicotine CPA model in mice. In addition to these two 
models measuring different affective aspects of the nicotine withdrawal syndrome 
(anxiety-related behavior vs. aversion), these signs involve different brain regions, and 
thus, potentially different nAChR subtypes. While the dorsal raphé nucleus is crucial in 
mediating nicotine’s effects on anxiety (Cheeta et al., 2001), the aversive response involves 
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the basolateral amygdala (Zanoveli et al., 2007). In the present study, we characterized a 
nicotine CPA model in mice to further evaluate the affective component of nicotine 
withdrawal. We determined the rate of acquisition, and the role of sex, age, and genotype 
on development of aversion. We also identified the role of specific nicotinic receptor 
populations through the use of various nicotinic receptor antagonists. 
B. Methods 
Animals 
Male 129P3/J (129) and male and female B6 mice were purchased from Jackson 
Laboratories. The B6 mouse is an inbred strain that has been used extensively in 
pharmacological studies. Additionally, transgenic animals used in our studies were 
generated using 129 embryonic stem cells, and maintained on a B6 background. The mice 
were 8-10 weeks of age at the start of all studies. This is an adult age in the mouse, and 
published studies utilizing mice between 8-12 weeks of age do not report major behavioral 
differences to nicotine in mice in this age range. Male adult and adolescent ICR mice were 
purchased from Harlan Laboratories. Adult mice were 8-10 weeks of age and weighed 
approximately 20-25 g at the start of the experiment. Adolescent mice were approximately 
3 weeks of age [postnatal day (PND) 21] at the start of the experiment. Animals were 
maintained in an Association for Assessment and Accreditation of Laboratory Animal 
Care-approved animal care facility and the studies were approved by the Institutional 
Animal Care and Use Committee of Virginia Commonwealth University. 
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Drugs 
 
(-)-Nicotine hydrogen tartrate salt, mecamylamine hydrochloride, dihydro--erythroidine 
(DHβE) and methyllycaconitine citrate (MLA) were purchased from Sigma-Aldrich Inc. 
(St. Louis, MO, USA). Hexamethonium dichloride was purchased from Sigma /RBI 
(Natick, MA). All drugs were dissolved in physiological saline (0.9% sodium chloride) at a 
volume of 10 ml/kg body weight. Hexamethonium injections were administered 
intraperitoneally (i.p.). All other drugs were administered subcutaneously (s.c.). Doses are 
expressed as the free base of the drug. 
Chronic nicotine administration 
Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model 
2004 (28 days) Durect Corporation,
 
Cupertino, CA] filled with (-)-nicotine or saline 
solution. The concentration of
 
nicotine was adjusted according to animal weight and the 
mini pump flow rate, resulting
 
in 36 mg/kg/day for 14 or 28 days. Because the period of 
early adolescence lasts approximately from PND 21 to 36, adult and adolescent mice used 
for the age assessment were chronically infused with 48 mg/kg/day for 7 days to ensure a 
sufficient level of dependence. The mini pumps were surgically implanted
 
s.c. under sterile 
conditions with sodium pentobarbital anesthesia
 
(45 mg/kg, i.p.). An incision was made in 
the back of the animal,
 
and a pump was inserted. The wound was closed with wound clips,
 
and the animal was allowed to recover on a heated pad before being returned
 
to its home 
cage. 
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Nicotine CPA 
The mice were chronically exposed to nicotine for 7 or 14 days prior to initiation of testing 
to induce dependence. Infusion continued throughout the duration of testing. The CPA 
protocol was conducted over the course of four days in a biased fashion. The CPA 
apparatus consisted of a three-chambered box with a white compartment, a black 
compartment, and a center grey compartment. The black and white compartments also had 
different floor textures to help the mice further differentiate between the two 
compartments. Day 1 of CPA testing was the pre-conditioning day. The mice were placed 
in the grey center compartment for a 5 minute habituation period, followed by a 15 minute 
test period. During habituation, mice did not have access to the other compartments. 
During the test period, mice were allowed to roam freely between compartments. The CPA 
boxes were connected to a computer, which recorded the amount of time the mouse spent 
in each compartment. A pre-preference score was determined for each mouse and was used 
to pair the mouse with the antagonist to its initially preferred compartment. On days 2 and 
3 of CPA testing, all mice received injections of saline in the morning and were 
immediately confined to their non-drug-paired compartment for 30 minutes. No less than 
four hours later, mice received an injection of antagonist and were immediately confined to 
their drug-paired compartment for 30 minutes.  Day 4 was the antagonist-free test day. 
Mice moved freely between compartments as on day 1 and activity counts and time spent 
on each side were recorded via photosensors using Med Associates interface and software. 
Data were expressed as time spent on drug-paired side minus time spent on saline-paired 
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side. A reduction in time spent in the initially preferred compartment was interpreted as 
CPA. 
Statistical analysis 
For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA). 
All studies were analyzed with one-way ANOVAs [with treatment as the between subject 
factor] or two-way ANOVAs [with treatment and sex as the between subject factors] using 
the Neuman-Keuls post-hoc test.  p values of less than 0.05 were considered significant.  
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C. Results 
Acquisition of aversion in the CPA model 
 
To determine the rate of acquisition of aversion in the CPA model, mice were subjected to 
one, two, or three conditioning sessions with mecamylamine (3.5 mg/kg, s.c.) before the 
drug free test day. One mecamylamine conditioning session was sufficient to produce 
significant aversion in chronic nicotine infused mice. A significant aversive response was 
also noted after two conditioning sessions; however, there was no significant effect after 
three days of mecamylamine conditioning (Fig 2A). Next, it was important to determine 
the length of the conditioning session required to develop aversion, as well as the level of 
dependence necessary to precipitate an aversive response; thus, mice were placed in the 
chambers for 30 or 60 minutes after mecamylamine injection, and testing was initiated 
after 7 or 14 days of chronic nicotine infusion. Mice developed a significant CPA after 7 
and 14 days of prior nicotine infusion, but only after a 30 minute mecamylamine 
conditioning session (Fig. 2B). No significant aversion was noted after the 60 minute 
conditioning session (Fig. 2B). Based on these results, for the remaining experiments, mice 
were chronically exposed to nicotine for 14 days prior to initiation of testing, and subjected 
to two 30 minute mecamylamine conditioning sessions to ensure development of aversion. 
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Figure 2. Acquisition of aversion in the CPA model. A. Mice acquire aversion in the 
CPA model after one and two conditioning sessions; however, no significant effect 
was observed after three conditioning sessions. B. Aversion is precipitated in mice 
chronically infused with nicotine for 7 and 14 days prior to test initiation. 30 minute 
conditioning sessions are sufficient to develop aversion. The effect is lost after 60 
minute conditioning sessions. Each point represents  S.E.M. of  10-12 mice per 
group.  * denotes p<0.05.  
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Assessment of various antagonists in the CPA model 
 
The role of various nicotinic receptors in the aversion associated with nicotine withdrawal 
was evaluated using nicotinic receptor antagonists. We first wanted to determine the 
involvement of central and peripheral nAChR populations in nicotine- withdrawal 
aversion. Mecamylamine, a non-selective receptor antagonist that blocks both central and 
peripheral nicotinic receptors, dose-dependently precipitated aversion in mice. A 
significant CPA was observed with 3.5 mg/kg (s.c.) mecamylamine, but not with 1 or 2 
mg/kg (Fig. 3A). Further, the highest dose of mecamylamine used for the studies did not 
precipitate aversion in chronic saline infused mice, suggesting that the dose used is not 
behaviorally active by itself (Fig. 3B). Hexamethonium (1 and 5 mg/kg, i.p.), a peripheral 
nicotinic receptor antagonist that does not cross the blood brain barrier, did not produce 
significant aversion as seen in mice treated with mecamylamine (Fig. 3C). Because the 
α4β2 and α7 subtypes are major subtypes in the brain, we wanted to evaluate the role of 
these receptor subtypes in nicotine withdrawal. We measured aversion after conditioning 
with the β2-selective antagonist, DHE, and the α7 antagonist, MLA.  DHβE dose-
dependently precipitated aversion at 0.5 and 2 mg/kg (s.c.), while MLA did not precipitate 
aversion at 10 mg/kg (s.c.), a dose that effectively blocks 7 nicotinic receptors (Ward et 
al., 1990) (Fig. 3D).  
 
34 
 
 
 
Figure 3.  Assessment of various antagonists in the CPA model. A. Mecamylamine 
dose-dependently precipitates aversion in the CPA model. B. The dose of 
mecamylamine used in the model, 3.5 mg/kg, does not precipitate aversion in saline 
infused mice, suggesting that the dose is not behaviorally active by itself.                    
C. Hexamethonium (hex), a peripheral nicotinic receptor antagonist, does not 
precipitate aversion in chronic nicotine infused mice. D. The 2-selective antagonist, 
DHBE, but not the 7 antagonist, MLA, dose-dependently precipitates aversion in 
chronic nicotine infused mice. Each point represents  S.E.M. of 10-12 mice per 
group. * denotes p<0.05 vs. saline groups.   
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Sex and strain assessment in the CPA model 
The transgenic mice used in our studies are maintained on a B6 background and derived 
from 129 embryonic stem cells. It was therefore necessary to evaluate the background 
strains of our transgenic mice in order to make the most efficient interpretation of our KO 
results. Additionally, because of the limited number of KO animals produced in each litter, 
it is sometimes necessary to use both male and female animals for our studies; thus, we 
also evaluated differences between male and female B6 mice in our CPA model. Results 
show that mecamylamine (3.5 mg/kg, s.c.) precipitated aversion in male B6 and 129 mice 
(Fig. 4). While there was a trend toward a more severe aversive response in B6 mice than 
129 mice, the difference was not statistically significant (p= .25 for B6 vs. 129 mice) 
(Fig.4). Female B6 mice were also evaluated in the nicotine CPA model. As noted, 
mecamylamine (3.5mg/kg, s.c.) precipitated significant aversion in male B6 mice, but CPA  
was absent in female B6 mice (Fig. 5). Based on these results, only male mice were used 
for subsequent studies. 
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Figure 4.  CPA assessment using 129 and B6 male mice. Mecamylamine precipitates 
aversion in the 129 and B6 inbred strains. Although there was a trend toward a 
higher level of aversion in B6 mice, the difference was not significant (p= .25 for B6 
vs. 129 group). Each point represents  S.E.M. of 12 mice per group. * denotes p < 
0.05 vs. the corresponding saline group.  
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Figure 5. Assessment of male and female B6 mice in the development of aversion in 
the CPA model. Chronic nicotine infused male B6 mice develop aversion in the CPA 
model; however, nicotine infused female B6 mice do not develop aversion in this 
testing scheme. Each point represents  S.E.M. of 12 mice per group. * denotes p<0.05 
vs. the corresponding saline group.   
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Evaluation of age differences in the CPA model 
To complete characterization of a nicotine CPA model in mice, we wanted to evaluate the 
importance of age in the development of CPA. Early adolescent and adult mice were tested 
in the CPA model to evaluate age effects. Mecamylamine (3.5 mg/kg, s.c.) precipitated 
significant aversion in adult mice, but no significant effect was observed in adolescent 
mice, suggesting that adolescents are less sensitive to the aversive effects of nicotine 
withdrawal (Fig. 6). By itself, mecamylamine did not precipitate significant aversion in 
adult or adolescent saline controls, suggesting that the dose used was not behaviorally 
active in saline mice. 
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Figure 6.  Age differences in development of aversion in the CPA model.                      
A. Mecamylamine (3.5 mg/kg, s.c.) precipitates aversion in adult mice, but B. not in 
early adolescent mice. The dose of mecamylamine used did not precipitate aversion in 
saline-treated adult or adolescent mice. Each point represents  S.E.M. of 10-12 mice 
per group. * denotes p<0.05 vs. control groups.   
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D. Discussion 
The present research aimed to characterize a nicotine CPA model in the mouse. The 
adaptation of such a model for mouse studies allows us to define the underlying receptor 
mechanisms of affective nicotine withdrawal through the use of genetically modified mice. 
The major findings showed that mecamylamine and DHβE, but not hexamethonium or 
MLA, precipitated significant aversion in the CPA model, suggesting that the aversion 
associated with nicotine withdrawal is mediated by central populations of β2-containing 
nAChRs.  Further, we show that sex and age are contributing factors to the development of 
nicotine CPA. 
Acquisition of a significant CPA was observed after one and two conditioning 
sessions, but surprisingly, a significant effect was lost after three conditioning sessions.  It 
is possible that some adaptation to the aversive stimuli occurred during the three day 
consecutive conditioning, thus decreasing the degree of CPA expression on test day. In the 
current study, mice were conditioned to mecamylamine for three consecutive days. Prior 
nicotine CPA studies conducted in rats used one (Suzuki et al., 1996; Suzuki et al., 1999; 
Ise et al., 2002; Malin et al., 2006) or four mecamylamine conditioning sessions on 
alternating days (O’Dell et al., 2007). In another recent study by Guillem et al. (2007), rats 
were treated for five consecutive conditioning sessions with no adaptation to the aversive 
stimuli; however, this study was conducted in rats, where species differences could be a 
factor. Conditioning sessions in the Guillem study were also shorter than our sessions, and 
were initiated 3 days after mini pump implantation; hence, differences in the level of 
41 
 
nicotine dependence are possible. Results also showed that 7 or 14 days of prior nicotine 
exposure was sufficient to obtain mecamylamine-precipitated aversion after a 30 minute, 
but not 60 minute conditioning session. The half-life of mecamylamine in the rodent is 
approximately 1 hour (Debruyne et al., 2003); therefore, it is possible that mecamylamine’s 
effects in the mouse began to diminish during the 60 minute conditioning session. In our 
study, a fairly high dose of mecamylamine (3.5 mg/kg) was necessary to precipitate a 
significant CPA. Significant aversion was not precipitated at 2 mg/kg mecamylamine; thus, 
it is possible that the half-life dose of mecamylamine is not sufficient to precipitate 
significant CPA in chronic nicotine infused mice.  
Results using different antagonists suggest the involvement of central, but not 
peripheral nicotinic receptor populations. While mecamylamine, a non-selective nicotinic 
receptor antagonist that acts on both central and peripheral nicotinic receptor populations, 
precipitated significant aversion in chronic nicotine infused mice, hexamethonium, a 
peripheral nicotinic receptor antagonist that does not cross the blood brain barrier, did not 
precipitate aversion at any dose tested. These results are consistent with studies which 
indicate that affective nicotine withdrawal signs are mediated solely by central nicotinic 
receptor populations (Watkins et al., 2000). Additionally, results suggest that the 2, but 
not the 7 nicotinic receptor subunit, is involved in development of nicotine CPA. DHE, 
a 2-selective antagonist, dose-dependently precipitated a significant CPA, while MLA did 
not precipitate CPA at a dose that effectively blocks 7 nicotinic receptors (Ward et al., 
1990). The current results are consistent with previous studies from our lab showing that 
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DHβE precipitates anxiety-related behavior in the plus maze test in nicotine-dependent 
mice (Damaj et al., 2003). It is also noted that DHβE was more potent than mecamylamine 
in this assessment, as DHβE was able to precipitate aversion at lower doses than 
mecamylamine. Taken together, the results suggest that 2-containing nicotinic receptor 
subtypes are involved in affective nicotine withdrawal behaviors and that CPA is a 
centrally mediated effect. To further evaluate these conclusions, a complementary 
approach using nAChR KO mice to evaluate nAChR subunit involvement in the CPA 
model is presented in chapters 3 and 4. 
Our evaluation using male and female B6 mice suggests that sex factors contribute 
to the development of nicotine withdrawal aversion. Mecamylamine precipitated a 
significant CPA in male, but not female B6 mice. Prior evaluations of female mice in 
nicotine withdrawal revealed that female mice did not express an anxiety-related response, 
suggesting that female mice are less sensitive to affective nicotine withdrawal (Kota et al., 
2008). Another explanation could be the influence of sex hormones. Indeed, sex hormones 
can modulate the effects of nicotine and may contribute to differences in nicotine’s 
responses between males and females (Damaj, 2001). Human studies also suggest that 
hormonal changes during different menstrual cycle phases impact severity of the nicotine 
withdrawal syndrome (Carpenter et al., 2006). In the current study, we did not control for 
the estrous cycle in female mice. Consequently, it is possible that the female mice were in 
different phases of the estrous cycle, thus impacting our results. Results also suggest that 
genotypic factors may contribute to development of nicotine CPA. While significant 
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aversion was precipitated in both male 129 and B6 mice, aversion appeared to more intense 
in B6 mice, although the difference in aversion scores was not significant. These results are 
consistent with results showing that physical nicotine withdrawal and anxiety-related 
behavior is more intense in B6 mice than 129 mice (Damaj et al., 2003). Studies testing 
additional mouse strains may be necessary to support a role for the involvement of 
genotypic factors in the development of nicotine CPA. 
 In our final assessment, results revealed a significant contribution of age to the 
development of significant aversion. Mecamylamine (3.5 mg/kg, s.c.) precipitated aversion 
in chronic nicotine infused adult, but not adolescent mice. Our findings are consistent with 
previous findings from Kota el al. (2007), showing that male adolescent mice are less 
sensitive to the affective measures of nicotine withdrawal than male adult mice, as 
adolescents do not express an anxiety-related response on the plus maze. Further, O’Dell et 
al. (2007) showed that CPA was lower in chronic nicotine infused adolescent rats versus 
adult rats using a biased experimental design. It is possible that adolescent rodents may be 
less able than adults to associate environmental cues with aversive nicotine withdrawal 
effects; however, the aforementioned study addressed this possibility using another 
aversive stimulus, lithium chloride (LiCl) injections. The effect was shown to be specific to 
nicotine withdrawal aversion, as there was no significant difference between adolescents 
and adults in learning place aversion to LiCl (O’Dell et al., 2007).  Additionally, in the 
current study, two conditioning sessions were used to acquire a nicotine CPA. The 
possibility that adolescent mice require more conditioning sessions to acquire a significant 
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CPA cannot be ruled out; however, such an assessment was beyond the scope of the 
current study.   
In summary, the results of our study demonstrate that our mouse nicotine 
withdrawal models are useful in assessing the pharmacological, biochemical, and genetic 
mechanisms associated with a motivational component of drug dependence. Further, due to 
sex and age differences that may confound our results, only male adult KO mice were used 
in our nicotine withdrawal assessments. The next several chapters will utilize the CPA 
model, as well as precipitated and spontaneous nicotine withdrawal models, to characterize 
nAChR involvement and post-receptor mechanisms that contribute to nicotine withdrawal 
behaviors. 
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THE ROLE OF α46β2* NICOTINIC RECEPTORS IN NICOTINE 
WITHDRAWAL 
 
A. Introduction 
 
The β2 nAChR subunit is a central, highly expressed subunit that coassembles with 
many subunits to form functional receptors, including 4, α5, and 6 nAChRs, in the 
mesocorticolimbic drug pathway on DA neurons and terminals (Wada et al., 1989, 1990; 
Le Novère and Changeux, 1995; Le Novère et al., 1996; Klink et al., 2001). The  α4α5β2* 
and α4α6β2* nAChR subtypes are involved in nicotine-stimulated DA release in the 
striatum (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). The α6 and α5 
nAChR subunits are also expressed in brain areas that have been implicated as having a 
role in nicotine dependence behaviors.  Expression of 6-containing nAChRs in the brain 
is largely confined to catecholaminergic nuclei, such as the VTA, SN, and LC ( Le Novère 
et al., 1996; Klink et al., 2001 ), while the more widely expressed α5 nAChR subunit is 
found in the cerebral cortex (Gerzanich et al., 1998), cerebellum, thalamus (Flora et 
al.,2002) , striatum (Zoli et al.,2002), hippocampus, SN, and VTA (Wada et al., 1990), as 
well as peripherally in sympathetic and parasympathetic ganglia (De Biasi, 2002).   
Studies have utilized the available nicotine withdrawal models to assess nAChR 
involvement in nicotine dependence behaviors, both pharmacologically, and using 
transgenic animals. The 2-selective antagonist DHE was shown to precipitate anxiety-
related behavior (Damaj et al., 2003) and elevations in reward threshold in chronic nicotine 
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infused rodents (Bruijnzeel and Markou, 2004), implicating a role for 2-containing 
nAChRs in affective withdrawal behaviors. The 6 subunit plays a role in the locomotor 
stimulating effects of nicotine (Le Novère et al., 1999), an effect suggested to be due to 
enhanced mesolimbic DA transmission (Benwell and Balfour, 1992). Furthermore, studies 
show that α5 KO mice are resistant to nicotine-induced seizures (Salas et al., 2003). While 
the available studies provide some insight into the nAChR subtypes involved in nicotine 
withdrawal, and suggest a possible role for these subunits in nicotine addictive behaviors, 
evidence of a behavioral role for β2, α5, and 6 nAChRs is still lacking. Despite the 
importance of affective signs in contributing to relapse, few studies address this aspect of 
withdrawal. Additionally, many studies utilize nAChR antagonists, which do not have high 
selectivity for specific subunits. A complementary approach would be the use of transgenic 
mice for specific nicotinic receptor subunits. Indeed, the use of nAChR KO mice provides 
greater specificity than would be achieved using current pharmacological agents.   
In the current study, using precipitated, spontaneous, and CPA models of nicotine 
withdrawal, we determined the contribution of the 2, α6, and 5 nAChR subunits in both 
physical and affective signs of nicotine withdrawal using β2 and α5 nAChR KO mice and 
the 6-selective nAChR antagonist -conotoxin H9A;L15A (MII[H9A;L15A]) (McIntosh 
et al., 2004). 
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B. Methods 
Animals 
Male B6 mice were obtained from Jackson Laboratories. Breeding pairs of mice lacking 
the 2 subunit of the nicotinic receptor (B6 background) and WT littermates were shipped 
from Institut Pasteur, Paris, France (see Picciotto et al., 1995 for information regarding 
initial breeders).  Mice null for the 5 nicotinic receptor subunit (B6 background) and WT 
littermates were shipped from Baylor College of Medicine, Houston, Texas (see Salas et 
al., 2003 for information regarding initial breeders).  For all experiments, 5 KO mice 
were backcrossed to at least 8-10 generations, and 2 KO mice were backcrossed at least 
10-12 generations.  Mutant and WT controls were obtained from crossing HT mice. This 
breeding scheme controlled for any irregularities that might occur with crossing solely 
mutant animals.  
Drugs 
 (-)-Nicotine hydrogen tartrate salt and mecamylamine hydrochloride were purchased from 
Sigma-Aldrich Inc. (St. Louis, MO, USA). Drugs were dissolved in physiological saline 
(0.9% sodium chloride) and injected s.c. at a volume of 10 ml/kg body weight. All doses 
are expressed as the free base of the drug. The 6*-selective antagonist, MII[H9A;L15A], 
was synthesized as previously described in  McIntosh et al. (2004). The highest dose for 
MII[H9A;L15A] (30 pmol) intracerebroventricular (i.c.v.) injection was calculated based 
on the functional IC50 at the α6 subunit (McIntosh et al., 2004). 
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Chronic nicotine administration 
Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model 
2004 (28 days) Durect Corporation,
 
Cupertino, CA] filled with saline or (-)-nicotine (36 
mg/kd/day) as described in Chapter 2.  
I.c.v. surgery 
Mice were anesthetized with sodium pentobarbital (45 mg/kg, i.p.) on the evening prior to 
testing, and a scalp incision was made to expose the bregma. Unilateral injection sites were 
prepared using a 26-gauge needle with a sleeve of polyurethane (PE) tubing to control 
depth of the needle at a site 2 mm rostral and 2 mm lateral to the bregma at a depth of 2 
mm. Animals were sutured in such a way to enable an injection volume of 5 µl using a 26-
gauge needle with a sleeve of PE tubing into the lateral ventricle on the morning of testing. 
The needle was held in place for 20 seconds to ensure drug delivery. 
Nicotine withdrawal assessment 
Mice were implanted with mini pumps containing nicotine or saline for 14 days. On the 
morning
 
of day 15, mice were injected with mecamylamine
 
(2 mg/kg, s.c.) or saline, and 
withdrawal signs were measured
 
10 minutes after injection.  The mice were first evaluated 
for 5 minutes in the plus maze test for anxiety-related behavior. The mice were then 
observed for somatic signs of withdrawal for 20 minutes. Hyperalgesia was evaluated 
immediately after the somatic sign observation period.  The specific testing sequence was 
chosen based on prior studies from the lab showing that this order of testing reduced 
within-group variability and produced the most consistent results. For spontaneous 
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withdrawal studies, mini pumps were removed on the morning of day 14 and testing was 
initiated 18-24 hours later, on day 15.  
Elevated plus maze. An elevated plus-maze, prepared with grey
 
Plexiglas, consisted of two 
open arms (23 x 6.0 cm) and two
 
enclosed arms (23 x 6 x 15 cm in wall height) that 
extended
 
from a central platform (5.5 x 5.5 cm). It was mounted on a
 
base raised 60 cm 
above the floor. Fluorescent lights (350 lux
 
intensity) located in the ceiling of the room 
provided the only
 
source of light to the apparatus.  The animals were placed in
 
the center of 
the maze, and allowed to roam freely between the open and closed arms. The time spent in 
the open and closed arms
 
was automatically recorded by a photocell beam system.  The
 
test 
lasted 5 minutes, and the apparatus was thoroughly cleaned
 
after removal of each animal.  
A decrease in the amount of time spent on the open arms was indicative of increased 
anxiety-related behavior.  Results were expressed as the mean  S.E.M. number of seconds 
spent in the open arms. As a control, the number of times each animal crossed from one 
side of the plus maze to the other was measured, noted as the total average number of arm 
crosses.  This was to ensure that the reduction in time spent on the open or closed arms was 
not a reflection of a lack of overall activity. 
Somatic signs. Mice were observed for 20 minutes in empty transparent activity
 
cages (32 x 
18 cm) for typical somatic withdrawal behaviors. Typical nicotine withdrawal signs that 
were tallied included
 
head shakes, paw tremors, body tremors, and backing. Ptosis, curls, 
and jumps were also tallied collectively as “other” somatic signs. Results were expressed 
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as the mean ± S.E.M. number of signs displayed by mice
 
during the 20 minute observation 
period. 
Hyperalgesia. The nicotine withdrawal-induced hyperalgesia response was evaluated using 
the hot plate test (Thermojust
 
Apparatus). The hot plate is a rectangular heated surface 
surrounded by plexiglass and maintained at 52°C. The device is connected to a manually 
operated timer that records the amount of time the mouse spends on the heated surface 
before showing signs of nociception (e.g. jumping, paw licks). The timer has an automatic 
cut-off of 40 seconds to avoid tissue damage. A decreased latency on the hot plate was 
counted as increased pain sensitivity (hyperalgesia). Results were expressed as the mean  
S.E.M. latency (reaction time for jumping or paw-licking) displayed by the mice.  
Nicotine CPA 
β2 and α5 assessment 
Mecamylamine-precipitated CPA for 2 and α5 KO mice was conducted using male KO 
and WT littermates as described in Chapter 2.  
α6 assessment 
 
After the mecamylamine conditioning session on the evening of day 3, i.c.v. injection sites 
were prepared. On day 4, mice received i.c.v. injections of vehicle or MII[H9A;L15A] 
(22.5 or 30 pmol),  5 minutes before being placed in the test chambers.  
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 Statistical analysis 
For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA). 
Studies using transgenic mice were analyzed with two-way ANOVAs [with genotype and 
treatment as between subject factors] using the Neuman-Keuls post-hoc test. p values of 
less than 0.05 were considered significant.  
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C. Results 
Evaluation of affective and physical signs of nicotine withdrawal using the precipitated  
 
model 
 
 To assess the involvement of specific nAChR subtypes in nicotine withdrawal, a 
nicotine withdrawal model was adapted to allow measurement of both physical and 
affective aspects of nicotine withdrawal in one setting. Mecamylamine (2 mg/kg, s.c.) 
precipitated significant nicotine withdrawal signs in mice chronically exposed to nicotine 
(36 mg/kg/day) for 14 days (Fig. 7). Results show a significant reduction in the amount of 
time spent on the open arms of the elevated plus maze in chronic nicotine infused mice 
treated with mecamylamine when compared to control groups, indicating an anxiety-
related response in these mice (Fig. 7A).  The average number of arm crosses was tallied as 
a measure of locomotor activity on the plus maze. No significant difference in the number 
of crosses between arms was noted between groups, suggesting that the decrease in open 
arm time was not attributed to reduced activity on the plus maze (Table 1).  Nicotine-
dependent mice also showed enhanced nicotine withdrawal somatic signs after 
mecamylamine injection (Fig. 7B), as well as significant nicotine-withdrawal induced 
hyperalgesia as measured by a decreased latency on the hot plate compared to saline 
controls (Fig. 7C).  Saline mini pump mice that received an injection of mecamylamine and 
nicotine mini pump mice that received an injection of saline on test day did not differ from 
saline-saline control animals, indicating that the mecamylamine dose utilized did not 
produce effects on its own, and that the nicotine mini pump mice were not experiencing 
nicotine withdrawal on test day.  
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Figure 7. Assessment of physical and affective nicotine withdrawal signs in B6 mice 
using the precipitated model. After treatment with mecamylamine (2 mg/kg, s.c.) on 
test day, nicotine-dependent mice show A. anxiety-related behavior noted by a 
reduction in the time spent on the open arms, B. significant somatic signs, and C. 
withdrawal-induced hyperalgesia, noted by a decreased latency on the hotplate. Each 
point represents the mean  S.E.M. of 8 mice per group. * denotes p < 0.05 vs. control 
groups.  
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Table 1: Total average number of arm crosses in the plus maze after precipitated 
nicotine withdrawal.  
 
Using the precipitated model, nicotine-dependent mice were treated with 
mecamylamine (2 mg/kg, s.c.) on test day (day 15), and the total number of crosses 
between open and closed arms of the plus-maze test was counted.  Numbers are 
presented as the total average number of arm crosses  SEM for 8 mice per group. 
 
 
 
B6  mice Sal-Sal Sal-Mec Nicotine-Sal Nicotine-Mec 
 3.7   0.64 4.2  0.67 3.3  0.42 4.2  0.51 
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Role of the 2 nAChR subunit in nicotine withdrawal 
 The 14 day – precipitated nicotine withdrawal model was used to measure the 
affective and physical signs of nicotine withdrawal in chronic nicotine infused β2 KO 
mice.  Results in Figure 8A show that chronic nicotine infused β2 KO mice displayed a 
loss of withdrawal induced anxiety-related behavior when compared to WT counterparts, 
indicated by no difference in the amount of time spent on the open arms of the place maze 
compared to control animals. No significant difference in the number of arm crosses 
between groups was noted (Table 2). However, chronic nicotine infused β2 KO and WT 
mice both displayed significantly more somatic signs than saline infused WT and KO mice 
(Fig. 8B) and displayed a similar decrease in hot plate latency, indicating a significant 
hyperalgesia response (Fig. 8C).  Saline control β2 KO mice did not differ from WT 
counterparts in any withdrawal test. 
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Figure 8. The 2 nAChR subunit is involved in the affective signs, but not the physical 
signs of nicotine withdrawal. When compared to WT chronic nicotine infused mice, 
chronic nicotine infused 2 KO mice show A. no reduction in the time spent on the 
open arms of the plus maze, indicating a loss of anxiety-related behavior, but B. 
significant nicotine withdrawal somatic signs and C. a decreased hotplate latency, 
indicating the presence of the hyperalgesia response. Each point represents the mean 
 S.E.M. of 8 mice per group. * denotes p < 0.05 vs. saline groups and vs. nicotine KO 
group for the plus maze test.  
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Table 2: Total average number of arm crosses in the plus maze test after precipitated 
nicotine withdrawal in β2 and α5 KO mice.  
 
Using the precipitated model, chronic nicotine infused mice were treated with 
mecamylamine (2 mg/kg, s.c.) on test day (day 15), and the total number of crosses 
between open and closed arms of the plus-maze test was counted.  Numbers are 
presented as the total average number of arm crosses  SEM for 8 mice per group.  
 
2 mice Sal-WT Sal- KO Mec-WT Mec-KO 
 3.6  0.59 3.6  0.32 4  0.46 3.3  0.59 
5 mice Sal –WT Sal- KO Mec-WT Mec-KO 
 2.8  0.51 3  0.49 3.3  0.42 3.2  0.40 
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Assessment of 2 nAChR KO mice in a spontaneous withdrawal model       
It was important to demonstrate that the precipitated nicotine withdrawal behaviors 
observed in transgenic mice were not an assessment of the mecamylamine-dependent 
behavioral effects on specific nAChR subunits. Therefore, we used the spontaneous 
withdrawal model to assess nicotine withdrawal signs in 2 KO mice 18-24 hours after 
withdrawal from nicotine. Results of the spontaneous withdrawal assessment in 2 KO 
mice are shown in Figure 9. As observed in the mecamylamine-precipitated model, 
nicotine- withdrawn 2 KO mice displayed significant somatic signs and hyperalgesia, but 
a loss of anxiety-related behavior after cessation of nicotine treatment.   
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Figure 9.  Assessment of nicotine withdrawal signs in 2 nAChR KO mice using the 
spontaneous withdrawal model. 2 KO mice withdrawn from nicotine 18-24 hours 
show A. a loss of anxiety-related behavior on the plus maze, indicated by the lack of a 
reduction in the time spent on the open arms, but B. significant somatic signs, and C. 
withdrawal-induced hyperalgesia, indicated by a decreased hotplate latency. Each 
point represents 8 mice per group. * denotes p< 0.05 vs. saline groups. 
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Role of the α5 nAChR subunit in nicotine withdrawal 
 The evaluation of nicotine withdrawal in α5 KO mice is shown in figure 10. 
Chronic nicotine infused WT and α5 KO mice spent significantly less time on the open 
arms of the elevated plus maze compared to saline infused WT and KO mice, indicating 
the presence of an anxiety-related response (Fig. 10A, Table 2). Somatic sign observation 
of chronic nicotine infused α5 KO mice revealed a significant reduction in paw tremors, 
backing, and total somatic signs compared to chronic nicotine infused WT littermates (Fig. 
10B) Both WT and α5 KO chronic nicotine infused mice displayed a decreased latency on 
the hot plate, indicating a significant hyperalgesia response (Fig. 10C).  There were no 
significant differences between saline infused KO and WT mice for any withdrawal test.   
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Figure 10. The 5 nAChR subunit plays a role in some physical aspects of nicotine 
withdrawal, but not the affective signs. Nicotine-dependent 5 KO mice show A. 
significant anxiety-related behavior in the plus maze test, indicated by a reduction in 
time spent on the open arms, but B. display a significant reduction in total average 
number of somatic signs when compared to WT counterparts. C. The nicotine-
induced hyperalgesia response is still present in 5 KO mice, indicated by a decreased 
hotplate latency. Each point represents the mean ± S.E.M. of 6-8 mice per group.  * 
denotes  p < 0.05 vs. saline groups. +  denotes p < 0.05 vs. saline groups and vs. WT 
mec group 
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Role of the α6 nAChR subunit in nicotine withdrawal 
The role of 6*nAChRs in physical and affective nicotine withdrawal signs was 
evaluated using a spontaneous withdrawal model. As expected, nicotine withdrawn mice, 
compared to saline infused mice, spent significantly less time on the open arms of the plus 
maze, indicating withdrawal-associated anxiety-like behavior, exhibited decreased latency 
on the hot plate, indicating a withdrawal-induced hyperalgesia response, and displayed 
indications of somatic withdrawal (Fig. 11).  
 Pretreatment with the highest (30 pmol) dose of MII[H9A;L15A], blocked the 
expression of an anxiety-related response in nicotine-withdrawn mice. There was no 
significant difference in time spent on the open arms of the plus maze between saline 
infused mice and animals infused with MII[H9A;L15A] (Fig. 11A). The average number 
of arm crosses was tallied as a measure of locomotor activity on the plus maze. There was 
no significant difference between mice treated with vehicle and 30 pmol MII[H9A;L15A], 
suggesting that the observed effects on the plus maze were not the  result of a difference in 
activity (veh= 2.4   0.3 vs. 30 pmol= 2.4  0.7, p=0.91). 
 Somatic withdrawal assessment revealed that nicotine-withdrawn mice treated with 
vehicle, 22.5 or 30 pmol MII[H9A;L15A] i.c.v. displayed significantly more total somatic 
signs than saline infused mice,  indicating that MII[H9A;L15A] had no effect on somatic 
withdrawal at any dose tested (Fig. 11B). The hot plate assessment also revealed a 
significant hyperalgesia response in all nicotine-withdrawn mice compared to saline 
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exposed mice, regardless of i.c.v. injection, indicating that MII[H9A;L15A] had no effects 
on the nicotine withdrawal-induced hyperalgesia response at the doses tested (Fig. 11C). 
Saline infused mice treated with 30 pmol MII[H9A;L15A] i.c.v. did not differ from saline 
infused mice treated with vehicle i.c.v. in any behavioral test, indicating that the antagonist 
at the highest dose used was not behaviorally active by itself (Fig. 11). 
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Figure 11. MII[H9A;L15A] dose-dependently blocks expression of the nicotine 
withdrawal-induced anxiety-related response in mice. Nicotine withdrawn mice 
treated with 30 pmol MII[H9A;L15A] display A. a loss of anxiety-related response, 
but B. no change in average number of somatic signs or C. hyperalgesia response. 
Each point represents the mean  S.E.M. of 12 mice per group.  * denotes p< 0.05 vs. 
saline groups; + denotes p< .05 vs. 30 pmol MII[H9A;L15A] 
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Role of the 2, 5, and 6 nAChR subunits in affective signs using the CPA model 
In Chapter 2, we adapted a nicotine CPA model to further assess affective 
withdrawal signs in transgenic mice. Our CPA assessment using 2 and 5 nAChR KO 
mice, and the α6 selective antagonist MII[H9A;L15A], are shown in Figures 12 and 13 
respectively. There was a loss of significant CPA in chronic nicotine infused 2 KO mice 
(Fig. 12A).  In contrast, mecamylamine precipitated CPA was present in chronic nicotine 
infused 5 KO mice (Fig. 12B). In the α6 assessment, mecamylamine precipitated CPA in 
chronic nicotine infused mice treated with vehicle (Fig. 13). MII[H9A;L15A], however, 
dose-dependently blocked expression of aversion in nicotine-infused mice. Pre-treatment 
with 30 pmol, but not 22.5 pmol MII[H9A;L15A],  on test day blocked the expression of 
mecamylamine-precipitated CPA in nicotine-dependent  mice (Fig. 13).  
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Figure 12. Assessment of the role of the 2 and 5 nAChR subunits in affective 
nicotine withdrawal signs using the CPA model. A. Nicotine-dependent 2 KO mice 
show a loss of significant CPA; however, B. 5 nAChR KO mice express 
mecamylamine-precipitated CPA. Each point represents the mean ± S.E.M. of 8-10 
mice per group.  * denotes p < 0.05 vs. saline groups and vs. mec KO group in the 2 
assessment. 
 
67 
 
 
-200
-150
-100
-50
0
50
100
150
sal - vehicle
sal -  30 pmol, MII[H9A; L15A]
nic - vehicle
nic - 22.5 pmol, MII[H9A; L15A]
nic - 30 pmol MII[H9A; L15A]
*
*
 
Figure 13. Assessment of the role of the α6 nAChR subunit in affective nicotine 
withdrawal signs using the CPA model. Nicotine-infused mice treated with 30, but not 
22.5 pmol MII[H9A;L15A], did not express significant CPA. The 30 pmol dose of 
MII[H9A;L15A] had no effect in saline treated mice. Each point represents the mean 
 S.E.M. of 12 mice per group.* denotes p< 0.05 vs. saline and 30 pmol 
MII[H9A;L15A] treated groups. 
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D. Discussion 
The major goal of this study was to determine the role of major nAChR subtypes in 
the physical and affective signs of nicotine withdrawal. Therefore, using precipitated, 
spontaneous, and CPA nicotine withdrawal models to measure both physical and affective 
signs of nicotine withdrawal, we found a loss of anxiety-related behavior and nicotine 
withdrawal aversion, but normal physical withdrawal in β2 KO mice and in mice after pre-
treatment with the selective α6 antagonist, MII[H9A;L15A], suggesting that β2 and α6 
containing nAChRs are involved in affective, but not physical nicotine withdrawal. Studies 
with α5 KO mice revealed a reduction in somatic signs, but normal hyperalgesia and 
affective withdrawal, suggesting a role for the α5 subunit in the somatic signs associated 
with nicotine withdrawal. 
Before proceeding with our studies using KO mice, we adapted a nicotine 
withdrawal model that would allow us to measure both physical and affective nicotine 
withdrawal signs in one setting. Results showed that mecamylamine precipitates anxiety-
related behavior, somatic signs, and hyperalgesia in chronic nicotine infused mice. The 
half-life of mecamylamine in the rodent is approximately 1 hour (Debruyne et al., 2003). 
We were able to effectively measure one affective and two physical nicotine withdrawal 
signs within this one hour time frame. Our spontaneous withdrawal test using transgenic 
mice also confirmed that the observed precipitated- withdrawal behavioral effects were not 
an assessment of mecamylamine-dependent effects on nAChR subunits.  
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Results suggest that 2 nAChRs are involved in affective, but not physical nicotine 
withdrawal. There was no reduction in somatic signs and hyperalgesia was present in 
nicotine-withdrawn 2 KO mice. These data are consistent with previous studies assessing 
the role of 2 nAChRs in somatic signs of nicotine withdrawal using 2 KO mice (Salas et 
al., 2004; Besson et al., 2006). Both studies found that mecamylamine precipitated nicotine 
withdrawal somatic signs in chronic nicotine infused 2 KO mice in a similar fashion to 
what was observed in nicotine-infused WT littermates; however, neither study measured 
affective signs in β2 KO mice. In the current study, we assessed two affective signs of 
nicotine withdrawal in 2 KO mice and found that 2 KO mice displayed a lack of 
anxiety-related behavior in the plus maze, as well as a lack of mecamylamine-precipitated 
aversion in the CPA model. Our studies using transgenic mice are complemented by 
previous pharmacological nicotine withdrawal studies which utilized the 2-selective 
antagonist, DHβE, to precipitate anxiety-related behavior and elevations in reward 
threshold, also measures of affective signs of nicotine withdrawal (Damaj et al., 2003; 
Bruijnzeel and Markou, 2004). Further, in the previous chapter, our pharmacological 
studies showed that DHβE dose-dependently precipitated aversion in the CPA model. Due 
to the issue of compensation in transgenic animals, the complementary pharmacological 
approach strengthens our interpretation of the current results. Taken together, these studies 
suggest an important role for 2-containing nicotinic receptors in affective nicotine 
withdrawal behaviors.  
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Central administration of the selective α6 antagonist, MII[H9A;L15A], had no 
effect on physical withdrawal, but dose-dependently blocked anxiety-related behavior in 
the plus maze, as well as expression of aversion in the CPA model. These results indicate a 
role for 6 receptors in affective, but not physical nicotine withdrawal behaviors. 
Interestingly, 22.5 pmol MII[H9A;L15A] had no effect on the expression of CPA; 
however, 30 pmol MII[H9A;L15A], a dose not more than half, significantly blocked the 
effect. Currently the in vivo pharmacokinetics of MII[H9A;L15A] are not known; thus, it is 
possible that, like nicotine, the drug has a sharp dose response curve and produces its 
effects at a narrow range of concentrations. The LC, in addition to the VTA, has abundant 
α6 receptor expression, and both areas have been implicated in withdrawal from drugs of 
abuse. Studies show that intra-LC injections of a D1 receptor agonist attenuated morphine 
withdrawal signs in rats (Dizgah et al., 2005). Further, the α6* nAChR is expressed with 
the α4β2* subtype (Wada et al., 1989, 1990; Klink et al., 2001), and the current study, 
along with previous studies, suggests that β2*nAChRs are critical for affective, but not 
physical withdrawal (Damaj et al., 2003; Besson et al., 2006; Jackson et al., 2008). Taken 
together, these results suggest a role for the α4α6β2* nAChR subtype in affective nicotine 
withdrawal. 
The role of the 5 nAChR subunit in nicotine withdrawal has not previously been 
addressed. Assessment of the 5 subunit showed a reduction in somatic signs in chronic 
nicotine infused 5 KO mice after mecamylamine treatment, while anxiety-related 
behavior and hyperalgesia were still present.  Additional evaluation of affective signs 
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revealed the expression of mecamylamine-precipitated aversion in 5 KO mice.  These 
findings suggest that the 5 subunit is involved to an extent in some physical aspects of 
nicotine withdrawal, but not affective nicotine withdrawal signs.  It has been reported that 
the 4 subunit is involved in the physical signs of nicotine withdrawal, as nicotine-infused 
β4 KO mice displayed a significant reduction in somatic signs and a significant loss of 
hyperalgesia in the tail-flick, but not the hot plate assessment (Salas et al., 2004). Spinal 
and supraspinal nAChR populations mediate the hyperalgesia response (Schmidt et al., 
2001; Damaj et al., 2002). While the hot plate assessment involves supraspinal receptor 
populations, the tail-flick test measures responses from spinal receptor populations. The 4 
subunit is coexpressed with the 3 and 5 subunits in the peripheral ganglia (Salas et al., 
2004).  This may explain why there was an effect for β4 in the tail-flick, but not the hot 
plate assessment, as well as why the hyperalgesia response was present using the hot plate 
in our α5 assessment. Somatic signs of nicotine withdrawal were also shown to be partially 
mediated by peripheral nAChR populations; therefore, we propose that ganglionic 54*-
containing nAChR subtypes mediate somatic signs of nicotine withdrawal. This hypothesis 
is evaluated further in the next chapter. Because the 5 subunit can co-assemble with both 
2 and 4 nAChRs, it is likely that the role of 5 in nicotine withdrawal differs depending 
on nAChR subunit composition.   
As mentioned, one of the problems in interpretation of results obtained with KO 
mice is whether compensatory changes in expression of other genes occur as a result of 
deletion of a particular gene. Although this issue has not yet been directly explored with 
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the nicotinic KO mice, it should be noted that behavioral differences observed with these 
KO mice were reproduced using various nicotinic antagonists, at least for the α7 and 2 
subunits, as seen in the next chapter and previous chapter respectively, as well as with 
previous studies from the lab (Damaj et al., 2003). In addition, no compensatory changes of 
other nicotinic subunits were reported in these particular KO strains (Orr-Urtreger et al., 
1997; Salas et al, 2004; Picciotto et al., 1995).  Although we cannot completely rule out 
effects on other systems, these findings argue against a role for compensatory changes and 
suggest a direct role for these subunits in nicotine withdrawal.  
Additionally, the issue of selectivity of nAChR agonists and antagonists has also 
produced some difficulty in data interpretation. While several -conotoxins have affinity for 
both 3 and 6 nAChR subunits, MII[H9A;L15A] is a much more potent at 6* than at the 
3* nAChRs (McIntosh et al., 2004). In the current study, we injected 22.5-30 pmol of 
peptide. Based on diffusion studies by Matta et al. (1995), the highest dose (30 pmol) would 
correspond to a tissue concentration of ~ 1.2 M.  At 1 M, MII[H9A;L15A] has no effect 
on , or  nAChRs.  The peptide is also > 2000-fold selective for 
6/323 nAChRs compared to  and  nAChRs.  The IC50 at  and  
nAChRs is 4.8 M and 7.8 M respectively; thus, at concentrations used, there would be 
significantly less blockade of these receptor subtypes. The IC50 at  and  
nAChRs is 2.4 nM and 270 nM respectively (McIntosh et al., 2004); therefore, at the 
concentrations used in our studies, selective block of 6* nAChRs is expected.   
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 The results of this study present a role for β2 and 6-containing nAChRs in 
affective nicotine withdrawal. In addition, the present findings indicate that the α5 subunit 
is not essential for affective withdrawal. Together with previous studies, these data suggest 
that 62* and/ or α4α6β2*, but not α4α5β2* nAChR subtypes, are critical for affective 
withdrawal. An examination of Ca
2+
-dependent post-receptor mechanisms that contribute 
to these behavioral effects is addressed in Chapter 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
IDENTIFICATION OF ADDITIONAL NICOTINIC RECEPTOR SUBUNITS  
 
INVOLVED IN NICOTINE WITHDRAWAL 
A. Introduction 
 
 In the previous chapter, we began our identification of nAChR subunits involved in 
nicotine withdrawal with the β2, α5, and α6 nAChRs. We began our assessment with the 
β2 nAChR because it is a central, highly expressed subunit that has been implicated in 
several nicotine dependence behaviors, including reward and reinforcement (Picciotto et 
al., 1995; Walters et al., 2006). The α4, α5, and α6 nAChR subunits coassemble with β2 
nAChRs to form functional receptors that are involved release of DA (Champtiaux et al., 
2003; Salminen et al., 2004; Lai et al., 2005), a neurotransmitter involved in behaviors 
associated with nicotine dependence.  
The homomeric 7 nAChR is also a major subtype found on neurons in the 
mesocorticolimbic drug pathway, and has been implicated in physical withdrawal 
behaviors. Pharmacologically, MLA, an 7 antagonist, was shown to precipitate mild 
somatic signs (Damaj et al., 2003) and changes in locomotor activity (Nomikos et al., 
1999).  Nicotine-withdrawn 7 KO mice also did not display withdrawal-induced 
hyperalgesia or decreases in locomotor activity (Grabus et al., 2005). A role for β4* 
nAChRs has also been suggested. It was shown that 4 KO mice do not display somatic 
signs or hyperalgesia after nicotine withdrawal (Salas et al., 2004).  The α3 subunit is 
coexpressed with α5 and β4 nAChRs in the peripheral ganglia, MHb, and IPN (Wada et al., 
1990; Zoli et al., 1995; Quick et al., 1999; Whiteaker et al., 2002). Further, α3 nAChR 
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subunits are expressed in brain areas that have been implicated as having a role in nicotine 
dependence behaviors, and can coassemble with β2 nAChRs to form functional receptors 
on DA neurons and terminals (Le Novère and Changeux, 1995; Le Novère et al., 1996; 
Klink et al., 2001).  In Chapter 3, our assessment of α5 KO mice in withdrawal revealed 
that α5 KO mice display a significant reduction in somatic signs, but normal affective 
withdrawal, suggesting a role for this subunit in somatic nicotine withdrawal. Recent 
genetic studies suggest that a common haplotype in the CHRNA5/CHRNA3/CHRNB4 
gene cluster, which codes for the α5, α3, and β4 subunits respectively, predisposes to 
nicotine dependence (Berrettini et al., 2008).  
Evidence of a behavioral role for α7 and α3 nAChRs  in nicotine dependence is still 
lacking; thus, the goal of this research was to determine the role of α7 and α3  nAChRs in 
nicotine withdrawal behaviors. Using α7 KO mice, the α6/α3β2* selective antagonist α-
conotoxin MII (MII) , and  the α3β4* selective antagonist α-conotoxin AuIB (AuIB),  we  
questioned 7, α3β2*, and  α3β4* nAChR contributions to nicotine withdrawal using the 
precipitated, spontaneous, and CPA models.  Because the α3 subunit has been shown to 
coassemble with both β2 and β4 nAChRs in the brain, the use of two antagonists, which 
differentiate between α3β2* and α3β4* nAChR subtypes , would also allow us distinguish 
between α3 coassembly with the  β4 and β2 nAChR subunits in nicotine withdrawal. 
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B.  Methods 
Animals 
Male B6 mice were purchased from Jackson Laboratories. Mice lacking the 7 subunit of 
the nicotinic receptor (B6 background) and WT littermates were purchased from Jackson 
Laboratories (B6.129S7-charna7tm1bay, number 003232; see Orr-Urtreger et al., 1997 for 
information regarding initial breeders). For all experiments 7 KO mice were backcrossed 
to at least 8-10 generations and maintained on a breeding scheme as discussed in Chapter 
3.  
 
Drugs  
 
(-)-Nicotine hydrogen tartrate salt and mecamylamine hydrochloride were purchased from 
Sigma-Aldrich Inc. (St. Louis, MO, USA). The α6/α3β2*-selective antagonist MII and the 
α3β4*-selective antagonist AuIB were synthesized as described in Cartier et al., 1996 and 
Luo et al., 1998 respectively. The compounds were dissolved in physiological saline (0.9% 
sodium chloride) and administered to each animal by i.c.v. injection. The highest doses for 
MII (8 pmol) and AuIB (18 pmol) i.c.v. injections were calculated based on the functional 
IC50s of each at its respective subtypes (Cartier et al., 1996; Luo et al., 1998).  
Chronic nicotine administration 
Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model 
2004 (28 days) Durect Corporation,
 
Cupertino, CA] filled with saline or (-)-nicotine (36 
mg/kd/day) as described in Chapter 2.  
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I.c.v. surgery 
I.c.v. surgery and injection was performed as described in Chapter 3. Briefly, a scalp 
incision was made to expose the bregma, and unilateral injection sites were prepared using 
a 26-gauge needle with a sleeve of PE tubing to control depth of the needle at a site 2 mm 
rostral and 2 mm lateral to the bregma at a depth of 2 mm. On the morning of testing, a 
volume of 5 µl using a 26-gauge needle with a sleeve of PE tubing was injected into the 
lateral ventricle and held in place for 20 seconds to ensure drug delivery. 
 
Nicotine withdrawal assessment 
Studies using α7 KO mice were conducted using the precipitated withdrawal assessment as 
described in Chapter 3. In brief, α7 KO mice were treated with mecamylamine (2 mg/kg, 
s.c.) on the morning of day 15, 10 minutes before testing. Studies using MII and AuIB 
were conducted using the spontaneous withdrawal model as described in Chapter 3. Mice 
were injected i.c.v. with vehicle, MII (2.5 or 4 pmol), or AuIB (15 or 18 pmol) on the 
morning of day 15, 18-24 hours after mini pump removal, and withdrawal signs were 
measured 5 minutes after injection. Spontaneous withdrawal experiments were conducted 
using the same testing scheme as mentioned with precipitated studies. 
Nicotine CPA  
α7 assessment 
Mecamylamine-precipitated CPA for α7 KO mice was conducted using male KO and WT 
littermates as described in Chapter 2.  
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α3β2*  and α3β4* assessment 
After the mecamylamine conditioning session on day 3, i.c.v. injection sites were prepared. 
On day 4, mice received i.c.v. injections of vehicle, MII (2.5 or 4 pmol), or AuIB (15 or 18 
pmol), 5 minutes before being placed in the test chambers.  
Statistical analysis 
For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA). 
Studies using transgenic mice were analyzed with two-way ANOVAs [with genotype and 
treatment as between subject factors] using the Neuman-Keuls post-hoc test. p values of 
less than 0.05 were considered significant.  
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C. Results 
Role of the α7 nAChR subunit in nicotine withdrawal 
 The role of α7 nAChR receptors in nicotine withdrawal is shown in Figure 14.  
Chronic nicotine infused WT and α7 KO mice spent significantly less time on the open 
arms of the plus maze than saline infused mice, indicating the presence of an anxiety-
related response (Fig. 14A). No significant difference in the number of arm crosses 
between groups was noted (Table 3). Significant withdrawal somatic signs were also 
observed in chronic nicotine infused WT and α7 KO mice (Fig. 14B).  Significant 
hyperalgesia was observed in chronic nicotine infused WT mice after mecamylamine 
treatment; however, chronic nicotine infused α7 KO mice showed a loss of nicotine-
withdrawal induced hyperalgesia, indicated by no significant decrease in hot plate latency 
compared to saline controls (Fig. 14C). Saline infused KO mice did not differ from WT 
counterparts in any withdrawal test. 
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Figure 14. The 7 nAChR subtype is involved in some physical aspects of nicotine 
withdrawal, but not the affective signs. Chronic nicotine infused 7 KO mice showed 
A. a reduction in the time spent on the open arms of the plus maze, indicating an 
anxiety-related response, and B. significant nicotine withdrawal somatic signs. 
However, C. a loss of nicotine withdrawal-induced hyperalgesia response, as noted by 
the lack of a decrease in hotplate latency, was observed in chronic nicotine infused 7 
KO mice when compared to WT counterparts. Each point represents the mean  
S.E.M. of 8 mice per group. * denotes p< 0.05 vs. saline groups and vs. nicotine KO 
group for the hyperalgesia test.  
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Table 3: Total average number of arm crosses in the plus maze test after precipitated 
nicotine withdrawal in α7 KO mice.  
 
Using the precipitated model, chronic nicotine infused mice were treated with 
mecamylamine (2 mg/kg, s.c.) on test day (day 15), and the total number of crosses 
between open and closed arms of the plus-maze test was counted.  Numbers are 
presented as the total average number of arm crosses  SEM for 8 mice per group.  
 
7 mice Sal-WT Sal- KO Mec-WT Mec-KO 
 2.7  0.42 3.5  0.48 3  0.53 2.7  0.28 
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Assessment of 7 nAChR KO mice in a spontaneous withdrawal model       
It was important to demonstrate that the precipitated nicotine withdrawal behaviors 
observed in transgenic mice were not an assessment of the mecamylamine-dependent 
behavioral effects on specific nAChR subunits. Therefore, we used the spontaneous 
withdrawal model to assess nicotine withdrawal signs in 7 KO mice 18-24 hours after 
withdrawal from nicotine. Spontaneous withdrawal studies using 7 KO mice were 
comparable to mecamylamine-precipitated studies as shown in Figure 15. Nicotine-
withdrawn 7 KO mice showed significant somatic signs and anxiety-related behavior, but 
no withdrawal-induced hyperalgesia response. 
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Figure 15.  Assessment of nicotine withdrawal signs in 7 nAChR KO mice using the 
spontaneous withdrawal model. 7 KO mice withdrawn from nicotine 18-24 hours 
show A. anxiety-related behavior on the plus-maze, indicated by a reduction in the 
time spent on the open arms, and B. significant somatic signs, but C. a loss of 
withdrawal-induced hyperalgesia, noted by the lack of a decreased hotplate latency. 
Each point represents 8 mice per group. * denotes p< 0.05 vs. saline groups. 
 
 
 
 
84 
 
Role of α3β2* nAChRs in nicotine withdrawal 
  To evaluate the role of α3β2* nAChRs in nicotine withdrawal, we used the 
α6/α3β2* selective antagonist, MII. In Chapter 3, the α6-selective antagonist, 
MII[H9A;L15A], was used to evaluate the role of α6-containing nAChRs in nicotine 
withdrawal. MII[H9A;L15A] is able to effectively discriminate between α3 and α6 
nAChRs; thus, we used MII, which has significantly less selectivity for α6-containing 
nAChRs than MII[H9A;L15A] (McIntosh et al., 2004), to separate the α6 component, and 
assess the role of α3β2* nAChRs in nicotine withdrawal. Results show that MII dose-
dependently blocked an anxiety-related response in nicotine-withdrawn mice (Fig. 16A). 
Nicotine-withdrawn mice treated with 4, but not 2.5 pmol MII, did not display a reduction 
in time spent on the open arms of the plus maze as observed in nicotine-withdrawn vehicle 
treated mice. The number of arm crosses was tallied and there was no significant difference 
in arm crosses between vehicle and MII (4 pmol, i.c.v.) treated saline infused mice (veh= 
3.1 ± 0.7; MII= 2.3 ± 0.5, p= 0.26) and no significant difference in time spent on the open 
arms, suggesting that the highest does of MII was not behaviorally active by itself (Fig. 
16A).  
 Somatic sign assessment revealed a dose-dependent attenuation of total somatic 
signs after MII treatment (Fig. 16B), while MII had no effect in the hyperalgesia response 
at any dose tested (Fig. 16C).  
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Figure 16. MII dose-dependently blocks expression of the nicotine withdrawal-
induced anxiety-related response and somatic signs in mice. Nicotine withdrawn mice 
treated with 4 pmol, but not 2.5 pmol MII, display A. a loss of anxiety-related 
response, B. attenuation of somatic signs, but C. a normal hyperalgesia response. 
Each point represents the mean  S.E.M. of 12 mice per group.  * denotes p< 0.05 vs. 
saline groups; + denotes p< .05 vs. 4 pmol MII 
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Role of α3β4* nAChRs in nicotine withdrawal 
 The α3β4*-selective antagonist AuIB was evaluated in our nicotine withdrawal 
models.  AuIB, purified from the venom of the “court cone”, Conus aulicus, blocks the 
α3β4 receptor subtype with > 100 fold higher potency than other receptor combinations, 
such as α3β2 and α4β4 (Luo et al., 1998). Nicotine-withdrawn mice treated with vehicle 
i.c.v. displayed a significant anxiety-related response, and treatment with AuIB had no 
effect on the anxiety-related response at any dose tested (Fig. 17A). There was no 
significant difference in time spent on the open arms of the plus maze between any 
nicotine-withdrawn mouse group, regardless of i.c.v. treatment. Evaluation of saline 
infused mice revealed no significant difference in the amount of time spent on the open 
arms and no significant difference in the number of arm crosses between vehicle or AuIB 
treated mice (veh= 3.2 ± 0.4 ; AuIB= 2.7 ± 0.5, p=  0.41), suggesting that the highest dose 
of AuIB (18 pmol) was not behaviorally active alone. 
 In the somatic sign assessment, AuIB induced a dose-dependent decrease in total 
somatic signs. Nicotine-withdrawn mice treated with 15 pmol AuIB displayed a significant 
reduction in somatic signs compared to vehicle treated mice, while a dose of 18 pmol AuIB 
attenuated somatic signs in nicotine withdrawn mice (Fig. 17B). The hyperalgesia response 
was not affected by treatment with AuIB. Nicotine-withdrawn mice treated with saline or 
AuIB displayed a significant hyperalgesia response compared to saline infused animals, 
and there was no significant difference between nicotine withdrawn mice that received 
vehicle or AuIB (Fig. 17C). 
  
87 
 
 
Figure 17. AuIB dose-dependently reduces somatic signs, but has no affect on anxiety-
related behavior or the hyperalgesia response. Nicotine withdrawn mice treated with 
18 pmol MII display A. no change in anxiety-related response or C. hyperalgesia 
response, but B. attenuation of total somatic signs. Each point represents the mean  
S.E.M. of 12 mice per group.  * denotes p< 0.05 vs. saline groups; + denotes p< .05 vs. 
saline and nicotine-vehicle groups; $ denotes p< 0.05 vs. nicotine-vehicle and 15 pmol 
AuIB groups 
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Role of the α7, α3β2*, and α3β4*nAChR subtypes in affective signs using the CPA 
model 
To further evaluate the role of the α7, α3β2*, and α3β4* nAChR subtypes in 
affective nicotine withdrawal, we tested α7 KO mice and mice after treatment with α3β2* 
and α3β4* in our CPA model. Our initial assessment suggested that α7* nAChRs were not 
involved in the affective withdrawal response. Results show that mecamylamine (3.5 
mg/kg, s.c.) precipitated aversion in α7 WT and KO mice (Fig. 18).  The CPA assessment 
also revealed that MII (4 pmol, i.c.v.) had no effect on expression of CPA on test day (Fig. 
19A). Because our assessment in the plus maze revealed that MII blocked the anxiety-
related response, we tested a higher dose of MII to determine if we could produce an effect. 
An 8 pmol dose of MII also had no effect on expression of CPA on test day (Fig. 19A). 
Nicotine infused mice treated with 18 pmol AuIB expressed a significant aversion similar 
to that observed in nicotine infused vehicle treated mice, indicating that expression of CPA 
was not blocked by AuIB (Fig. 19B). Saline infused mice treated with AuIB (18 pmol) or 
MII (8 pmol) did not significantly differ from saline infused vehicle treated mice, 
suggesting, by themselves, the highest doses of AuIB and MII used for the study were not 
behaviorally active.  
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Figure 18. Mecamylamine precipitates aversion in nicotine-infused α7 WT and KO 
mice. Nicotine-infused KO mice treated with mecamylamine (3.5 mg/kg, s.c.) did not 
differ from their WT counterparts in the CPA assessment. * denotes p > 0.05 vs. 
saline counterparts. 
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Figure 19. The α6/α3β2* selective antagonist MII and the α3β4* antagonist AuIB 
have no effect on expression of nicotine CPA. Mecamylamine precipitated CPA in 
chronic nicotine-infused mice; however, neither A. 8 pmol MII nor B. 18 pmol AuIB 
had an effect on expression of mecamylamine-precipitated aversion. Each point 
represents the mean  S.E.M. of 12 mice per group.* denotes p< 0.05 vs. saline 
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D. Discussion 
These behavioral studies using pharmacological agents and genetically modified 
mice suggest that 7* and α3β4* nAChRs are involved in physical nicotine withdrawal 
signs, while α3β2* nAChRs are involved in the somatic signs and anxiety-related response 
associated with nicotine withdrawal. Nicotine infused α7 KO mice displayed significant 
anxiety-related behavior, CPA, and somatic signs after mecamylamine injection, but a loss 
of the hyperalgesia response, suggesting a role for α7 in some physical, but not affective 
withdrawal. I.c.v. injection of the selective α6/α3β2* antagonist, MII, blocked the 
expression of anxiety-related behavior and somatic signs, but not expression of nicotine 
CPA, while treatment with the α3β4* antagonist only blocked the expression of somatic 
signs, suggesting that the α3β4* nAChR subtype is involved in somatic, but not affective 
withdrawal signs, while the α3β2* subtype appears to be involved in nicotine withdrawal-
induced somatic signs and the anxiety-related response. 
Assessment of the α7 nAChR subunit using transgenic mice showed that nicotine- 
dependent 7 KO mice expressed anxiety-related behavior, CPA, and somatic signs, but a 
loss of hyperalgesia.  In the previous chapter, we found that MLA did not precipitate 
aversion in the CPA model in chronic nicotine infused mice, thus, complementing our 
results using transgenic animals. A previous 7 nAChR KO study from our laboratory 
using the oral route of chronic nicotine administration and the spontaneous nicotine 
withdrawal model produced similar findings (Grabus et al., 2005).  The oral route of 
administration, however, yields variable amounts of nicotine intake, making it difficult to 
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control the actual dose of nicotine reaching the receptor; therefore, we wanted to assess the 
role of the 7 subunit using a more consistent exposure method. Taken together, these 
results suggest that 7 nAChRs are involved in physical, not affective, nicotine withdrawal 
signs.  
The data also suggest that our two physical measures of nicotine withdrawal 
(somatic signs and hyperalgesia) are mediated by different nAChR subtype populations. 
While 7 KO mice showed a loss of the hyperalgesia response, these mice exhibited 
somatic signs of nicotine withdrawal. The 7 nAChR subunit is expressed in the peripheral 
ganglia, as well as centrally.  Although hyperalgesia is measured as a physical sign in the 
mouse, studies have suggested that spinal and supraspinal nAChR populations mediate the 
hyperalgesia response (Schmidt et al., 2001; Damaj et al., 2002). Our hyperalgesia measure 
was conducted using the hot plate, which measures supraspinal mechanisms; thus, we 
cannot rule out the possibility that the nicotine withdrawal induced hyperalgesia response 
is mediated by neuronal α7 nAChRs.  It is also noted that MLA, the 7 antagonist, 
precipitated mild somatic signs of withdrawal in WT mice (Damaj et al., 2003), while our 
assessment revealed the presence of typical nicotine withdrawal somatic signs in 7 KO 
mice.  It was also shown, however, that MLA can antagonize 6, 3, and 3 nAChR 
subunits at doses typically utilized to block 7 nAChRs (Mogg et al., 2002); thus, it is 
possible that the observed behavioral responses were attributed to effects on other nAChR 
subtypes. 
93 
 
An i.c.v. injection of MII, the α6/α3β2* selective antagonist, dose-dependently 
blocked the expression of anxiety-related behavior and somatic signs, but not expression of 
CPA. One possible explanation as to why we saw an effect with MII in the plus maze, but 
not the CPA assessment is that anxiety-related behavior and CPA are mediated by two 
different brain regions; the dorsal raphé nucleus (Cheeta et al., 2001) and the basolateral 
amygdala (Zanoveli et al., 2007) respectively; thus, it is possible that the two behaviors are 
mediated by different subtypes. Furthermore, the α6 and α3 nAChR subunits share 
considerable sequence homology (Le Novère and Changeux, 1995). Indeed, studies 
suggest that MII may not discriminate well between α3 and α6 nAChRs (Kuryatov et al., 
2000); however, the MII analog, MII[H9A;L15A], effectively discriminates between α3 
and α6 nAChR subunits (McIntosh et al., 2004). Our results from Chapter 3 showed a role 
for α6-containing nAChRs in nicotine CPA and the anxiety-related response, but not 
physical withdrawal. These results suggest that α6-containing nAChRs, and not α3β2* 
nAChRs ,are important for nicotine CPA, while both α6 and α3β2* nAChRs are involved 
in the withdrawal-induced anxiety-related response; however, because MII does not 
discriminate well between α3 and α6 nAChRs, we cannot rule out the possibility that the 
effects of MII in the plus maze are attributed to actions at α6β2* nAChRs. Results using 
MII[H9A;L15A] showed that CPA was blocked at a dose of 30 pmol MII[H9A;L15A], but 
there was no effect at the 8 pmol MII dose used in the current study. Because 
MII[H9A;L15A] has higher selectivity for α6-containing receptors than MII, higher doses 
of MII may be required to block α6-containing receptors, and thus, expression of CPA. MII 
also dose-dependently blocked the expression of nicotine withdrawal somatic signs. 
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Although results from Chapter 2 showed that β2-containing receptors are not involved in 
somatic nicotine withdrawal signs, based on the current data, we cannot rule out the 
possibility that the α3β2* subtype is involved in this aspect of nicotine withdrawal. 
The α3β4* selective antagonist, AuIB, given centrally, also dose-dependently 
attenuated somatic signs, but had no effect in the plus maze or CPA assessments. Studies 
using transgenic mice revealed an attenuation of somatic signs in β4 KO mice after 
mecamyalmine-precipitated withdrawal (Salas et al., 2004). Somatic withdrawal signs were 
shown to be mediated by central, as well as peripheral nAChR populations by systemic and 
central administration of chlorisondamine, a noncompetitive nAChR antagonist that does 
not readily cross the blood brain barrier (Watkins et al., 2000). Chlorisondamine, however, 
is not selective for specific nAChR subtypes. Additionally, the β4 KO mouse used in the 
Salas et al. (2004) study is a general KO; thus, central and peripheral nAChR populations 
cannot be differentiated. Although the α3β4* subtype is both peripherally and centrally 
expressed, these studies suggest a role for central α3β4* nAChRs in somatic nicotine 
withdrawal. The α3β4* subtype has limited expression in the CNS, but was shown to 
dominate function in the MHb (Quick et al., 1999); therefore, α3β4* expression 
specifically in the MHb may be important for somatic nicotine withdrawal. 
Based on studies from the previous chapter, and the current study, our data suggests 
that the α4α6β2* nAChR subtype is involved in affective nicotine withdrawal, while α7*, 
α5, and α3β4* nAChRs mediate physical nicotine withdrawal. Specifically, α7* nAChRs 
mediate the withdrawal induced hyperalgesia response, and the α5 and α3β4* subtypes 
95 
 
play a role in somatic withdrawal. These studies also stress the importance of receptor 
subunit composition in nicotine withdrawal. While β2-containing receptors were shown to 
be involved in affective, but not physical withdrawal, the α3β2* subtype was implicated in 
somatic nicotine withdrawal signs, and played no role in expression of nicotine CPA. The 
next chapter will focus on the involvement of intracellular Ca
2+
-dependent mechanisms in 
the nicotine withdrawal syndrome. 
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THE ROLE OF CALCIUM-DEPENDENT MECHANISMS IN NICOTINE 
WITHDRAWAL 
A.  Introduction 
Activation of nAChRs leads to increases in intracellular Ca
2+
 via various routes. Upon 
nicotine binding, there is a direct Ca
2+
 influx through the Ca
2+
 permeable nAChR. The 
resulting increase in intracellular Ca
2+
 leads to an indirect Ca
2+
 influx by Ca
2+
 induced Ca
2+
 
release from intracellular Ca
2+
 stores, and through VGCC as a result of membrane 
depolarization following nAChR activation (Rathouz and Berg, 1994; Dajas-Bailador et 
al., 2002). The subsequent rise in intracellular Ca
2+
 leads to activation of various 
downstream second-messengers, including CaMKII, the most abundant Ca
2+
-dependent 
kinase in the neuron (Deisseroth et al., 1998), and a protein involved in several essential 
processes, including neurotransmitter release (Schulman and Hanson, 1993) and induction 
of  LTP (Lisman et al., 2002). 
Studies suggest a role for L-type VGCCs and CaMKII in the effects of several 
drugs of abuse.  L-type VGCCs are upregulated in the cortex and limbic structures of rats 
showing signs of morphine withdrawal (Antkiewicz-Michaluk et al., 1990; Zharkovsky et 
al., 1993) and blockade of L- type VGCCs attenuates signs of morphine physical 
dependence in rats (Michaluk et al., 1998; Vitcheva and Mitcheva, 2004; Esmaeili-Mahani 
et al., 2008).  L-type VGCC blockers also inhibit chronic cocaine and amphetamine-
induced behavioral and neurochemical changes (Karler et al., 1993; Pierce and Kalivas, 
1997; Pierce et al., 1998). Additionally, blockade of L-type VGCC or suppression of 
CaMKII activity in the VTA augments acute cocaine-induced behavioral hyperactivity 
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(Licata et al., 2004). Nicotine studies show that pharmacological blockade of L-type 
VGCCs attenuates mecamylamine-precipitated somatic signs of nicotine withdrawal in 
mice (Biala and Weglinska, 2005). Studies from our lab showed that L-type VGCC 
blockers and CaMKII inhibitors block development and expression of nicotine-induced 
antinociception at the spinal level (Damaj, 2005). Biochemical studies show that L-type 
VGCCs, as well as α4β2* nAChRs, are upregulated in mouse cerebral cortical neurons 
after 7 days chronic nicotine exposure, leading to an increased Ca
2+
 influx (Katsura et al., 
2002). Further, the signaling pathway that results in nicotine-induced ERK phosphorylation 
in mouse primary cortical neurons involves L-type VGCCs and CaMKII (Steiner et al., 
2007). In PC12 cells, an increase in intracellular Ca
2+
 after stimulation of nicotinic 
receptors activates CaMKII  (MacNicol and Schulman, 1992), and  data from our lab 
shows that an acute systemic injection of nicotine is sufficient to elevate CaMKII in the 
spinal cord (Damaj, 2000).  Recent studies revealed that alterations in the phosphorylation 
state of neuronal CaMKII occur after chronic exposure to various drugs of abuse such as 
cocaine, amphetamine and morphine (Tan, 2002; Wang Z et al., 2003; Licata et al., 2004).  
Although the current studies evaluating Ca
2+
-dependent mechanisms in nicotine 
dependence provide evidence of a role for Ca
2+
signaling, the behavioral studies only assess 
the physical aspect of nicotine withdrawal, and not the affective component, which is 
suggested to be of greater motivational significance in contributing to relapse (Koob et al., 
1993; Markou et al., 1998). Additionally, there is no available behavioral correlation for 
the biochemical studies, which evaluate nicotine-induced Ca
2+
 mechanisms in vitro; thus, 
the relevance of these mechanisms to nicotine withdrawal is unclear. The goal of the 
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current study was, therefore, to elucidate the behavioral relevance of L-type VGCC and 
CaMKII in physical and affective nicotine withdrawal. Using our adapted spontaneous 
nicotine withdrawal and CPA models, mice were treated with one of two structurally 
different L-type VGCC blockers, nimodipine or verpamil, the L-type VGCC activator, (±) 
Bay K8644, the CaMKII inhibitor KN93, or its inactive analog KN92, and physical and 
affective withdrawal signs were measured. KN93 can also inhibit other kinases, such 
CaMKIV (Enslen et al., 1994); therefore, to complement our studies of CaMKII inhibition, 
we measured physical and affective nicotine withdrawal signs in nicotine-dependent 
CaMKII HT mice in our mecamylamine-precipitated model. 
B. Methods 
 
Animals 
Male B6, male B6.129P2-Camk2atm1Sva/J HT, and female B6129P3 mice were 
purchased from Jackson Laboratories. CaMKII mutant mice were generated as described 
by Silva et al., 1992a, and were backcrossed at least 16 generations. Initial attempts to 
generate CaMKII KO mice were unsuccessful, as female CaMKII HT mice on a B6 
background do not care for the pups, resulting in death of the entire litter. It was proposed 
by Dr. A. Silva that incorporation of a mixed background would produce CaMKII HT 
females that would nurse the pups; thus, in an effort to alleviate this problem, male 
CaMKII HT mice were paired with female WT B6129P3 hybrid mice (Jackson 
Laboratories) to produce F2 CaMKII HT mice on a mixed background. The male CaMKII 
HT mice and female hybrid CaMKII HT mice would not breed; thus no KO litters were 
produced. This led to the use of F2 CaMKII HT hybrids for our withdrawal studies. 
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Animals were 8-10 weeks of age, were group-housed in a 21°C humidity-controlled 
AAALAC-approved animal care facility with ad libitum access to food and water. 
Experiments were performed during the light cycle and were approved by the Institutional 
Animal Care and Use Committee of Virginia Commonwealth University. 
Drugs 
(-)-Nicotine hydrogen tartrate salt, mecamylamine hydrochloride, verapamil hydrochloride, 
(±)Bay K8644, and KN93 were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). 
Nimodipine was purchased from Research Biochemical International (RBI) (Natick, MA). 
KN92 was purchased from Seikagaku Corporation (Tokyo, Japan). Nicotine and 
mecamylamine were dissolved in physiological saline (0.9% sodium chloride) and injected 
s.c. at a volume of 10 ml/kg body weight. Verapamil, nimodipine, and (±)Bay K8644 were 
dissolved in a vehicle solution made of 5% ethyl alcohol, 5% emulphor oil, and 90% saline 
and administered by i.p. injection. KN92 and KN93 were diluted in saline and administered 
by i.c.v. injection. Doses are expressed as the free base of the drug. 
I.c.v. surgery 
I.c.v. surgery and injection were performed as described in Chapter 3. Briefly, a scalp 
incision was made to expose the bregma, and unilateral injection sites were prepared using 
a 26-gauge needle with a sleeve of PE tubing to control depth of the needle at a site 2 mm 
rostral and 2 mm lateral to the bregma at a depth of 2 mm. On the morning of testing, a 
volume of 5 µl using a 26-gauge needle with a sleeve of PE tubing was injected into the 
lateral ventricle and held in place for 20 seconds to ensure drug delivery. 
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Chronic nicotine administration protocol 
Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model 
2004 (28 days) Durect Corporation,
 
Cupertino, CA] filled with saline or (-)-nicotine (36 
mg/kd/day) as described in Chapter 2. Due to ceiling effects with 36 mg/kg/day nicotine, in 
the (±)Bay K8644 assessment, mice used for this test were infused with 24 mg/kg/day 
nicotine.  
Locomotor activity 
Mice were injected with vehicle (i.p.) and immediately placed into individual photocell
 
activity cages (28 x 16.5 cm; Omnitech, Columbus, OH) for a 30 minute habituation 
period. After habituation, mice were injected with vehicle or the assigned dose of 
nimodipine (1- 10 mg/kg, i.p.) and immediately returned to the locomotor cages.  
Interruptions of the
 
photocell beams (two banks of eight cells each) were recorded
 
for the 
next 30 min.  Data are expressed as the number of photocell
 
interruptions.
  
Nicotine withdrawal assessment 
 Withdrawal studies were conducted using the spontaneous withdrawal assessment as 
described in Chapter 3. In brief, for Ca
2+
 channel and pharmacological CaMKII studies, 
mini pumps were removed on day 14, and testing initiated on day 15, approximately 18-24 
hours after mini pump removal. Mice were injected with vehicle, nimodipine (0.25 or 1 
mg/kg, i.p.), verapamil (1 mg/kg, i.p.), or (±)Bay K8644 (0.25 and 0.5 mg/kg, i.p.) 15 
minutes prior to initiation of testing or with KN93 or KN92 (0.0025- 0.01 µg/µl, i.c.v.) 5 
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minutes prior to testing. Mecamylamine-precipitated studies were conducted as described 
in Chapter 3. For KN93 precipitated studies, mice were injected i.c.v. and testing was 
initiated 5 minutes after the injection. The withdrawal testing sequence was conducted as 
described in previous chapters. 
Nicotine CPA  
Nicotine CPA testing was conducted as described in Chapter 2. Alterations to the 
procedure are described below. 
Nimodipine assessment 
On days 2 and 3 of CPA training, all mice received injections of saline in the morning. In 
the afternoon, mice received an injection of nimodipine (1 mg/kg, i.p.) or vehicle 15 
minutes prior to mecamylamine injection. Mice were placed in the assigned chamber 
immediately after mecamyalmine injection for 30 minutes. 
KN93 assessement 
On day 4, test day, mice received i.c.v. injections of vehicle, KN93 (.01 g/l), or KN92 
(.01 g/l) 5 minutes before being placed in the test chambers. 
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Statistical analysis 
For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA).  
Data were analyzed with one-way ANOVAs with treatment as the between subject factor 
or two-way ANOVAs with treatment and genotype as between subject factors for the HT 
studies. Significant results were further analyzed using the Neuman-Keuls post-hoc test. p 
values of less than 0.05 were considered significant.  
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C. Results 
Role of L-type VGCCs in physical and affective nicotine withdrawal 
Before beginning our studies using L-type VGCC blockers, we wanted to determine the 
appropriate doses to use for our studies that would not have effects on locomotor activity. 
Preliminary data showed that nimodipine dose-dependently decreased locomotor activity in 
mice. Mice treated with 3 or 10 mg/kg nimodipine displayed a significant decrease in 
activity compared to vehicle treated mice (Fig. 20). There was no significant difference in 
activity between vehicle treated mice or mice treated with 1 or 2 mg/kg nimodipine. Based 
on this data, doses no higher than 2 mg/kg nimodipine were used for withdrawal studies.   
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Figure 20. Nimodipine dose-dependently reduces locomotor activity in mice. Doses of 
3 and 10 mg/kg nimodipine significantly reduced locomotor activity during the 30 
minute test period; therefore, doses no higher than 2 mg/kg were used for our studies. 
Data are expressed as the number of photocell
 
interruptions ± SEM for 6 mice per 
group. * denotes p < 0.05 vs. vehicle, 1 and 2 mg/kg nimodipine groups 
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As expected, nicotine-withdrawn mice pre-treated with vehicle showed a significant 
decrease in the amount of time spent on the open arms of the plus maze, indicating an 
anxiety-related response. Significant somatic signs and a significant decrease in hot plate 
latency compared to saline controls were also observed (Figure 21). Nimodipine dose-
dependently reduced physical signs in nicotine-withdrawn mice. Mice treated with 1 mg/kg 
nimodipine, but not 0.25 mg/kg, showed a significant decrease in total somatic signs and a 
significant increase in hot plate latency, indicating a loss of the hyperalgesia response (Fig. 
21B and 21C). There was no significant difference in time spent on the open arms of the 
plus maze in nicotine-withdrawn mice treated with nimodipine compared to vehicle, 
suggesting that nimodipine had no effect on anxiety-related behavior (Fig. 21A). 
Verapamil, an L-type VGCC blocker structurally different from nimodipine, had effects 
similar to nimodipine in nicotine-withdrawn mice. Verapamil (1 mg/kg, i.p.) significantly 
reduced somatic signs and significantly increased hot plate latency in nicotine-withdrawn 
mice; however, verapamil had no effect on anxiety-related behavior as measured by the 
plus maze (Fig. 21). The Ca
2+
 channel blocker doses had no significant effect in saline 
infused mice, indicating that, by themselves, the doses used were not behaviorally active 
(Fig. 21). 
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Figure 21. L-type VGCCs are involved in physical, but not affective withdrawal. 
Nimodipine (1 mg/kg, i.p.) and verapamil (1 mg/kg, i.p.)  B. attenuated somatic 
withdrawal signs and C. attenuated the hyperalgesia response as measured by a 
significant increase in hot plate latency; however, A. had no effect on anxiety-related 
behavior as measured by the amount of time spent on the open arms of the plus maze. 
Each point represents the mean ± SEM 8 mice per group. * denotes p < 0.05 vs. saline 
controls and vs. nicotine (nic) –nimodipine (nim)/verapamil (ver) for the hot plate 
assessment. + denotes p < 0.05 vs. nic –vehicle (veh). $ denotes p < 0.05 vs. saline 
controls, nic- nim, 1 mg/kg and nic-min 0.25 mg/kg 
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L-type VGCC blockers have been shown to inhibit α3* and 7* nAChR-mediated currents 
and downstream signaling in vitro at doses typically used to block L-type VGCC (Wheeler 
et al., 2006); therefore, mice were treated with the L-type VGCC activator, (±)Bay K8644, 
after nicotine withdrawal to complement results observed with L-type VGCC blockers. 
Because (±)Bay K8644 has significant effects on locomotor activity as measured by the 
number of arm crosses on the plus maze (saline-veh: 4 ± 0.27 crosses vs. saline-BayK: 11 
± 1.67 crosses), animals were not evaluated in the plus maze, as changes in locomotor 
activity can confound results in this test. (±)Bay K8644 dose-dependently enhanced 
somatic signs and the hyperalgesia response in nicotine-withdrawn mice. Compared to 
vehicle treated nicotine-withdrawn mice, mice treated with 0.5 mg/kg (±)Bay K8644, but 
not 0.25 mg/kg, exhibited significantly more somatic signs (Fig. 22A) and a significant 
decrease in hot plate latency (Fig. 22B), indicating an enhanced response in both 
behavioral tests. 
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Figure 22. (±)Bay K8644 dose-dependently enhances physical withdrawal signs.          
Nicotine-withdrawn mice treated with (±)Bay K8644 (BayK, 0.5 mg.kg, i.p.) exhibited 
A. a significant increase in somatic signs and B. and a significant decrease in hot plate 
latency when compared to nicotine-withdrawn vehicle (veh) treated mice. Each point 
represents the mean ± SEM of 8 mice per group. * denotes p < 0.05 vs. saline controls. 
+ denotes p < 0.05 vs. nicotine- veh mice  
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Evaluation of L-type VGCCs using the CPA model 
 Results suggested that L-type VGCCs are involved in physical, but not affective 
nicotine withdrawal. To further assess this effect, the aversion associated with nicotine 
withdrawal was measured using the CPA model. Mice were pre-treated with nimodipine (1 
mg/kg, i.p.), 15 minutes prior to mecamylamine injection during conditioning. 
Mecamylamine (3.5 mg/kg, s.c.) precipitated significant CPA in chronic nicotine infused 
mice compared to saline infused mice (Fig. 23). Pre-treatment with nimodipine had no 
effect on development, as mice pre-treated with nimodipine expressed significant aversion 
compared to saline counterparts at a dose that did not produce significant behavioral effects 
in saline-infused mice (Fig. 23).  
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Figure 23. L-type VGCCs are not involved in development of mecamylamine-
precipitated CPA. Mecamylamine precipitates aversion in nicotine infused mice. Pre-
treatment with nimodipine had no effect on the development of mecamylamine-
precipitated aversion. Each point represents the mean ± SEM of 12 mice per group. * 
denotes p < 0.05 vs. saline group. 
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Role of CaMKII in physical and affective nicotine withdrawal 
  To assess the role of CaMKII in nicotine withdrawal, we began with a 
pharmacological assessment using KN-93, a CaMKII inhibitor. KN93 is potent, cell-
permeable, and can be dissolved in water instead of DMSO, thus avoiding side effects of 
this vehicle (Gao et al., 2006). As a control, we also used the inactive analog of KN93, 
KN92, which does not inhibit kinase activity. KN93, however, inhibits other kinases, such 
as CaMKIV (Enslen et al., 1994); therefore, to complement our pharmacological 
assessment, we tested transgenic mice in our withdrawal model. While the initial goal was 
to obtain CaMKII KO mice for our studies, female HT mice either did not care for the 
pups, so we could not maintain live litters, or the mice did not breed; therefore, we used 
CaMKII HT mice to complement our pharmacological studies.   
  Nicotine-withdrawn mice were treated with vehicle or a range of KN93 doses prior 
to initiation of testing. KN93 dose-dependently reduced somatic signs in nicotine-
withdrawn mice (Fig. 24B). Mice treated with 0.0025 g/l showed a significant reduction 
in the total number of somatic signs compared to nicotine-withdrawn mice treated with 
vehicle, while somatic signs were attenuated in nicotine-withdrawn mice treated with 0.005 
and 0.01 g/l KN93 (Fig. 24B). In the hyperalgesia assessment, nicotine-withdrawn 
vehicle treated mice displayed a significant reduction in hot plate latency compared to 
saline infused animals (Fig. 24C). Treatment with KN93 had no effect on hot plate latency 
at any dose tested (Fig. 24C). Interestingly, there was a significant reduction in the amount 
of time spent on the open arms of the plus maze in KN93 treated nicotine-withdrawn mice 
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compared to vehicle treated nicotine withdrawn mice. The highest dose of KN93 (0.01 
g/l) reduced the amount of time spent on the open arms of the plus maze compared to 
vehicle treated nicotine-withdrawn mice, indicating an enhanced anxiety-related response 
after KN93 treatment (Fig. 24A). There was no significant difference in the number of arm 
crosses between groups, suggesting that the effect was not attributed to differences in 
locomotor activity (Table 4). Nicotine-withdrawn mice treated with the inactive analog, 
KN92 (0.01 g/l, i.c.v.) did not differ from their vehicle treated counterparts in any 
behavioral test, and the highest dose of KN93 (0.01 g/l) was not behaviorally active in 
saline infused mice. 
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Figure 24. KN93 attenuates somatic signs, but enhances anxiety-related behavior.    
Nicotine-withdrawn mice were treated with various doses of KN93. Results show  A. 
KN93 dose-dependently reduces time spent on the open arms of the plus maze, 
suggesting an enhanced anxiety-related response, B. a dose-dependent attenuation of 
somatic signs after KN93 treatment, but  C. no effect on the hyperalgesia response 
after any KN93 dose tested. The highest dose of KN93 (0.01 µg/µl) did not produce 
effects in saline treated mice, indicating that the dose is not behaviorally active by 
itself. The inactive analog KN92 also did not produce behavioral effects in any 
withdrawal assessment. Each point represents the mean ± SEM of 10 mice per group. 
* denotes p < 0.05 vs. saline groups. + denotes p < 0.05 vs. nicotine-vehicle group. 
114 
 
Table 4. Average number of arm crosses in the KN93 plus maze assessment 
 
Nicotine-withdrawn mice were treated with vehicle (veh), KN93, or the inactive 
analog KN92, and the total number of crosses between open and closed arms of the 
plus-maze test was counted.  Numbers are presented as the total average number of 
arm crosses  SEM for 8 mice per group.  
 
Treatment group 
 
Average number of arm crosses 
Saline MP- veh 
 
2.4 ± 0.3 
Saline MP- KN93, 0.01 g/l 
 
2.5 ± 0.6 
Nicotine MP- veh 
 
2 ± 0.5 
Nicotine MP- KN93, 0.0025 g/l 
 
2.2 ± 0.6 
Nicotine MP- KN93, 0.005 g/l 
 
2 ± 0.6 
Nicotine MP- KN93, 0.01 g/l 
 
2 ± 0.3 
Nicotine MP- KN92, 0.01 g/l 
 
2.2 ± 0.4 
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Results suggested that CaMKII has opposite roles in nicotine withdrawal. While there was 
an attenuation of somatic signs, we observed an enhancement of the anxiety-related 
response. To further examine this response, we tested the effect of KN93 in a precipitated 
nicotine withdrawal model. Mini pumps were not removed on day 14, and withdrawal 
signs were measured the morning of day 15 following administration of saline, 
mecamylamine, or KN93.  Pretreatment with mecamylamine (2mg/kg, s.c.) or KN93 (0.01 
g/l, i.c.v.) precipitated a significant decrease in the open arms of the plus maze in 
chronic nicotine infused mice, indicating an anxiety-related response (Fig. 25A).  While 
mecamylamine also precipitated a significant increase in somatic signs and a significant 
decrease in hot plate latency in nicotine-infused mice, KN93 failed to precipitate physical 
nicotine withdrawal signs (Fig. 25B and 25C).  
 
 
 
 
 
 
 
116 
 
 
Figure 25.  KN93 precipitates anxiety-related behavior, but not physical withdrawal 
signs. Withdrawal was precipitated with KN93 or mecamylamine in chronic nicotine 
infused mice. Mice show A.  a significant decrease in the amount of time spent on the 
open arms of the plus maze, indicating an anxiety-related response after KN93 and 
mecamylamine treatment. B. KN93 did not precipitate somatic signs or C. a 
hyperalgesia response in chronic nicotine infused mice as seen after mecamylamine 
injection. Each point represents the mean ± SEM of 8 mice per group. * denotes p< 
0.05 vs. saline group. + denotes p< 0.05 vs. mecamylamine group. 
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 While KN93 is a selective CaMKII inhibitor, it may also inhibit other CaMKs, such 
as CaMKIV (Enslen et al., 1994); therefore, to complement our pharmacological approach, 
we measured withdrawal signs in nicotine infused CaMKII HT mice after mecamylamine 
injection. Mecamylamine precipitated an anxiety-related response in nicotine infused 
CaMKII WT mice (Fig. 26A). Interestingly, saline infused CaMKII HT mice had 
significantly higher plus maze baseline activity than their WT counterparts, and 
mecamylamine did not precipitate an anxiety-related response in nicotine infused HTs  
(Fig. 26A). There was also no significant difference between nicotine infused HT and WT 
mice in either physical measure, as mecamylamine precipitated a significant increase in 
somatic signs and decrease in hot plate latency in both nicotine infused HT and WT mice 
(Fig. 26B and 26C).  
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Figure 26. Evaluation of the role of CaMKII in nicotine withdrawal using CaMKII 
HT mice.  A. Saline infused CaMKII HT mice spend significantly more time on the 
open arms compared to WT mice, indicating higher baseline levels on the plus maze, 
while nicotine infused CaMKII HTs did not display an anxiety response. B. Nicotine 
infused CaMKII HTs and WTs both exhibit significant somatic signs after 
mecamylamine injection compared to saline counterparts. C. Mecamylamine 
precipitates a significant hyperalgesia response in CaMKII HT and WT mice. Each 
point represents the mean ± SEM of 10 mice per group.    * denotes p < 0. 05 vs. saline 
groups. + denotes p < 0.05 vs. WT mice 
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Role of CaMKII in affective withdrawal using the CPA model  
In an attempt to generate CaMKII KO mice, male CaMKII HT mice were bred with 
female WT B6129P3 hybrid mice to produce F2 CaMKII HT mice on a mixed background 
for our studies; therefore, we evaluated development of CPA in the hybrid background 
strain. Results show that both male and female B6129 mice develop significant 
mecamylamine-precipitated aversion in the CPA model (Fig. 27). For pharmacological 
CaMKII studies assessing expression of CPA, vehicle, KN93, or KN92 were administered 
to mice on test day, 5 minutes prior to entering the chamber.  Mecamylamine (3.5 mg/kg, 
s.c.) precipitated aversion in nicotine infused mice treated with vehicle i.c.v. (Fig. 28A). 
KN93 (0.01 g/l, i.c.v.), but not KN92 (0.01 g/l, i.c.v.) showed a strong trend toward 
enhanced expression of mecamylamine-precipitated CPA that did not reach statistical 
significance (p= 0.06). The dose of KN93 used did not produce CPA in saline infused 
mice. Activity counts showed no significant between group differences in activity on test 
day (Table 5), suggesting that results were not attributed to differences in chamber activity. 
To complement the pharmacological approach, CaMKII HT mice were evaluated using the 
CPA model. Mecamylamine precipitated significant aversion in CaMKII WT and HT mice 
(Fig. 28B). There was no significant difference in activity count between groups (Table 5). 
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Figure 27. Assessment of male and female B6129P3 hybrid mice in the development of 
aversion in the CPA model. Nicotine infused male and female B6129P3 hybrid mice 
develop aversion after mecamylamine conditioning in the CPA model. Each point 
represents  S.E.M. of 12 mice per group. * denotes p<0.05 vs. the corresponding 
saline group 
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Figure 28.  Inhibition of CaMKII enhances the aversion associated with nicotine 
withdrawal. A. Nicotine infused mice treated with KN93 on test day express a strong 
trend that did not reach statistical significance toward enhanced CPA compared to 
nicotine-infused mice treated with vehicle (veh) or KN92 (p=0.06). B. Mecamylamine 
precipitates aversion in CaMKII WT and HT mice. There was no significant 
difference in the level of aversion between WT and HT mice. Each point represents 
the mean ± SEM of 12 mice per group. * denotes p < 0. 05 vs. saline groups. 
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Table 5. Average activity counts in the CPA model for the CaMKII assessment 
 
Mice were treated with vehicle (veh) or KN93 (0.01g/l)  i.c.v. for the 
pharmacological assessment on test day. CaMKII HT and WT mice were also 
evaluated in the CPA model. Activity counts were taken for each compartment in the 
CPA chamber. Numbers represent the total activity counts in drug-paired 
compartment on test day for each group and are presented as the average activity 
count on test day (post-conditioning day) ± S.E.M. for 12 mice.  
 
Treatment groups Average activity counts- 
drug-paired compartment 
Saline MP- veh 438 ± 78.1 
Saline MP-KN93 369.9 ± 34.2 
Nicotine MP- veh 437 ± 97.8 
Nicotine MP- KN93 455.8 ± 185.1 
Nicotine MP- KN92 492.9 ± 92.9 
Saline CaMKII WT 624.1 ± 45 
Nicotine CaMKII WT 671 ± 50.5 
Nicotine CaMKII HT 692.9 ± 36.4 
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D. Discussion 
The main goal of this study was to investigate the role of L-type VGCCs and 
CaMKII in nicotine withdrawal. The overall results suggest that Ca
2+
-dependent 
mechanisms are involved in physical and affective nicotine withdrawal. L-type VGCC 
blockers attenuated nicotine withdrawal somatic signs and the hyperalgesia response, and 
(±)BayK 8644, an L-type VGCC activator, enhanced these signs. There was no effect in 
the plus maze or CPA model, suggesting a role for L-type VGCCs in physical, but not 
affective withdrawal. The results of the CaMKII assessment were not as clear. The 
pharmacologically CaMKII assessment revealed that KN93 dose-dependently attenuated 
somatic withdrawal signs, but enhanced the affective response, suggesting differential roles 
for CaMKII in somatic and affective nicotine withdrawal. Surprisingly, the transgenic data 
using CaMKII HT mice suggests a role opposite that of the pharmacological assessment.  
The L-type VGCC blockers, nimodipine and verapamil, attenuated the expression 
of nicotine withdrawal-induced somatic signs and the hyperalgesia response, but had no 
effect on the anxiety-response or CPA, suggesting a role for L-type VGCCs in physical, 
but not affective nicotine withdrawal. These results are consistent with a previous study by 
Biala and Weglinska (2005), which treated mice with various L-type VGCC blockers after 
mecamylamine-precipitated withdrawal. Despite the complementary results, in our study, 
we show that the doses used in the Biala study (5 and 10 mg/kg of each L-type VGCC 
blocker), significantly depress locomotor activity in mice, which could impact data 
interpretation in a withdrawal study. Further, the Biala study used the mecamylamine-
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precipitated model to evaluate expression of nicotine withdrawal. It is unknown whether 
the combination of mecamylamine and L-type VGCCs produces a drug interaction that 
influences the results; thus, to avoid such an interaction, the current study utilized a 
spontaneous nicotine withdrawal model and L-type VGCC blocker doses that do not 
impact locomotor activity. L-type VGCC blockers have been shown to inhibit α3* and α7* 
nAChR-mediated currents and downstream signaling in vitro at doses typically used to 
block L-type VGCC (Wheeler et al., 2006); therefore, mice were also treated with the L-
type VGCC activator, (±)Bay K8644. Nicotine-withdrawn mice treated with (±)Bay K 
showed enhanced somatic signs and an enhanced hyperalgesia response. Taken together, 
these results suggest an important role for L-type VGCCs in physical, but not affective 
nicotine withdrawal. The results may also highlight a potential role for indirect sources of 
nicotine-induced Ca
2+
 influx. Upon nicotine binding, there is a direct Ca
2+
 influx through 
the Ca
2+ 
permeable nAChR. The resulting increase in intracellular Ca
2+
 leads to an indirect 
Ca
2+ 
influx through VGCC as a result of membrane depolarization following nAChR 
activation. Because physical signs are altered by L-type VGCC pharmacological agents, 
this would suggest an important role for a mechanism of Ca
2+
 influx that occurs as a result 
of nAChR activation. 
 The intracellular rise in Ca
2+
 through nAChRs leads to activation of CaMKII. Our 
data in chapter 6 shows that acute nicotine induces increases in CaMKII activity in the 
VTA and NAc. Additionally, previous data reports increases in CaMKII function in PC12 
cells (MacNicol and Schulman, 1992), and in the spinal cord membrane after nicotine 
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treatment (Damaj, 2000). Our pharmacological data showed that the CaMKII inhibitor 
KN93 dose-dependently attenuated somatic signs, but enhanced the expression of the 
anxiety-related response. There was also a trend toward enhancement of CPA expression 
after KN93 treatment on test day. It is possible, in the CPA model, that a floor effect 
prevented the aversive response after KN93 treatment from reaching significance. Using a 
lower dose of nicotine (24 mg/kg/day instead of 36 mg/kg/day) in the CPA model for 
future studies may prevent this floor effect, and provide clearer results. Overall, these 
results imply that CaMKII has differential roles in somatic and affective nicotine 
withdrawal. While KN93 enhanced the anxiety-related response, suggesting that CaMKII 
activity is decreased after nicotine withdrawal, the antagonist attenuated somatic signs, 
suggesting that CaMKII is increased after nicotine withdrawal.  
 In Chapters 3 and 4, we found that somatic and affective nicotine withdrawal signs 
are mediated by different subtypes; thus, it is possible that the opposing roles of CaMKII in 
somatic and affective withdrawal could reflect the involvement of different nAChR 
subtypes. It may also be possible that the effect of KN93 is attributed to blockade of 
nAChRs. KN93 has been shown to reversibly block α3* and α7* nAChR-mediated 
responses in vitro (Liu and Berg, 1999). Our studies in Chapter 4 implicate the α3 nAChR 
subunit in somatic nicotine withdrawal; thus, it may be possible that the attenuation of 
somatic signs by KN-93 is attributed to blockade of α3-containing nAChRs. It is currently 
unknown if KN93 blocks α4β2* nAChRs, which was shown in Chapter 3 to be necessary 
for affective nicotine withdrawal. An electrophysiological evaluation that is beyond the 
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scope of our studies would be necessary to examine α4β2* nAChR responses after KN93 
treatment. Additionally, KN-93 inhibits L-type VGCCs in vitro (Gao et al., 2006). 
Although KN-93 had no effect on the hyperalgesia response, as was observed with L-type 
VGCC blockers, we cannot rule out the possibility that the effects on somatic signs may 
involve inhibition of this target. 
While the pharmacological results suggested a role for CaMKII in somatic and 
affective nicotine withdrawal, the assessment using CaMKII HT mice produced different 
results. There was no significant difference in somatic signs or hyperalgesia response 
between nicotine and saline infused CaMKII HT and WT mice after mecamylamine 
treatment, suggesting that CaMKII is not involved in the development of physical nicotine 
withdrawal signs. Interestingly, there was a loss of the anxiety-related response in nicotine 
infused CaMKII HT mice, as there was no decrease in time spent on the open arms after 
mecamylamine treatment, and no difference between CaMKII HT and WT mice in 
development of a significant CPA. The difference in affective measures may be explained 
by the fact that the anxiety-related behavior and aversive responses involve two different 
brain regions. Although these results suggest that CaMKII is involved in the nicotine 
withdrawal-induced anxiety-related response, the transgenic mouse data suggests CaMKII 
function is increased after nicotine withdrawal, which is the opposite of what was observed 
in the pharmacological KN93 assessment. One possible explanation for the discrepancy 
between our pharmacological and transgenic data is the lack of selectivity of KN93. KN93 
blocks CaMKIV activity at an IC50 of 3 µM, a concentration only 4-fold higher than the 
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IC50 value for CaMKII (0.8 µM) (Hook and Means, 2001). It is therefore possible that the 
observed effects are attributed to blockade of CaMKIV activity rather than CaMKII. 
However, based on diffusion studies by Matta et al. (1995), the highest dose of KN93 
(0.01µg/µl) would correspond to a tissue concentration of ~ 0.7 M, which is below the 
IC50 value sufficient to block CaMKIV activity. Another possibility is that the comparison 
of CaMKII HT mice to the pharmacological data is unclear. The CaMKII HT mice possess 
50% of the CaMKII enzyme, and it is unknown whether this enzyme level is sufficient for 
expression of the alterations in nicotine withdrawal observed after KN93 treatment. It is 
possible that total blockade of CaMKII activity is necessary for expression of attenuated 
somatic signs and an enhanced anxiety-related response. The CaMKII HT mice were also 
bred on a mixed genetic background containing B6 and B6129 hybrids. Many studies 
support an important role for a genetic component to nicotine dependence; thus, we cannot 
rule out the possibility that the mixed genetic background contributed to the observed 
phenotype in CaMKII HT mice. Our breeding attempts found that the CaMKII HT mothers 
maintained on a B6 background breed and give birth to live litters, but do not care for the 
pups; thus we could not obtain CaMKII KO mice for our studies. For future studies, rather 
than incorporating a mixed background strain, we will attempt to foster the pups from HTs 
maintained on a B6 background with WT mice to obtain KOs. 
The overall results of this study suggest that different Ca
2+
-dependent mechanisms 
are involved in physical and affective nicotine withdrawal. L-type VGCCs mediate somatic 
signs and hyperalgesia, suggesting the importance of the indirect Ca
2+
 influx in expression 
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of physical nicotine withdrawal. The role of CaMKII in nicotine withdrawal behaviors is 
more complex. Pharmacological data supports a role for CaMKII in having opposing roles 
in nicotine withdrawal, as an antagonist attenuates somatic signs, yet enhances affective 
signs; however, the transgenic assessment did not elucidate a role for CaMKII in nicotine 
withdrawal. While the current study, taken together with previous biochemical studies, 
does implicate a role for CaMKII in nicotine dependence, further work is necessary to 
examine the behavioral specifics of CaMKII in nicotine withdrawal. The next chapter 
focuses on exploring the relationship between changes in the function of CaMKII and 
synapsin I, a CaMKII substrate necessary for neurotransmitter release after nicotine 
withdrawal, and in vivo nicotine withdrawal induced behavioral alterations. 
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IN VITRO CHARACTERIZATION OF MOLECULAR MECHANISMS OF 
NICOTINE WITHDRAWAL: A ROLE FOR CAMKII AND SYNAPSIN I 
A.  Introduction 
In the previous chapter, we found that Ca
2+
 -dependent mechanisms, specifically L-
type VGCC and CaMKII, are involved in nicotine withdrawal behaviors. While L-type 
VGCC blockers attenuated physical withdrawal signs, L-type VGCC activators had the 
opposite effect. Further, CaMKII inhibitors attenuated somatic signs, but enhanced 
anxiety-related behavior and aversion. Since these studies showed that these Ca
2+
-
dependent mechanisms are relevant to nicotine withdrawal behaviors, we wanted to 
examine the relationship between the altered behavioral response in vivo, and the in vitro 
Ca
2+
-dependent molecular mechanisms involved in nicotine withdrawal.  We focused our 
studies on CaMKII and its presynaptic substrate, synapsin I. 
Synapsin I is a presynaptic vesicle-associated protein that is essential for 
neurotransmitter release. It is phosphorylated and activated by various protein kinases, 
including PKA, MAPK, cyclin-dependent protein kinases (cdks), and CaMKII, which 
phosphorylates the protein at Ser-566 and Ser-603 (De Camilli et al., 1990; Hilfiker et al., 
1999). Phosphorlyation of synapsin I by CaMKII in particular causes the protein to 
dissociate from the synaptic vesicle and allows the vesicle to move to and fuse with the 
plasma membrane for neurotransmitter release (De Camilli et al., 1990; Greengard et al., 
1993). Indeed, experimental data indicates an important role of synapsin I phosphorylation 
by CaMKII in the regulation of neurotransmitter release. It was shown that introduction of 
activated CaMKII into rat synaptosomes induces release of glutamate and noradrenaline, 
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and this release is reduced by CaMKII inhibitors (Nichols et al., 1990). Further, using giant 
squid synapses, it was shown that CaMKII injected presynaptically facilitates 
neurotransmitter release by phosphorylation of synapsin I (Llinás et al., 1991). Synapsin I 
has also been suggested as a candidate for mediating molecular processes associated with 
learning and memory, such as LTP. There was an increase in synapsin I concentration in 
dentate gyrus slices after induction of LTP (Lynch et al., 1994). This effect was also 
observed in vivo, where LTP was induced in the dentate gyrus of rats by increasing 
neuronal activity, and increases in synapsin I mRNA were detected (Hicks et al., 1997).  
This is of particular relevance since it has been suggested that addiction and 
learning and memory share common molecular substrates and pathways, such as 
intracellular signaling cascades that lead to activation of the transcription factor CREB 
(Nestler, 2001b; Nestler, 2002). In fact, like CaMKII, synapsin I activity and expression 
are altered by various drugs of abuse.  Synapsin I mRNA was increased in the LC, 
amygdala, spinal cord, and pontine central gray area after chronic morphine treatment in 
rats, suggesting that increases in synapsin I in these particular brain areas, which are 
important for opiate action, may be part of the molecular mechanisms underlying opiate 
tolerance and withdrawal (Matus-Leibovitch et al., 1995). Further, increased synapsin I 
phosphorylation and subsequent DA release were noted after amphetamine sensitization in 
rats, and after chronic amphetamine treatment in rat striatal synaptosomes (Iwata et al., 
1996; Iwata et al., 1997a; Iwata et al., 1997b). Taken together, these studies indicate a role 
for CaMKII and synapsin I in mechanisms associated with neurotransmitter release in drug 
dependence. 
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The current study focuses on investigating the changes in CaMKII and synapsin I 
function after nicotine withdrawal, and provides initial results, which suggest that the 
changes in function of these two proteins are relevant to nicotine withdrawal behaviors. 
Using CaMKII 
32
 P activity assays and western blot analysis, we measured nicotine-
induced changes in CaMKII and synapsin I function in the VTA and NAc. The VTA and 
NAc are part of the mesocorticolimbic drug pathway, and several studies have implicated 
these two brain regions as having a role in mediating behaviors associated with nicotine 
dependence. Before proceeding with our withdrawal biochemical studies, we began with 
an acute nicotine assessment to determine how CaMKII and synapsin I are regulated by 
nicotinic receptors in the aforementioned brain regions. Although studies suggest an 
important role for nAChRs in the VTA in mediating nicotine withdrawal behaviors, the 
DA terminals that project from the VTA and the presynaptic nAChRs that mediate 
neurotransmitter release are located in the NAc. It is proposed that the decreased DA 
release following cessation of nicotine exposure is responsible for many of the mood 
disorders, craving, and anhedonia that persist in many smokers long after quitting 
(Benowitz, 2008). Because decreased DA release occurs in the NAc following precipitated 
and spontaneous withdrawal (Hildebrand et al., 1998; Rada et al., 2001), our chronic and 
withdrawal studies focus on CaMKII and synapsin I function in the NAc. To identify these 
changes in protein function, we used various nAChR antagonists to examine the acute 
nicotine-induced effects of nicotine in the VTA and NAc, followed by an assessment of 
nicotine’s chronic effects on CaMKII and synapsin I function in the NAc. For the 
withdrawal evaluation in the NAc, we precipitated withdrawal using the β2-selective 
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antagonist, DHβE, and the α7 antagonist, MLA, and complemented our pharmacological 
approach using coinciding nAChR KO mice. Overall, the current assessment provides 
initial targets, which aid in the elucidation of post-receptor molecular mechanisms that 
may contribute to nicotine withdrawal behaviors. 
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B. Methods 
Animals 
Male B6 mice, β2 KO mice, and α7 KO mice and respective WT littermates were obtained 
and bred as described in Chapters 3 and 4. 
Drugs 
(-)-Nicotine hydrogen tartrate salt, mecamylamine hydrochloride, DHE, and MLA were 
purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA).  Nimodipine was purchased 
from Research Biochemical International (Natick, MA).   Nimodipine was dissolved in a 
vehicle solution made of 5% ethyl alcohol, 5% emulphor oil, and 90% saline. Drugs were 
administered at a volume of 10 ml/kg body weight. Doses are expressed as the free base of 
the drug. 
Chronic nicotine administration protocol 
Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model 
2004 (28 days) Durect Corporation,
 
Cupertino, CA] filled with saline or (-)-nicotine (36 
mg/kd/day) as described in Chapter 2.  
Biochemical studies 
Acute studies 
Mice were treated with various antagonists [mecamylamine (2 mg/kg, s.c.), DHβE (2 
mg/kg, s.c.), nimodipine (10 mg/kg, i.p.)] or saline prior to nicotine (2 mg/kg, s.c.) 
administration. This dose of nicotine was chosen because our studies found that there was 
a significant increase in CaMKII activity in the VTA and NAc after treatment with this 
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dose of nicotine (Fig. 29). The VTA and NAc were dissected 10 minutes after saline, 
mecamylamine, or DHβE injection, or 15 minutes after nicotine or nimodipine injection, 
and placed immediately in cold extraction buffer. 
Chronic studies 
Mice were chronically infused with nicotine for 14 days as described in the chronic 
administration protocol. The NAc was dissected on day 14 and placed immediately in cold 
extraction buffer. 
Withdrawal studies 
Chronic nicotine and saline infused mice were injected with DHβE (2 mg/kg, s.c.) or MLA 
(10mg/kg, s.c.) to precipitate withdrawal. nAChR KO mice were injected with 
mecamylamine (2 mg/kg, s.c.). The NAc was dissected 10 minutes after antagonist 
injection. Brain sections were placed in cold extraction buffer immediately after dissection. 
CaMKII 
32
 P activity assay 
CaMKII activity was measured using an assay kit (Upstate biotechnology, Lake Placid, 
NY).  Following experimental treatment, brain tissues were homogenized in Ca
2+
-free Tris 
buffer that contains 1 mM PMSF.  Homogenates were normalized for protein 
concentration. Samples were centrifuged in order to separate the membrane and the cytosol 
containing-kinase. The activity of CaMKII in the membrane portion was measured. 
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Standard phosphorylation reaction solutions contained 70 g protein, 10 mM MgCl2, 1 
Ci of [32P]ATP, 10 mM Pipearzine-N,N’-bis(2-ethanesulfonic acid) (PIPES) (pH 7.4), 5 
M CaCl2 and 5 g calmodulin.  Standard reactions were performed in a shaking water 
bath at 30°C.  Ca
2+
-dependent calmodulin-protein kinase II activity was determined using 
the following calculations: [(count-specific binding) x (correcting factor)]/[(specific 
radioactivity)x time (10 min)]. Activity was expressed as the number of pmol 
32
P 
incorporated into calmodulin protein kinase II substrate peptide/min/mg of protein in the 
presence (dependent reaction) or absence (independent reaction). 
Western blot assay 
VTA and NAc sections were homogenized in extraction buffer containing 50 mM Tris, 1 
% SDS, 1 mM PMSF, 1 mM EDTA, 5 mM EGTA, 1 mM Na+ orthovanadate, 20 µg/ml 
leupeptin, 10 µg/ml aprotinin, and 1 µM okadaic acid .  Protein concentrations were 
determined using the Bradford assay and 20 g of protein were incubated with sample 
buffer and heated for 5 minutes at 95C.  Samples were then separated by SDS-
polyacrylamide gel electrophoresis on a 10% TRIS-HCL gel and subjected to 
immunoblotting. α-CaMKII (1:1000; Sigma, St. Louis, MO), α-pCaMKII (1:10000; Fisher 
Scientific, USA), Synapsin I (1:2000; Chemicon International, Inc, USA), or pSynapsin I 
Ser 603 (an antibody specific for the site phosphorylated by CaMKII) (1:2000; Sigma, St. 
Louis, MO) primary antibodies and -tubulin antibody (1:5000; Upstate, Temecula, CA) 
were incubated overnight at 4C. Secondary antibodies (1:5000; LiCor Biosciences, Inc., 
Lincoln, NE) were incubated for 1 hour at room temperature. Bound antibody was detected 
using the LiCor Odyssey Infrared Imaging System (LiCor Biosciences, Inc., Lincoln, NE). 
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α-CaMKII bands were detected at 50 kDa, α-pCaMK II bands were detected at 52 kDa, 
Synapsin I bands were detected at 80 kDa, pSynapsin I Ser 603 bands were detected at 78 
kDa, and -tubulin bands were detected at 55 kDa. 
Staistical analysis 
For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA).  
Data were analyzed with one-way ANOVAs with treatment as the between subject factor 
or two-way ANOVAs with treatment and genotype as between subject factors. Significant 
results were further analyzed using the Neuman-Keuls post-hoc test. p values of less than 
0.05 were considered significant. 
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C. Results 
Effect of acute nicotine administration on CaMKII activity in the VTA and NAc 
Before starting our withdrawal assessment, we first wanted to determine how CaMKII is 
regulated after acute nicotine, as acute drug responses are an important part of the initial 
cascade that occurs in response to drug exposure. CaMKII activity was measured in the 
VTA and NAc after acute systemic nicotine administration (2 mg/kg, s.c.). Results show 
that acute nicotine induces increases in CaMKII activity in the VTA (Fig. 29A) and NAc 
(Fig. 29B).  
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Figure 29. Acute nicotine induces increases in CaMKII activity in the VTA and NAc. 
Mice were treated with an acute systemic injection of nicotine (2 mg/kg, s.c.), and 
brain sections were dissected and prepared for analysis using a CaMKII 
32
 P activity 
assay. Activity was expressed as the number of pmol 
32
P incorporated into calmodulin 
protein kinase II substrate peptide/min/mg of protein in the presence (dependent) or 
absence (independent) of calcium. Each point represents the mean ± S.E.M. of 5 mice 
per group. * denotes p < 0.05 vs. saline group 
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Next, we wanted to determine if the nicotine-induced increase in CaMKII activity was 
mediated through nAChRs, and examine the involvement of L-type VGCCs, which may 
suggest a role for indirect sources of nicotine-induced Ca
2+
 influx. Mice were treated with 
the non-selective nAChR antagonist, mecamylamine (2 mg/kg, s.c.), or the L-type VGCC 
blocker, nimodipine (10 mg/kg, i.p.), 10 or 15 minutes prior to nicotine administration. 
Mecamylamine and nimodipine significantly blocked the acute nicotine-induced increase 
in CaMKII activity in the VTA (Fig. 30), suggesting that the nicotine-induced increase in 
CaMKII activity is mediated directly through nAChRs and involves indirect sources of 
nicotine-induced Ca
2+
 influx through L-type VGCC channels. The antagonist doses used 
did not produce a significant effect alone, as there was no significant difference in activity 
between naïve antagonist treated mice and saline treated mice (Fig. 30).  
 
140 
 
 
Figure 30. Acute nicotine induces an increase in CaMKII activity in the VTA that is 
mediated directly through nAChRs and indirectly through L-type VGCCs. Mice were 
treated with mecamylamine (2 mg/kg, s.c.) or nimodipine (10 mg/kg, i.p.) 10 or 15 
minutes prior to an acute systemic injection of nicotine (2 mg/kg, s.c.) Brain sections 
were dissected and prepared for analysis using a CaMKII 
32
 P activity assay. Activity 
was calculated as the number of pmol 
32
P incorporated into calmodulin protein 
kinase II substrate peptide/min/mg of protein in the presence (dependent) or absence 
(independent) of Ca
2+
, and expressed as % deviation from baseline response. Each 
point represents the mean ± S.E.M. of 5 mice per group. * denotes p < 0.05 vs. saline, 
mec, and mec + nic groups 
 
141 
 
Synapsin I activity in the VTA and NAc after acute nicotine administration 
Studies in the lab revealed that the acute nicotine induced increase in CaMKII activity in 
the VTA and NAc was significantly blocked by DHβE, but not MLA (Walters and Damaj, 
2008, submitted). Further, the acute nicotine-induced increase in CaMKII activity was 
present in α7, but not β2 KO mice (Walters and Damaj, 2008, submitted). These results 
suggest that the acute nicotine-induced increases in CaMKII activity are mediated by β2-
containing, and not α7, nAChRs. Western blot analysis also revealed that the total CaMKII 
protein level was unchanged after acute nicotine treatment (Walters and Damaj, 2008, 
submitted). Synapsin I is a substrate of CaMKII that is phosphorylated by the kinase at 
Ser-566 and Ser-603; thus, we wanted to see if synapsin I plays a role in the acute 
pharmacological effects of nicotine. Western blot analysis revealed a significant increase in 
pSynapsin I Ser 603 (p603) in the VTA (Fig. 31) and NAc (Fig. 32) after acute nicotine 
administration (2 mg/kg, s.c.). The acute nicotine-induced increases in p603 in the VTA 
(Fig. 31) and NAc (Fig. 32) were significantly blocked by mecamylamine, suggesting a 
nAChR-mediated effect.  To test the specificity of this effect, we treated mice with the β2-
selective antagonist, DHβE (2 mg/kg, s.c.) 10 minutes before nicotine administration. 
Similar to what was observed with pCaMKII activity, results show that the acute nicotine-
induced increase in p603 in the VTA (Fig. 33) and NAc (Fig. 34) were significantly 
blocked by DHβE at doses that are not biochemically active alone. There was no change in 
the total synapsin I protein level in either the VTA or NAc with any drug treatment (Figs. 
31-34). 
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Figure 31. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the VTA 
are blocked by mecamylamine. The dose of mecamylamine (mec, 2 mg/kg, s.c.) used 
was not active by itself. Results were calculated as the ratio of p603 or synapsin (SI) 
and α-tubulin and expressed as the % deviation from the baseline response. Each 
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline, 
mec, and mec + nic groups 
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Figure 32. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the NAc 
are blocked by mecamylamine. The dose of mecamylamine (mec, 2 mg/kg, s.c.) used 
was not active by itself. Results were calculated as the ratio of p603  or synapsin (SI) 
and α-tubulin and expressed as the % deviation from the baseline response. Each 
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline, 
mec, and mec + nic groups 
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Figure 33. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the VTA 
are blocked by the β2-selective antagonist, DHβE. The dose of DHβE (2 mg/kg, s.c.) 
used was not active by itself. Results were calculated as the ratio of p603  or synapsin 
(SI) and α-tubulin and expressed as the % deviation from the baseline response. Each 
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline, 
DHβE, and DHβE + nic groups 
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Figure 34. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the NAc 
are blocked by the β2-selective antagonist, DHβE. The dose of DHβE (2 mg/kg, s.c.) 
used was not active by itself. Results were calculated as the ratio of p603  or synapsin 
(SI) and α-tubulin and expressed as the % deviation from the baseline response. Each 
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline, 
DHβE, and DHβE + nic groups 
 
 
NAc 
146 
 
Synapsin I activity in the NAc after chronic nicotine exposure 
In order to understand the mechanisms involved in nicotine withdrawal, we first needed to 
examine changes in activity after chronic nicotine exposure. Mice were chronically infused 
with nicotine for 14 days. On day 14, the NAc was dissected and prepared for western blot 
analysis. Results show that chronic nicotine induces a significant increase in p603 
expression compared to chronically infused saline controls (Fig. 35), suggesting that 
tolerance does not develop to the acute nicotine-induced increase in p603. 
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Figure 35. Chronic nicotine induces an increase in pSynapsin I Ser 603 (p603) activity 
in the NAc. After 14 days of chronic nicotine exposure, there was a significant 
increase in p603 expression in the NAc compared to chronic saline controls. Each 
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline 
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CaMKII and Synapsin I activity in the NAc after nicotine withdrawal 
Stimulation of nAChRs in the VTA leads to alterations in neurotransmitter release in the 
NAc. Our data show that acute nicotine increases activity of important markers of 
neurotransmitter release (CaMKII and synapsin I). Further, after nicotine withdrawal, 
decreased DA release in the NAc was reported (Hildebrand et al., 1998; Rada et al., 2001), 
and it has been proposed that this deficient DA release in the NAc contributes to the mood 
disorders and overall negative affective state that accompanies nicotine withdrawal 
(Benowitz, 2008); therefore, we focused on changes in CaMKII and synapsin I function in 
the NAc after nicotine withdrawal. Based on the decreased DA release observed in the 
NAc after nicotine withdrawal, we hypothesized that there would be a decrease in CaMKII 
and synapsin I activity in the NAc after nicotine withdrawal. To assess changes in protein 
function, mice chronically infused with nicotine or saline for 14 days were treated with the 
β2-selective antagonist, DHβE (2 mg/kg, s.c.), or the α7 antagonist, MLA (10 mg/kg, s.c.), 
on the morning of day 15, and brain sections were dissected 10 minutes after injection. A 
spontaneous withdrawal assessment was also conducted to complement our precipitated 
biochemical results. Results show that DHβE (2 mg/kg, s.c.) at a dose that precipitates 
significant aversion in mice (Chapter 2) induced a significant decrease in pCaMKII and 
CaMKII total protein levels in the NAc (Fig. 36). Additionally, p603 and synapsin I total 
protein levels in the NAc of chronic nicotine infused mice were decreased after treatment 
with DHE, coinciding with the decreased CaMKII function (Fig. 37). Conversely, MLA 
did not precipitate a change in pCaMKII, CaMKII (Fig. 38), p603 or synapsin I (Fig. 39) 
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function in the NAc, suggesting that α7 nAChRs are not involved in nicotine-withdrawal 
induced changes in this brain region. 
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Figure 36. DHβE significantly reduces pCaMKII and CaMKII activity and level in 
the NAc after chronic nicotine administration. Mice chronically infused with nicotine 
for 14 days were injected with DHβE ( 2 mg/kg, s.c.) on the morning of day 15 to 
precipitate withdrawal. Each point represents the mean ± S.E.M. of 5 mice per group.  
* denotes p < 0.05 vs. saline group 
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Figure 37. DHβE significantly reduces pSynapsin I Ser 603 (p603) and Synapsin I (SI) 
activity and level in the NAc after chronic nicotine administration. Mice chronically 
infused with nicotine for 14 days were injected with DHβE ( 2 mg/kg, s.c.) on the 
morning of day 15 to precipitate withdrawal. Each point represents the mean ± 
S.E.M. of 5 mice per group.  *denotes p < 0.05 vs. saline group 
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Figure 38. MLA does not precipitate a change in pCaMKII or CaMKII activity or 
level in the NAc. Mice chronically infused with nicotine for 14 days were injected with 
MLA (10 mg/kg, s.c.) on the morning of day 15 to precipitate withdrawal. There was 
no significant difference between saline and nicotine infused mice after MLA 
treatment. Each point represents the mean ± S.E.M. of 5 mice per group.   
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Figure 39. MLA does not precipitate a change in pSynapsin I Ser 603 (p603)  or 
synapsin I (SI) activity or level in the NAc. Mice chronically infused with nicotine for 
14 days were injected with MLA (10 mg/kg, s.c.) on the morning of day 15 to 
precipitate withdrawal. There was no significant difference between saline and 
nicotine infused mice after MLA treatment. Each point represents the mean ± S.E.M. 
of 5 mice per group.   
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To complement our pharmacological approach using DHβE and MLA, we examined 
protein function in β2 and α7 KO mice. β2 and α7 KO  and WT mice were chronically 
infused with saline or nicotine for 14 days. On day 15, the mice were treated with 
mecamylamine (2 mg/kg, s.c.), and pCaMKII, CaMKII, p603, and synapsin I were 
measured in the NAc. There was a significant decrease in pCaMKII activity in chronic 
nicotine infused WT mice after mecamylamine treatment compared to saline counterparts; 
however, the decrease in pCaMKII activity was absent in β2 KO mice (Fig. 40). 
Additionally, the decrease in p603 activity in WT mice that was also absent in β2 KO mice 
(Fig. 41). Interestingly, there was no change in total CaMKII (Fig. 40) or synapsin I 
protein level (Fig. 41)   in WT mice after mecamylamine treatment in any group tested. 
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Figure 40. Assessment of pCaMKII and CaMKII activity and level in β2 KO mice. β2 
KO and WT mice chronically infused with nicotine for 14 days were injected with 
mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15 to precipitate 
withdrawal. There was a significant decrease in pCaMKII activity in WT mice that 
was not present in β2 KO mice. Interestingly, there was no change in total CaMKII 
protein level in any group tested after mecamylamine treatment. Each point 
represents the mean ± S.E.M. of 4-6 mice per group.  * denotes p < 0.05 vs. saline and 
β2 KO groups  
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Figure 41. Assessment of pSynapsin I Ser 603 (p603)  and synapsin I (SI) activity and 
level in β2 KO mice. β2 KO and WT mice chronically infused with nicotine for 14 
days were injected with mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15 
to precipitate withdrawal. There was a significant decrease in p603 activity in WT 
mice that was not present in β2 KO mice. Interestingly, there was no change in total 
synapsin I protein level in any group tested after mecamylamine treatment. Each 
point represents the mean ± S.E.M. of 4-6 mice per group.  * denotes p < 0.05 vs. 
saline and β2 KO groups 
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MLA, an α7 antagonist, did not precipitate a decrease in CaMKII or synapsin I function, 
suggesting that α7 nAChRs are not involved in the nicotine withdrawal-induced change in 
CaMKII or synapsin I function. To complement the results of this pharmacological study, 
we measured protein levels in nicotine-dependent α7 nAChR WT and KO mice after 
mecamylamine treatment. The assessment in α7 KO mice revealed a significant decrease in 
pCaMKII (Fig. 42) and p603 activity (Fig. 43) in both nicotine-infused α7 WT and KO 
mice after mecamylamine treatment. There was no change in the total protein level for 
either CaMKII or synapsin I in any group tested (Figs. 42 and 43). 
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Figure 42. Assessment of pCaMKII and CaMKII function in α7 KO mice. α7 KO and 
WT mice chronically infused with nicotine for 14 days were injected with 
mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15 to precipitate 
withdrawal. There was a significant decrease in pCaKII activity in α7 KO and WT 
mice. Interestingly, there was no change in total CaMKII protein level in any group 
tested after mecamylamine treatment. Each point represents the mean ± S.E.M. of 4-6 
mice per group.  * denotes p < 0.05 vs. saline groups 
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Figure 43. Assessment of pSynapsin I Ser 603 (p603)  and synapsin I function in α7 
KO mice. α7 KO and WT mice chronically infused with nicotine for 14 days were 
injected with mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15 to 
precipitate withdrawal. There was a significant decrease in p603 activity in α7 KO 
and WT mice with no change in total synapsin I protein level in any group tested 
after mecamylamine treatment. Each point represents the mean ± S.E.M. of 4-6 mice 
per group.  * denotes p < 0.05 vs. saline groups 
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D. Discussion 
The goal of the biochemical studies in this chapter was to examine the relationship 
between in vivo behavioral modifications and molecular mechanisms that mediate nicotine 
withdrawal behaviors. The current studies suggest that β2-containing nAChRs, but not α7 
nAChRs, are crucial in mediating the decreases in CaMKII and synapsin I activity in the 
NAc after nicotine withdrawal. DHβE blocked the increase in synapsin I activity in the VTA 
and NAc. Additionally, DHβE, but not MLA, precipitated a significant decrease in CaMKII 
and synapsin I activity and protein level. These results were complemented using β2 and α7 
nAChR KO, where it was shown that mecamylamine precipitated a significant decrease in 
CaMKII and synapsin I function in WT and α7 KO mice, but the decrease was not present in 
β2 KO mice after 14 days of chronic nicotine infusion.  
We began our studies by determining the acute effect of nicotine on CaMKII and 
synpasin I function, as this represents the initial cascade of events that occurs after acute 
nicotine exposure. Our studies revealed that acute systemic nicotine induced increases in 
CaMKII activity in the VTA and NAc. The increased activity was significantly blocked by 
the non-selective nAChR antagonist, mecamylamine, as well as by the L-type VGCC 
blocker nimodipine in the VTA. While these results indicate that the acute nicotine-induced 
increase in CaMKII activity is mediated directly through nAChR, it also suggests an 
important role for L-type VGCC, which may suggest the importance of indirect sources of 
Ca
2+
 influx in nicotine induced CaMKII activation. It must be noted that in vitro studies 
show that L-type VGCC blockers can block nAChR signaling at doses typically used to 
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block L-type VGCCs (Wheeler et al., 2006); thus, these results should be interpreted with 
caution, as they may reflect actions at targets other than L-type VGCC.  
 We also examined the CaMKII substrate, synapsin I, a vesicle associated protein 
essential for neurotransmitter release, after acute nicotine. As seen with CaMKII, there was 
a significant increase in synapsin I activity, but not total protein level after acute nicotine 
treatment. This nicotine-induced increase in activity was significantly blocked by 
mecamylamine, and by DHβE in the VTA and NAc at doses used to precipitate affective 
nicotine withdrawal behaviors (Chapter 2 and 3). Previous studies from our lab also show 
that acute nicotine-induced increases in CaMKII in the VTA and NAc are mediated by β2*, 
but not α7* nAChRs (Walters et al., 2008, submitted). Taken together, these results imply 
that acute nicotine-induced increases in CaMKII and synapsin I activity are mediated by β2-
containing nAChRs in the VTA and NAc.  
Our chronic nicotine assessment revealed a significant increase in p603 expression 
after 14 days of chronic nicotine exposure. These results suggest that tolerance does not 
develop to the acute nicotine-induced increases in p603. In addition to the acute and chronic 
nicotine studies, we conducted a withdrawal assessment, which suggests an important role 
for β2*, but not α7* nAChRs in nicotine withdrawal. Although studies suggest an important 
role for nAChRs in the VTA in mediating nicotine withdrawal behaviors, the DA terminals 
that project from the VTA and the presynaptic nAChRs that mediate neurotransmitter 
release are located in the NAc; thus, our withdrawal studies focused on the NAc, where the 
actual release of neurotransmitter occurs. While MLA did not precipitate any change in 
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CaMKII or synpasin I function in the NAc, DHβE precipitated a significant decrease in 
CaMKII and synapsin I activity and protein level at doses that precipitated aversion in our 
CPA model (Chapter 2). To complement these pharmacological studies, we measured 
CaMKII and synapsin I function in the NAc from β2 and α7 KO mice and corresponding 
WT littermates after treatment with mecamylamine (2 mg/kg, s.c.) at a dose that precipitated 
withdrawal signs in nicotine-dependent mice (Chapters 2 and 3; Damaj et al., 2003). There 
was a significant decrease in CaMKII and synapsin I activity after treatment with 
mecamylamine in chronic nicotine infused WT mice; however, this decrease was absent in 
β2 KO mice. Conversely, a decrease in CaMKII and synapsin I activity was observed in α7 
KO mice after mecamylamine precipitated withdrawal. While DHβE precipitated a 
significant decrease in CaMKII and synapsin I total protein level, there was no change in the 
level of either protein after mecamylamine treatment. The phosphorylated, or activated, state 
of the protein is an indication of protein activity, while the protein level reflects the total 
expression of protein in the system. Both DHβE and mecamylamine decreased protein 
activity; however, the differences in protein level are difficult to interpret. Mecamylamine in 
general is a non-selective nAChR antagonist (Papke et al., 2001), and has less selectivity for 
α4β2* nAChRs than DHβE; however, we are unable to explain the differences in total 
protein level that occurred after treatment with the different antagonists. Regardless, the 
results still support our data suggesting a role for β2* nAChRs in nicotine withdrawal-
induced decreases in CaMKII and synapsin I activity. Because our chronic nicotine 
assessment revealed a significant increase in p603 expression, this rules against the 
possibility that our withdrawal data are the result of chronic nicotine exposure rather than 
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withdrawal. Although an examination of CaMKII was not provided, because p603 is the site 
specifically phosphorylated by CaMKII, we expect that there is also an increase in pCaMKII 
expression following chronic nicotine exposure. Together, our biochemical studies using 
pharmacological agents and the complementary transgenic mouse approach suggest that β2-
containing, but not α7* nAChRs are involved in nicotine induced changes in CaMKII and 
synapsin I function in the VTA and NAc after acute nicotine, and in the NAc after nicotine 
withdrawal.  
The α6β2* and α4α6β2* nAChR subtypes are located on presynaptic DA and 
GABAergic neurons in the VTA and are involved in nicotine-stimulated DA release in the 
striatum (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). Many studies 
support the vital role of the neurotransmitter DA in nicotine dependence.  The nicotine 
induced increase in VTA DA neuron firing rate (Grenhoff et al., 1986), and subsequent DA 
release in the NAc is a process thought to underlie the addictive properties of nicotine 
(Ponteiri et al., 1996). Alternatively, studies report decreased DA neuronal activity in the 
VTA (Liu and Jin, 2004) and decreased DA output in the NAc after nicotine withdrawal 
(Hildebrand et al., 1998; Rada et al., 2001). Indeed, it is hypothesized that this relative 
deficiency in DA release following cessation of nicotine exposure accounts for many of the 
mood disorders, craving, and anhedonia that persist in many smokers long after quitting 
(Benowitz, 2008).  Because CaMKII and synapsin I are essential for neurotransmitter 
release, these two proteins are sufficient biochemical markers of neurotransmitter release. 
The decrease in CaMKII and synapsin I function in the NAc after nicotine withdrawal may 
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correspond to the decrease in DA release observed in the NAc after nicotine withdrawal. 
Our behavioral pharmacological assessment in Chapter 5 revealed that the CaMKII 
inhibitor, KN-93, significantly enhanced the anxiety-related response and showed a strong 
trend for enhancement of nicotine CPA, also suggesting that CaMKII is decreased after 
nicotine withdrawal.  Further, our behavioral studies in Chapters 2 and 3 revealed a role for 
β2-containing receptors, specifically α6β2* and/or α4α6β2* nAChR subtypes in affective 
nicotine withdrawal behaviors. Although with the current results, we cannot make a direct 
correlation between our behavioral and biochemical studies, these initial results imply that 
β2-containing nAChRs, which are critical in affective nicotine withdrawal, also mediate the 
nicotine withdrawal induced decreases in CaMKII and synapsin I function in the NAc. 
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GENERAL DISCUSSION 
A.  Rationale and Summary of Overall Hypothesis 
In the United States, tobacco dependence is the leading cause of preventable 
mortality.  While the positive rewarding and reinforcing effects of nicotine motivate 
continued smoking behavior (Kenny and Markou, 2001), many studies suggest that 
avoidance of the negative emotional state produced by nicotine withdrawal represents a 
motivational component that promotes continued tobacco use and relapse after smoking 
cessation. Indeed, the most commonly reported reason for relapsing into smoking during 
quit attempts is the desire to relieve the discomforts of smoking withdrawal (US 
Department of Health and Human Sciences, 1988). Although there are smoking cessation 
therapies available, the success rate is modest, as only 20-25% of smokers remain abstinent 
after one year (Gonzales et al., 2006). Because smoking is such a widespread health 
problem, it is important to understand the molecular and behavioral mechanisms of 
nicotine withdrawal to generate more effective smoking cessation therapies.  
Despite the important contribution of withdrawal symptoms to the maintenance of 
tobacco use, few studies assess the negative motivational component associated with 
nicotine withdrawal. Currently, due to the low selectivity of most available nAChR 
antagonists, the identity of nAChR subtypes involved in nicotine withdrawal remains 
unclear. Furthermore, studies which address the signaling processes underlying nicotine 
withdrawal are lacking; therefore, our studies focused on elucidating the receptor and post-
receptor mediated mechanisms involved in nicotine withdrawal. To address this aim, our 
166 
 
studies focused on three areas of research. First, we identified the major nAChR subtypes 
involved in affective and physical nicotine withdrawal behaviors. Because of the 
importance of affective signs, we measured two different affective nicotine withdrawal 
behaviors; anxiety-related behavior and aversion. Because these signs involve different 
brain regions, with the dorsal raphé nucleus being crucial in mediating nicotine’s effects on 
anxiety (Cheeta et al., 2001), and the basolateral amygdala being involved in aversion 
(Zanoveli et al., 2007), it is possible that they may involve different nAChR subtypes. 
Second, we evaluated the role of important Ca
2+
-dependent mechanisms, such as L-type 
VGCCs and CaMKII, in nicotine withdrawal behaviors. Third, we conducted initial 
biochemical studies to aid in elucidating the relationship between the altered behavioral 
responses in vivo and the in vitro receptor-mediated Ca
2+
-dependent mechanisms involved 
in nicotine withdrawal. Overall, we hypothesized that major nAChR subtypes have 
differential roles in the nicotine withdrawal syndrome. Specifically, the α4α6β2* nAChR 
subtype is involved in affective nicotine withdrawal behaviors. This subtype also mediates 
nicotine-withdrawal induced decreases in CaMKII function in the NAc. The decrease in 
CaMKII function leads to decreased phosphorylation of CaMKII substrates, specifically 
synapsin I, a protein essential for regulation of neurotransmitter release.  
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B. Nicotinic receptor subtypes have differential roles in nicotine withdrawal 
The α4α6β2* nAChR subtype is specifically involved in affective nicotine withdrawal 
 Using spontaneous, precipitated, and CPA models adapted for mouse studies, we 
showed that major nAChR subtypes have differential roles in nicotine withdrawal. We 
began our study with the α4β2* nAChR subtype, a main nAChR subtype in the brain that 
is located on presynaptic dopaminergic and GABAergic neurons in the mesocorticolimbic 
drug pathway. In β2 KO mice, there was a loss of anxiety-related behavior and aversion in 
the CPA model compared to WT mice, but normal withdrawal-induced somatic signs and 
hyperalgesia (Figures 8, 9, and 12). These results were complemented using the β2-
selective antagonist, DHβE, which precipitated significant aversion in the CPA model (Fig. 
3). Previous studies from our lab also showed that DHβE precipitated anxiety-related 
behavior, but not somatic signs or hyperalgesia in chronic nicotine infused mice (Damaj et 
al., 2003). Immunoprecipitation and ligand-binding studies have also shown that the α5 
and 6 subunits are coexpressed with 4 and 2 subunits on midbrain dopaminergic 
neurons and terminals (Le Novère et al., 1996; Klink et al., 2001; Champtiaux et al., 2002; 
Zoli et al., 2002); therefore, we also evaluated the role of α5 and α6 nAChR subunits in 
nicotine withdrawal. Central administration of the α6-selective antagonist, 
MII[H9A;L15A], dose-dependently blocked the expression of the anxiety-related response 
and CPA in nicotine withdrawn mice, but had no effect on somatic signs or the 
hyperalgesia response (Figures 11 and 13). Additionally, the α6/α3β2* selective 
antagonist, MII, blocked the expression of anxiety-related behavior (Fig. 16), but not CPA 
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(Fig. 19), suggesting a role for the α6β2* subtype in the anxiety-related response. 
Conversely, α5 KO mice displayed significant anxiety-related behavior, CPA, and 
hyperalgesia, but a reduction in total somatic signs (Figures 10 and 12). Although α6β2*, 
α4α6β2*, and α4α5β2* subtypes are found in the mesocorticolimbic drug pathway and are 
involved in striatal DA release (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 
2005), the results suggest that the α62* and/or α4α6β2*, but not the α4α5β2* nAChR 
subtype, are specifically involved in affective nicotine withdrawal behaviors. Together 
with previous studies, these data suggest that α62* and/ or α4α6β2* nAChR subtypes are 
critical for affective nicotine withdrawal. 
The α7 subtype is involved in the nicotine withdrawal-induced hyperalgesia response 
The homomeric 7 nAChR is also a major subtype found on neurons in the 
mesocorticolimbic drug pathway and has been implicated in physical withdrawal 
behaviors. In fact, in our studies, mice null for the α7 subunit displayed a loss of nicotine 
withdrawal-induced hyperalgesia, but significant anxiety-related behavior, CPA, and 
somatic signs (Figures 14, 15 and 18). A previous 7 nAChR KO study from our 
laboratory using the oral route of chronic nicotine administration and the spontaneous 
nicotine withdrawal model produced similar findings, showing a loss of hyperalgesia in α7 
KO mice, but otherwise normal somatic signs and anxiety-related response (Grabus et al., 
2005). We also found that MLA, an α7 antagonist, did not precipitate aversion in the CPA 
model in chronic nicotine infused mice, thus, complementing our results using transgenic 
animals (Fig. 3). MLA was also shown to precipitate a significant hyperalgesia response in 
169 
 
nicotine dependent mice (Damaj et al., 2003). Overall, these results implicate a role for α7 
nAChRs in some aspects of physical withdrawal, but not affective nicotine withdrawal. 
The data also suggests that our two physical measures of nicotine withdrawal (somatic 
signs and hyperalgesia), are mediated by different nAChR subtype populations. Although 
7 KO mice showed a loss of the hyperalgesia response, somatic signs were still present. 
Hyperalgesia is measured as a physical sign in the mouse; however, studies have suggested 
that spinal and supraspinal nAChR populations mediate the hyperalgesia response 
(Schmidt et al., 2001; Damaj et al., 2002).  Our hyperalgesia measure was conducted using 
the hot plate, which measures supraspinal mechanisms; thus, we cannot rule out the 
possibility that the nicotine withdrawal induced hyperalgesia response is mediated by 
neuronal 7 nAChRs, which do not contribute to the centrally mediated component of 
somatic nicotine withdrawal.  It is also noted that MLA precipitated mild somatic signs of 
withdrawal in WT mice (Damaj et al., 2003). MLA can antagonize 6, 3, and 3 nAChR 
subunits at doses typically used to block 7 nAChRs (Mogg et al., 2002). Indeed, it was 
revealed that MLA precipitated significant somatic signs in nicotine dependent α7 KO 
mice (Salas et al., 2007). Our studies using α3 nAChR antagonists revealed a role for α3-
containing nAChRs in somatic nicotine withdrawal signs, as will be discussed in the next 
section. Conversely, α6-containing receptors are not involved in somatic nicotine 
withdrawal signs; thus, it is possible that the observed behavioral responses were attributed 
to effects on other nAChR subunits, such as the α3 and/or β3 subunits.  
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α3-containing nAChRs are involved in physical aspects of nicotine withdrawal 
The α3 subunit is coexpressed with α5 and β4 nAChRs in the peripheral ganglia, 
MHb and IPN (Wada et al., 1990; Zoli et al., 1995; Quick et al., 1999; Whiteaker et al., 
2002). The α3 nAChR subunit is also expressed in brain areas that have been implicated as 
having a role in nicotine dependence behaviors, and can coassemble with β2 nAChRs to 
form functional receptors on DA neurons and terminals (Le Novère and Changeux, 1995; 
Le Novère et al., 1996; Klink et al., 2001). It was shown that 4 KO mice do not display 
somatic signs after nicotine withdrawal (Salas et al., 2004), suggesting a role for the β4 
subunit in somatic nicotine withdrawal. Additionally, our data suggested a role for the α5 
subunit in somatic nicotine withdrawal, as α5 KO mice displayed a significant reduction in 
total somatic signs. It was also shown recently that a common haplotype in the 
CHRNA5/CHRNA3/CHRNB4 gene cluster, which codes for the α5, α3, and β4 subunits 
respectively, predisposes to nicotine dependence (Berrettini et al., 2008); therefore, we 
identified a role for α3-containing receptors in nicotine withdrawal behaviors using MII 
and AuIB, selective α3β2* and α3β4* nAChR subtype antagonists respectively.  
AuIB dose-dependently attenuated somatic nicotine withdrawal signs, but had no 
effect on expression of the anxiety-related response, hyperalgesia, or CPA (Figures 17 and 
19), suggesting a role for the α3β4* nAChRs in somatic, but not affective nicotine 
withdrawal. Results also show that the α3β2* selective antagonist, MII, dose-dependently 
blocked expression of the anxiety-related response and attenuated somatic signs (Fig. 16).  
MII had no effect on the hyperalgesia response at any dose tested (Fig. 16). Surprisingly, 
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MII did not block expression of CPA, even after doubling the dose used to block the 
anxiety-related response (Fig. 19). Taken together, these results also stress and important 
role for β2*, but not β4* nAChRs, in affective nicotine withdrawal. Studies suggest that 
MII may not discriminate well between α3 and α6 nAChRs (Kuryatov et al., 2000), as the 
α6 and α3 nAChR subunits share considerable sequence homology (Le Novère and 
Changeux, 1995). The MII analog and selective α6 antagonist, MII[H9A;L15A], 
effectively discriminates between α3 and α6 nAChR subunits (McIntosh et al., 2004). Our 
results from Chapter 3 showed a role for α6-containing nAChRs in nicotine CPA and the 
anxiety-related response, but not physical withdrawal, suggesting that α6-containing 
nAChRs, and not α3β2* nAChRs, are important for nicotine CPA, while both α6β2* and 
α3β2* nAChRs are involved in the withdrawal-induced anxiety-related response. Indeed, 
anxiety-related behavior and CPA are mediated by two different brain regions; the dorsal 
raphé nucleus (Cheeta et al., 2001) and the basolateral amygdala (Zanoveli et al., 2007) 
respectively; thus, it is possible that the two behaviors are mediated by different subtypes. 
The dorsal raphé nucleus also receives innervations from the MHb (Morris et al., 1999), a 
brain area rich in α3 nAChR expression (Quick et al., 1999); thus, the MHb may also be 
involved in anxiety-related behaviors. Conversley, because MII does discriminate well 
between α6 and α3 nAChR subunits, we cannot rule out the possibility that the observed 
MII effect in the plus maze test are attributed to actions at α6β2* nAChRs rather than 
α3β2*. 
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These results also implicate the importance of receptor subtype composition. While 
our data showed that β2-containing nAChRs were not involved in somatic nicotine 
withdrawal, because MII attenuated somatic withdrawal signs, it cannot be ruled out that 
the α3β2* subtype is involved in somatic nicotine withdrawal signs. Additionally, it is 
noted that α3β2* and α3β4* nAChRs are involved in somatic signs, but not the 
hyperalgesia response, whereas the α7 subtype was shown to be involved in the 
hyperalgesia response, but not somatic signs. These results are consistent with our proposal 
that the physical withdrawal signs measured in our model (somatic signs and hyperalgesia) 
are mediated by different nAChR subtypes. It is also possible that the brain regions in 
which these nAChR subtypes are expressed can influence their effects. 
The α5, α3, and β4 nAChR subunits coassemble in peripheral ganglia, MHb and IPN 
(Wada et al., 1990; Zoli et al., 1995; Quick et al., 1999; Whiteaker et al., 2002), and have 
all been shown to be involved in somatic nicotine withdrawal. Our studies using central 
administration of AuIB, a selective α3β4* antagonist, support a role for central α3β4* 
nAChRs in somatic nicotine withdrawal signs. Interestingly, somatic nicotine withdrawal 
signs are mediated by both central and peripheral nAChR populations (Watkins et al., 
2000); thus, we propose that α5 and α3β4* nAChRs contribute to expression of somatic 
signs through location in the peripheral ganglia, as well as centrally in the MHb and IPN. 
The MHb and IPN have been implicated in behaviors associated with drug dependence. A 
synthetic derivative of the African shrub ibogaine, 18-Methoxyroconaridine (18-MC), was 
shown to be an inhibitor of α3β4* nAChRs in vitro (Glick et al., 2002). When administered 
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into the MHb and IPN, 18-MC blocked morphine and nicotine self-administration (Glick et 
al., 2000; Glick et al., 2006), somatic morphine withdrawal signs (Panchal et al., 2005), 
and dopamine sensitization to morphine (Taraschenko et al., 2007) in rats. Although the 
available studies do not provide direct evidence of a α3α5β4* subtype composition in the 
brain, studies indicate that α3, α5, and β4 subunit mRNA was present in nearly 100% of 
neurons isolated from rat MHb (Sheffield et al., 2000). Overall, the data suggests that 
α3α5β4* gene clusters located in the MHb and in peripheral ganglia are important in 
somatic nicotine withdrawal.  
This extensive investigation of the identity of nAChR subtypes involved in various 
aspects of nicotine withdrawal yielded important findings. A pictorial depiction of the 
proposed subtypes involved in physical and affective nicotine withdrawal is presented in 
Figure 44. 
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Figure 44. Overall depiction of the role of major nAChR subtypes in physical and 
affective nicotine withdrawal signs as revealed in our studies and others. A. 
Represents the two aspects of the nicotine withdrawal syndrome. B. Representation of 
the specific signs categorized under each aspect of nicotine withdrawal that were 
measured in the current studies. C. The major nAChR subtypes that were found to 
be involved in the various aspects of nicotine withdrawal. In addition to the current 
studies, citations of studies that support our conclusions for the subtypes’ role in 
nicotine withdrawal are listed. 
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C. L-type VGCCs and CaMKII differentially regulate nicotine withdrawal 
 Studies have suggested a role for L-type VGCC and CaMKII in the effects of 
several drugs of abuse, including morphine, cocaine, amphetamine, and nicotine (Tan, 
2002; Wang Z et al., 2003; Licata et al., 2004; Biala and Weglinska, 2005). Although the 
current studies evaluating Ca
2+
-dependent mechanisms in nicotine dependence provide 
evidence of a role for Ca
2+
 signaling, studies assessing the affective component of nicotine 
withdrawal are lacking. There is also no available behavioral correlation for the 
biochemical studies which evaluate nicotine-induced Ca
2+
 mechanisms in vitro; thus, the 
relevance of these mechanisms to nicotine withdrawal is unclear. The study by Biala and 
Weglinska (2005) found that L-type VGCC blockers attenuated somatic nicotine 
withdrawal signs; however, the study utilized high doses of L-type VGCC blockers, which 
our studies found significantly reduced locomotor activity (Fig. 20). Furthermore, such 
high doses may inhibit α3* and α7* nAChR-mediated currents (Wheeler et al., 2006).  
 In our study, L-type VGCC blockers attenuated somatic signs and hyperalgesia in 
nicotine-withdrawn mice, but there was no effect on anxiety-related behavior or 
development of CPA (Figures 21 and 23).  Because L-type VGCC blockers have been 
shown to inhibit α3* and α7* nAChRs in vitro (Wheeler et al., 2006), we used an L-type 
VGCC activator, (±)Bay K8644, to complement our results. (±)Bay K8644 enhanced 
somatic nicotine withdrawal signs and the hyperalgesia response (Fig. 22). Taken together, 
our studies support a role for L-type VGCCs in physical, but not affective nicotine 
withdrawal. Clinically, this may suggest that L-type VGCC blockers would not be very 
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successful in alleviating withdrawal symptoms in abstinent smokers. Although somatic 
signs do contribute to the discomfort associated with the nicotine withdrawal syndrome, 
the affective signs are suggested to be of greater motivational significance in contributing 
to relapse (Koob et al., 1993; Markou et al., 1998). 
 While the L-type VGCC studies yielded clear results, the role of CaMKII in 
nicotine withdrawal behaviors appears more complex. While pharmacological blockade of 
CaMKII using the inhibitor KN93 dose-dependently attenuated somatic nicotine 
withdrawal signs, it enhanced the affective component of nicotine withdrawal (Figures 24 
and 28). To examine this effect further, we treated chronic nicotine infused mice with 
KN93 and found that the inhibitor precipitated anxiety-related behavior, but had no effect 
on somatic signs or hyperalgesia (Fig. 25). These pharmacological results suggest that 
CaMKII has opposing roles in nicotine withdrawal. While KN93 enhanced the anxiety-
related response, suggesting that CaMKII activity is decreased after nicotine withdrawal, 
KN93 attenuated somatic nicotine withdrawal signs, suggesting that CaMKII activity is 
increased after nicotine withdrawal. One explanation for this effect is that CaMKII 
function after nicotine withdrawal differs depending on the brain region and nAChR 
subtype involved. We proposed that affective withdrawal signs involve α4α6β2* nAChR 
subtypes in the VTA, while somatic nicotine withdrawal involves the α3α5β4* subtype in 
the MHb. After chronic antidepressant treatment, CaMKII activity differed based on the 
brain region and presynaptic compartment (i.e. synaptic vesicles vs. synaptic membranes) 
(Schneider et al., 2007). Additionally, our biochemical studies in Chapter 6 showed that 
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acute nicotine-induced changes in CaMKII function in the VTA are nicotinic receptor 
mediated effect (Fig. 30). Therefore, because we observed attenuation of somatic signs 
after KN93 treatment, it is possible that there is an increase in CaMKII function after 
nicotine withdrawal in the MHb that is mediated by α3α5β4* nAChRs. The enhanced 
anxiety-related response after KN-93 treatment and the trend observed in the CPA model 
suggest a decrease in CaMKII function after nicotine withdrawal, which may be mediated 
by α4α6β2* nAChR subtypes in the NAc and/or VTA. 
 Conversely, our transgenic assessment revealed an opposite role for CaMKII than 
that observed in our pharmacological assessment. Saline infused CaMKII HT mice had 
decreased baseline anxiety levels on the plus maze compared to WT counterparts, 
consistent with CaMKII mutants having increased exploratory behavior in the open field 
and Y-maze (Silva et al., 1992b), and there was a loss of anxiety-related behavior in 
nicotine-infused CaMKII HTs after mecamylamine treatment (Fig. 26). These results 
suggest that CaMKII activity is increased after nicotine withdrawal. There was no 
significant difference in somatic signs, hyperalgesia, or aversion in the CPA model 
between saline and nicotine infused mice (Figures 26 and 28). Several possible 
explanations for this discrepancy were discussed in Chapter 5. Overall, the results suggest 
that L-type VGCC and CaMKII are differentially regulated in nicotine withdrawal, 
although CaMKII, which was shown to be involved in both somatic and affective nicotine 
withdrawal, may be a more clinically relevant target. 
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Depression is an affective symptom associated with nicotine withdrawal. Indeed, 
the antidepressant, bupropion, is clinically approved for smoking cessation and has been 
proposed to act via promoting dopaminergic function (Nestler and Carlezon, 2006). 
Changes in synaptic plasticity are involved in the pathophysiology of depression and in the 
mechanism of antidepressants (Manji et al., 2001). CaMKII, being a kinase involved in 
synaptic plasticity, has been shown to be a target of antidepressants. Reduced α-CaMKII 
expression was found in the brains of subjects with bipolar and unipolar depression (Xing 
et al., 2002), and antidepressants activate CaMKII in hippocampal neuronal cell bodies by 
phosphorylation of Thr286 (Tiraboschi et al., 2004). An inhibitor of CaMKII exacerbated 
anxiety-related behavior in our studies, suggesting decreased CaMKII levels after nicotine 
withdrawal. Because antidepressants were shown to enhance CaMKII, it is possible that 
CaMKII is a relevant target in alleviating the depression and overall negative emotional 
state associated with nicotine withdrawal. Additionally, we cannot rule out the possibility 
that CaMKIV is involved in these effects, as KN93 also inhibits this kinase (Enslen et al., 
1994). Suppression of CaMKIV in the NAc increased anxiety-related behavior in rats 
(Schneider et al., 2007), suggesting that CaMKIV in the NAc is involved in mechanisms 
associated with anxiety. The effects of nicotine on CaMKIV to date have not been 
assessed; however, CREB, a downstream target of CaMKIV, was shown to be involved in 
mechanisms associated with nicotine dependence, including reward (Walters et al., 2005) 
and withdrawal (Pandey et al.,2001; Brunzell et al., 2003; Pluzarev and Pandey, 2004). 
Further, disruption of CREB function in the NAc is also associated with increased anxiety 
responses, while overexpression of CREB was shown to be anxiolytic (Barrot et al., 2002; 
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Barrot et al., 2005). Taken together, we propose that intracellular Ca
2+
-dependent kinases, 
such as CaMKII and CaMKIV, are involved in the affective component of nicotine 
withdrawal, and are critical targets for the alleviation of affective symptoms associated 
with nicotine withdrawal. Additionally, the NAc may be a target brain area involved in 
these emotional responses. 
D. Nicotine withdrawal-induced decreases in CaMKII and synapsin I function are 
mediated through β2-containing nAChRs 
 Studies suggest a role for CaMKII and synapsin I in various drugs of abuse such as 
cocaine, morphine, and amphetamine (Matus-Leibovitch et al., 1995; Iwata et al., 1996; 
Iwata et al., 1997a; Iwata et al., 1997b; Tan, 2002; Licata et al., 2004; Wang et al., 2003). 
Additionally, our behavioral studies showed that Ca
2+
-dependent mechanisms, such as L-
type VGCC and CaMKII, are involved in nicotine withdrawal behaviors; therefore, we 
wanted to determine the relationship between these nicotine withdrawal-induced 
behavioral modifications and the in vitro Ca
2+
-dependent molecular mechanisms involved 
in nicotine withdrawal. We measured CaMKII and synapsin I activity in the VTA and NAc 
after acute systemic nicotine administration and found that nicotine induced increases in 
the activity of both proteins, and these increases are mediated through β2-containing 
nAChRs (Figures 29; 31-34). Further, we measured activity and protein level in the NAc 
after chronic nicotine and nicotine withdrawal, as release of neurotransmitter and the 
presynaptic nAChRs that mediate neurotransmitter release are located in this brain region. 
Synapsin I activity was increased in the NAc after chronic nicotine (Fig. 35), suggesting 
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that tolerance does not develop to the acute nicotine-induced increase in this protein. 
Results from the nicotine withdrawal assessment show that DHβE, but not MLA, 
precipitate significant decreases in CaMKII and synapsin I activity and level at doses that 
precipitate significant aversion in the CPA model (Figures 3; 36-39). Our studies using 
transgenic animals complemented this data, as the mecamylamine-precipitated decrease in 
CaMKII and synapsin I activity in the NAc was present in α7 KO, but not in β KO mice 
(Figures 41-43). Taken together, these results suggest that β2*, but not α7*, nAChRs 
mediate the acute nicotine-induced increase in CaMKII and synapsin I activity in the VTA 
and NAc, as well as the nicotine withdrawal-induced decrease in activity and level in the 
NAc. 
 The α6β2* and α4α6β2* nAChR subtypes are located on presynaptic DA and 
GABAergic neurons in the VTA and are involved in nicotine-stimulated DA release in the 
striatum (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). Indeed, the 
nicotine induced increase in VTA DA neuron firing rate (Grenhoff et al., 1986), and 
subsequent DA release in the NAc is a process thought to underlie the addictive properties 
of nicotine (Ponteiri et al., 1996). Alternatively, studies report decreased DA output in the 
NAc after nicotine withdrawal (Hildebrand et al., 1998; Rada et al., 2001). It is 
hypothesized that this relative deficiency in DA release following cessation of nicotine 
exposure accounts for many of the mood disorders, craving, and anhedonia that persist in 
many smokers long after quitting (Benowitz, 2008).  CaMKII and synapsin I are sufficient 
biochemical markers of neurotransmitter release, as these proteins are essential for 
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neurotransmitter release. The decrease in CaMKII and synapsin I function in the NAc after 
nicotine withdrawal may correspond to the decrease in DA release observed in the NAc 
after nicotine withdrawal. Our behavioral pharmacological assessment in Chapter 5 
revealed that the CaMKII inhibitor, KN93, significantly enhanced the anxiety-related 
response and showed a strong trend for enhancement of nicotine CPA, which suggests that 
CaMKII is decreased after nicotine withdrawal (Figures 24 and 28). Further, our 
behavioral studies in Chapters 2 and 3 revealed a role for β2-containing receptors, 
specifically α6β2* and/or α4α6β2* nAChR subtypes in affective nicotine withdrawal 
behaviors (Figures 3, 8, 9, 11-13).  
Overall, these initial results show that CaMKII and synapsin I activity in the NAc are 
decreased after nicotine withdrawal, and these decreases are mediated through β2-
containing nAChRs. Although we did not test the α6 antagonists, MII and MII 
[H9A;L15A], or the α3 antagonists, MII and AuIB, in our in vitro  studies, we propose that 
the α6β2* and /or α4α6β2* subtypes, and not α3* or α7* containing nAChRs, mediate the 
nicotine withdrawal-induced decreases in CaMKII and synapsin I function in the NAc. As 
mentioned, these subtypes are presynaptically located on DA terminals in the striatum and 
are involved in DA release in this brain region. Further, MLA, an α7 antagonist, did not 
precipitate a decrease in CaMKII or synapsin I function, and the decrease in activity was 
present in α7 KO mice. Our behavioral studies implicate α7 and α3-containing nAChRs in 
physical nicotine withdrawal (Chapter 3), yet we saw no effect with MLA at doses that 
precipitated withdrawal in mice (Damaj et al., 2003). Based on this data, we propose that 
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while α7 and α3-containing nAChRs are involved in physical nicotine withdrawal signs, 
they are not relevant to the molecular changes that occur after nicotine withdrawal. It is 
noted that the L-type VGCC blocker nimodipine, also blocked the acute nicotine induced 
increase in CaMKII activity in the VTA (Fig. 30); however, because we did not evaluate 
the role of L-type VGCC in our biochemical assessment after nicotine withdrawal, we 
cannot determine if this effect is relevant to the decrease in protein activity after nicotine 
withdrawal. Additional studies using behaviorally relevant nimodipine doses (1-2 mg/kg, 
i.p.) are necessary to further evaluate this effect.    
E. Conclusions and Implications 
 Overall, our research contributes to the understanding of the behavioral and 
molecular mechanisms underlying nicotine withdrawal. These studies identified major 
nAChR subtypes, post-receptor Ca
2+
-dependent mechanisms, and brain regions important 
in nicotine withdrawal. Further, by demonstrating that the decreases in CaMKII and 
synapsin I function, which may contribute to the decreased DA release observed after 
nicotine withdrawal, are mediated through β2-containing nAChRs, which are crucial for 
expression of affective nicotine withdrawal signs, this study stresses the importance of 
affective nicotine withdrawal as a motivational component of relapse in smoking behavior. 
Studies suggest that although somatic signs are an important component of the nicotine 
withdrawal syndrome, the affective signs are of greater motivational significance in 
contributing to relapse (Koob et al., 1993; Markou et al., 1998). As mentioned, it is also 
hypothesized that this relative deficiency in DA release following cessation of nicotine 
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exposure accounts for many of the mood disorders, craving, and anhedonia that persist in 
many smokers long after quitting (Benowitz, 2008). Indeed, reduced α-CaMKII expression 
was found in the brains of subjects with bipolar and unipolar depression (Xing et al., 
2002), and anti-depressants have been shown to increase CaMKII phosphorylation in 
hippocampal neuronal cell bodies (Tiraboschi et al., 2004). Further, the anti-depressant, 
bupropion, which blocks nAChRs (Slemmer et al., 2000), and inhibits the DA transporter, 
thus enhancing DA function (Nestler and Carlezon, 2006), is clinically used as a smoking 
cessation therapy. Taken together, these studies suggest that presynaptic β2-containing 
nAChRs, specifically α6β2* and/or α4α6β2* subtypes, which mediate striatal DA release, 
CaMKII, and synapsin I, are critical components of the affective nicotine withdrawal 
syndrome, and may be clinically relevant to smoking cessation; thus, more research should 
focus on the role of these targets in development of nicotine dependence. Overall, the 
research in this dissertation contributes to the understanding of the behavioral and 
molecular mechanisms of nicotine withdrawal, and provides new insight into potential 
targets for more effective smoking cessation therapies. 
F. Future Studies 
 A major part of our effort during the Ph.D. work was dedicated to identifying the 
major nAChR subtypes involved in nicotine withdrawal. Using pharmacological methods 
and genetically modified mice, we showed that the various aspects of nicotine withdrawal 
are mediated by different nAChR subtypes. While we were able to identify the major 
subtypes involved (Fig. 44), more studies are needed to identify the exact composition of 
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these subtypes and important brain regions involved in nicotine withdrawal behaviors. To 
support our proposal for a role of the α3α5β4* subtype in somatic nicotine withdrawal 
signs, future studies include testing the α3β4* antagonist AuIB in α5 KO mice. Our studies 
showed a significant reduction in total somatic signs in α5 KO mice and a dose-dependent 
attenuation of somatic signs after central administration of AuIB. We will determine the 
role of the α3α54* subtype by determining if we can attenuate somatic signs in α5 KO 
mice with AuIB. This would also further implicate the MHb as a brain region involved in 
manifestation of somatic signs. 
 Additionally, our results show that β2-containing nAChRs mediate affective 
nicotine withdrawal signs. Because the α4β2* subtype is the most abundant subtype in the 
brain, we proposed that this subtype is involved in affective nicotine withdrawal behaviors. 
Our pharmacological data using the α6 and α6/α3β2* antagonists, MII[H9A;L15A] and 
MII respectively, suggest a role for α6β2* and/or α4α6β2* nAChRs in affective nicotine 
withdrawal. To further evaluate these results, we will obtain and breed α4 and α6 KO mice 
to test in our nicotine withdrawal models. This complementary approach will allow us to 
further differentiate between the importance of α6β2* and α4α6β2* subtypes in affective 
nicotine withdrawal.    
  Another major finding of our work was the involvement of L-type VGCCs and 
CaMKII in nicotine withdrawal behaviors. Indeed, results from our second specific aim 
clearly showed a role for L-type VGCCs in physical nicotine withdrawal, but not affective 
withdrawal. CaMKII results were more difficult to interpret due to differences between our 
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pharmacological and transgenic mouse data. We used CaMKII HT mice in our 
experiments because of our failed attempts to generate CaMKII KO mice, as CaMKII HT 
females do not care for their pups. To alleviate this problem, we will attempt to foster pups 
born from CaMKII HT mothers in order to obtain CaMKII KOs. Another option would be 
the use of CaMKII conditional KOs, which can be obtained from Jackson Laboratories. 
 Although our data from specific aim two do suggest a role for Ca
2+
-dependent 
mechanisms in nicotine withdrawal, we used another strategy to explore the involvement 
of these mechanisms. We examined the relationship between the altered behavioral 
responses in vivo and the in vitro receptor-mediated Ca
2+
-dependent mechanisms involved 
in nicotine withdrawal. For our third specific aim, results showed that there are decreases 
in CaMKII and synapsin I activity after nicotine withdrawal, and these decreases are 
mediated through β2-containing nAChRs. We propose that the nicotine withdrawal-
induced decreases are mediated through α4β2* and/or α4α6β2* nAChR subtypes, which 
are involved in affective nicotine withdrawal signs. To further examine this effect, we will 
evaluate CaMKII and synapsin I activity and level in the NAc of α4 and α6 KO mice after 
nicotine withdrawal. We complement the α6 KO mouse studies using the α6 antagonist, 
MII[H9A;L15A], and the α6/α3β2* antagonist, MII. Additionally, we propose that the 
α3β4* and/or α3α5β4* nAChR subtypes, which mediate somatic nicotine withdrawal 
signs, are not involved in the nicotine withdrawal induced decrease in CaMKII and 
synapsin I; therefore, we will also measure CaMKII and synapsin I activity and level in the 
NAc in α5 KO mice, and in mice after treatment with the α3β4* antagonist, AuIB. To 
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correlate the decrease in CaMKII and synapsin I activity with our behavioral results, we 
will complete a time course of the biochemical changes and compare them to our 
spontaneous withdrawal assessment. We hypothesize that the decrease in CaMKII and 
synapsin I activity is relevant to affective nicotine withdrawal behaviors; therefore, we 
expect to see a decrease in CaMKII and synapsin I activity and level in the NAc after 
spontaneous nicotine withdrawal that correlates with the increase in severity of affective 
withdrawal signs that occurs after the first few days after spontaneous nicotine withdrawal 
(Damaj et al., 2003). As the severity of the withdrawal syndrome peaks and subsides over 
the course of several days, we expect that activity and protein level of CaMKII and 
synapsin I will return to baseline levels.  
These proposed studies will further support our hypothesis of the importance of the 
α6β2* and/or α4α6β2* subtypes and the decrease in CaMKII and synapsin I function in the 
NAc in the manifestation of affective nicotine withdrawal behaviors. 
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